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contract as a Senior Clinical Lecturer in Transfusion Medicine within the 
University of Birmingham, UK.  The author currently holds a contract as a 
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Oxygenation Research network in Norway since 2013 and she was awarded a 
fellowship from the Medical Women’s Federation in 2016 to study within the 
Haukeland University Hospital. 
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The recent advances in military transfusion medicine have been described as 
a military medical revolution.1 2 Innovation is about the translation of theory 
into practice and the work presented here is primarily focussed on my 
contribution as a practitioner.  Successful innovation requires team work and 
collaborative effort between organisations and academic disciplines.  The 
author acknowledges the commitment and expertise of the wider Defence 
Medical Services, especially the military biomedical scientists.   
 
Throughout the last decade of 2006-2016, the Birmingham military-civilian 
blood supply partnership led by these scientists has provided a global, safe 
and secure supply of blood to British military personnel, whilst fully complying 
with changing EU and UK standards. New clinical and technical capabilities 
were developed in response to the emerging clinical challenges. The 
‘Operational Apheresis’ and ‘Blood to the Battlefield’ partnerships were 
recognised by several Military and Civilian Health Partnership Awards for both 
Innovation in ‘Service Development’ and ‘Deployed Healthcare’.   
 
Key partners in this development programme have been the US Armed 
Services Blood Programme, NHS Blood and Transplant, THOR, the NATO 
Blood Panel, the University Hospital Birmingham and the Blizard Institute. I 
am indepted to NHS Blood and Transplant for supporting me both as a military 
reservist and researcher. Special mention must be made of my sponsor Prof 
Tor Hervig and his colleagues in Bergen for enabling me to formalise this work 
as a thesis. Lastly, I thank my colleague, Dr Emma Watkins and my family, 
especially my husband Prof Jim Storr, for their unfailing support.  
 
It has been a privilege to contribute to a new body of knowledge which I hope 
leaves a legacy to wider healthcare. My philosophy is captured in a quote from 
my TED talk in 2014.3 ‘In the last decade there has been a revolution in 
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military medicine.  We have changed the paradigm of how care is delivered, 
from pre-hospital care, to hospital, through to rehabilitation.  There has been a 
revolution in the continuity of care, based on collaboration and cooperation 
instead of competition.  We have joined the dots to get the sort of survival that 





Introduction. Massive haemorrhage is the leading cause of preventable death 
following trauma.  The mortality rate is high unless actively managed from 
Point of Injury (POI). However, during the last decade advances in military 
medicine, including transfusion support, appear to have delivered 
extraordinary survival advantages.  A new transfusion policy was introduced in 
2007 in response to the emerging analysis of combat experience underpinned 
by a revised understanding of the pathophysiology of trauma.  Transfusion 
support was redesigned as part of Damage Control Resuscitation (DCR) to 
mitigate Trauma Induced Coagulopathy.  The Massive Transfusion Capability 
was an ambitious programme designed to provide transfusion support 
throughout the continuum of care.  The success has led to transfusion support 
being considered in military and civilian environments where there is a risk of 
haemorrhage but there is minimal medical infrastructure. Developments such 
as: a more portable cold chain; whole blood and lyophilised products offered 
Remote Damage Control Resuscitation (RDCR) whilst addressing the logistic 
tail. The delivery of the military capability has required considerable innovation 
during an era in which transfusion practice became subject to an increase in 
legislative and regulatory measures.  The overall objective of this study is to 
evaluate the recent developments in military transfusion practice and to 
assess the impact on civilian practice.     
Methods. The study describes the developments in military transfusion 
support in a linear sequence from 2006 to 2016. The adoption of military 
principles and practice is then explored in the context of civilian practice and 
national emergency transfusion preparedness for Mass Casualty Events 
(MCE).  The source material thesis is derived from the author’s military and 
civilian, professional and academic practice.  The thesis submission is 
structured around four aims; two military thematic areas which are the recent 
changes in UK military blood transfusion practice and the development of pre-
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hospital transfusion.  These are followed by two civilian themes; the 
introduction of Massive Transfusion Protocols (MTPs) and transfusion 
planning for Mass Casualty Events (MCEs). The military data has been 
extracted from the UK Joint Theatre Trauma Registry complimented by quality 
management systems.  The civilian data is derived from the relevant Trauma 
Registries, Patient Administration Systems and Laboratory Information 
Management Systems.  Descriptive statistics were used to summarize the 
number of components by year, speciality and patient demographics. 
Statistical analysis was performed using a variety of software tools.  
 
Results. The paradigm of military transfusion has changed in the last decade.  
The developments have been credited with contributing to survival of the 
critically injured. Survival is the product of the entire system of care, which – in 
this setting of combat, incorporates the early external haemorrhage control, 
hybrid resuscitation; rapid and physician-led recovery from the battlefield, 
damage control surgery, transfusion support and expert critical care. It is thus 
not possible to ascertain the individual contribution of transfusion however it 
has been an important element.  
 
Transfusion support is increasingly being considered in at risk environments 
with minimal infrastructure and logistic support.  The collection of Whole blood 
from a pre-tested Emergency Donor panel is a viable transfusion management 
option.   Knowledge sharing from the Bergen based Blood Far Forward 
program has enabled the further development of UK military practice.  In 
addition, the concept of the safe universal whole blood donor has informed the 
wider transfusion community leading to the acceptance of group O Low titre 
as a new standard. 
 
Massive Transfusion Protocols (MTP) have been successfully introduced into 
civilian practice for both trauma and other causes of massive haemorrhage.  
Massive Transfusion (MT) is a phenomenon of surgery not trauma and the 
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organisational principles can be applied to all causes of haemorrhage.  MT is 
resource intensive and has implications for both hospital and blood service 
organisation. However, the civilian studies have not demonstrated a survival 
advantage and the definitions of MT require standardisation to allow 
comparison of practice and the design of further studies.  
The pattern of blood use in civilian Mass Casualty Events differs from that 
seen in the recent military experience in Afghanistan and Iraq.  Far fewer 
injured require blood and few require Massive Transfusion and haemostatic 
component support.  However, military style planning has added value to the 
preparation for MCEs and the response to Major Incidents.  Elements of 
military planning have included the optimisation of pre-hospital care, 
haemorrhage control, transfusion triage, MTPs and emergency donor 
management.  Transfusion Emergency Preparedness should become an 
integrated part of healthcare emergency planning. 
Conclusions. Transfusion has emerged as an essential and successful 
element of modern combat care. The success must be placed in the context of 
the whole healthcare system, especially pre-hospital care.  The nature of 
military and civilian trauma differs however, many of the recent lessons 
identified have been intelligently applied to civilian hospital healthcare.  Military 
practice has also informed both pre-hospital emergency care, blood 
component development and transfusion planning for MCEs.  In turn, combat 
care has benefitted from civilian transfusion governance and regulatory 
expertise.  The continued military-civilian collaboration and innovation in 
transfusion practice has the potential to benefit not only the military, but also 
the wider healthcare community.   
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1: INTRODUCTION  
 
1.1 Catastrophic haemorrhage 
 
Setting the scene On 22 March 2017 at 14.40, an attacker drove a car along 
a pavement on Westminster Bridge in London, stabbed an unarmed policeman 
and was shot dead by police in the grounds of the UK Parliament. Five people 
died.  Initial police reports suggested that at least 50 people were injured, with 
31 requiring hospital treatment.  
 
Immediately after the attack, an ex- soldier tried to stop the bleeding and 
delivered CPR to the critically injured policeman.  Within minutes there was an 
armed response unit present with control of the situation.  Outside the Palace 
of Westminster, the emergency services had gone to work, setting up 
makeshift treatment areas for the wounded. An air ambulance carrying ‘Blood 
on Board’ landed in Parliament Square.  
 
Patients were triaged with the most seriously injured taken to Major Trauma 
Centres.  One example was Imperial College Healthcare NHS Trust where 
eight casualties were received.  Casualties were assessed by senior clinicians 
with rapid transfer to surgery.  Massive Haemorrhage Protocols were 
delivered as part of Damage Control Resuscitation  
 
NHS Blood and Transplant, the English Blood Transfusion Service was stood 
up at 15.15 hr. Orders were placed for group O red cells, group A plasma and 
platelets.  Emergency deliveries were made to 3 hospitals and validation of 
newly collected platelets was brought forward.  By 16.00 157 units of platelets 
were validated and released into the system.  All customer orders were met. 
 
This vignette describes an incident in which the medical response includes: pre-
hospital haemorrhage control and resuscitation by a trained first aider; the early 
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arrival of a helicopter borne medical team with blood on board; pre-hospital 
triage with the most severely injured transported to specialised trauma centres; 
early treatment with Massive Transfusion Protocols (MTP) and operational 
response by the blood service. In 2003, this co-ordinated response could not 
have taken place within either military or civilian practice.   
 
The lessons identified from the US and UK military casualties in Iraq, from 
2003, appear to have led to a ‘revolution’ in modern military and civilian trauma 
care which includes a revised role for blood transfusion.4 This thesis explores 
that journey of how military transfusion has developed during the last decade 




Massive haemorrhage is the leading cause of preventable death following 
trauma.5;6 The mortality rate is high unless actively managed from the point of 
wounding or injury.  During the last decade (2006-2016) the advances in 
military medicine, including preventative measures, appear to have delivered 
extraordinary survival advantages.7;8  These findings are welcome but not 
surprising.  History has taught us that conflict is a powerful stimulus to 
innovation, especially in trauma medicine.  DeBakey proposed that ‘rapid 
progress in trauma care occurs when the results of translational research are 
promptly integrated into clinical practice.9  Experience with a high volume of 
severely injured casualties expedites the process’.  Historically, these 
conditions converge during times of conflict.10  
 
The early experience from recent operations in Iraq from 2003 onwards had 
identified that haemorrhage was the cause of death of many ‘survivable 
casualties’.11 Urgent action was required.  The UK response was crystallised 
in an internal report issued by the Director General of the Army Medical 
Services (UK) in August 2004. The report was entitled ‘Increasing surviving on 
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the battlefield’. It called for new programs focused on advances in  pre-
hospital care to provide ‘tools’ to the frontline soldier.  The management of life-
threatening haemorrhage was prioritised over and above the traditional ABC 
of resuscitation, i.e. Airways, Breathing, and Circulation.  The new paradigm 
became <C>ABC where the C represented catastrophic haemorrhage.  A 
‘ladder of haemorrhage control’ was developed starting with a pressure 
dressing and elevation and then progressing with new haemostatic 
dressings,12 tourniquets,13  injectable haemostatic agents and surgery. See 
Figure 1.  
 
 
Figure 1.  Ladder of haemorrhage control (Adapted from Mallison, 2011)14  
 
Damage control surgery 
 
The definitive management of physical haemorrhage in combat is Damage 
Control Surgery (DCS).  The term ‘Damage Control’ was first adapted by 
Rotondo and Schwab in 1993.15  The concept was taken from the United 
States Navy who initially used the term as “the capacity of a ship to absorb 
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damage and maintain mission integrity”. Articles on the damage control 
sequence were available from the mid-1990s16.  In summary, DCS limits the 
immediate surgical interventions in severely injured trauma patients to those 
that address life-threatening injuries such as haemorrhage.  Further surgery is 
deferred until metabolic and physiological derangements have been 
addressed.  These derangements included the ‘lethal triad’ of hypothermia, 
acidosis and coagulopathy which had long been recognised as a significant 
cause of death in patients with traumatic injuries. In 1982, a study described a 
“bloody vicious cycle” in which haemorrhage together with tissue injury cause 
this predictable triad of complicating factors.17  Resuscitation had focused on 
the rapid reversal of acidosis and prevention of hypothermia.  However, Hess 
et al. contended in their 2006 review, that the direct treatment of coagulopathy 
was relatively neglected.10  The coagulopathy following trauma was then seen 
largely as a byproduct of resuscitation, haemodilution, hypothermia and 
delays by blood banking logistics.  Other contributions included consumption 
caused by disseminated intravascular coagulation (DIC) and platelet 
dysfunction caused by colloids used for resuscitation.18  A greater 
understanding was required of the epidemiology and underlying 
pathophysiology of trauma induced coagulopathy (TIC) if the problem was to 
be successfully addressed.   
 
Trauma induced coagulopathy  
 
During the early 2000s, the historic view of the lethal triad was being replaced 
by epidemiologic and molecular evidence for a distinct syndrome of trauma-
associated coagulopathy or physiological bleeding.  The seminal work by 
Brohi et al. 200319 in London,  described the phenomenon that one third of 
civilian trauma patients had abnormal clotting on admission to hospital.  The 
coagulopathy appeared to be an independent marker of morbidity and 
mortality. The findings from London were subsequently confirmed by studies 
from the USA20 and Germany21.  The cause of the early coagulopathy was 
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thought to be due to an intrinsic response to tissue damage.  Evolving work 
from Brohi22 introduced the concept of an Acute Coagulopathy of Trauma-
Shock (ACoTS) in which hyperfibrinolysis, activation of protein C and up-
regulation of thrombomodulin pathways all contributed significantly to this 
early coagulopathy. This process, as well as endothelial activation and 
subsequent coagulation changes, was thought to be mediated by 
hypoperfusion and tissue hypoxia. The term TIC has increasingly replaced the 
term ACoTS. 23 Figure 2 depicts the various inter-related contributions to this 
evolving concept and the implications for potential management.  The 
concepts underpinned the subsequent development of ‘an integrated and 
coherent pre-hospital shock resuscitation plan that addressed the 
intravascular treatment of coagulopathy’.24   
 
Figure 2. Diagram showing some of mechanisms leading to coagulopathy in 
the injured. TIC = Trauma Induced Coagulopathy.  




The goals of shock resuscitation had been to restore blood pressure and urine 
output to reverse the metabolic consequences of hypoperfusion. Pre-hospital 
trauma life support and advanced trauma life support early resuscitation 
practice was based on using crystalloid and colloid solutions.  However, 
aggressive crystalloid based resuscitation may worsen the presenting acidosis 
and coagulopathy as well as increase acute respiratory distress syndrome 
(ARDS), abdominal compartment syndrome, systemic inflammatory response 
syndrome (SIRS) and multiple organ failure.24  The revised aim was to 
minimise the use of crystalloid and to accept hypotensive resuscitation for the 
first hour.25 Holcomb and others argued that where feasible, blood 
components should be used early in the resuscitation phases instead of 
crystalloids.26  Plasma provides intravascular volume, buffering capacity and 
clotting factors. However, there is evidence that plasma based resuscitation 
does not correct conventional laboratory coagulation tests.27;28  It may be that 
the protective effect of plasma is due to its ability to restore the endothelial 
glycocalyx and syndecan-1, which plays an important role in maintaining 
vascular stability.29 30  Whatever the mechanism, recent animal studies 
endorse the biologically plausible approach of haemostatic resuscitation.31 
 
The emerging concept of Haemostatic Resuscitation using blood components 
was directly at odds with the prevailing civilian transfusion practice.32 The 
reason for this was twofold, firstly that blood is often in short supply and 
second, blood as a biological material is associated with adverse effects, 
including infection. The historic and recent scandals of infected blood products 
were well known to both physicians and politicians. Recent evidence had 
demonstrated that red cells could be safely withheld in the haemodynamically 
stable patient.33  Civilian guidelines for transfusion within the UK and most 
other countries had moved towards a more conservative and cautious 
approach focussed on minimising, rather than appropriate, blood use.  The 
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appropriate use of blood was formalised within the UK as ‘Better Blood 
Transfusion’,34 which was the forerunner of the subsequent Patient Blood 
Management (PBM) movement.35   
 
Changing newly established practice back to transfusion led resuscitation 
would require evidence and endorsement from blood services. Creating the 
evidence base for change would be a challenge.  Massive transfusion was 
uncommon (1-2%) in civilian trauma practice making it difficult to develop and 
test new management concepts.36  However, recent military practice offered a 
unique opportunity to inform a change in practice with quality, prospectively 
collected data.  For the first time in UK and US warfare, data for all admitted 
trauma casualties were entered into a joint theatre trauma registry (JTTR).37  
Using a retrospective review of the US JTTR data, Holcomb demonstrated 
that 5-7% of US combat casualties required massive transfusion, i.e.10 or 
more units of red cells.  In addition, the early evidence, subsequently 
published from Borgman et al., suggested that early transfusion with plasma 
and platelets saved lives.24 Borgman’s retrospective analysis of 246 patients 
showed that the overall mortality rate was 19% when a high ratio (1:1.4) of 
plasma to red cells was used in contrast to a mortality rate of 65% when the 
plasma to RCC ratio was low at 1:8.  As a result, Holcomb and others 
proposed a radically different approach to resuscitation for the critically injured 
based on a pre-emptive plasma rich MTP.24   
 
Global massive transfusion practice 
 
Massive transfusion was traditionally defined as the transfusion of ten or more 
units of red cells in less than 24 hr.38  The definition is historic and is intended 
to represent the replacement of an average adult blood volume.  The author 
suggests that it existed in part, due to practical clinical and laboratory 
accounting practice.  The use of fluids in resuscitation practice had 
traditionally been sequential. Most massively transfused patients were initially 
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treated with crystalloid and colloids followed by red cells. The use of plasma 
and haemostatic components were prescribed once coagulopathy had been 
confirmed.32;39  In 2005, Malone et al. reviewed massive transfusion practice 
around the globe.38   Most of the protocols were from within the US.  Mention 
is made of protocols  obtained from Canada, France,40;41 Finland and the 
UK.39 It is  probable that this list was based on researchers and practitioners 
known to the researchers and was not comprehensive.   Despite this 
limitation, the conclusions were valuable.   
 
Malone et al. proposed a pragmatic MTP based on a simple 1:1:1 ratio of red 
blood cells (RBC): plasma: platelets.38 The practicalities for such protocols 
were defined by the different local platelets preparation.  For instance, the 
apheresis pack in the US provided the equivalent of a pool of 6-11 buffy coat 
derived platelets, whereas other countries such as the UK were using pools of 
4-5 buffy coats.  The details of the transfusion protocol were important.  For 
instance, if platelets were not given until after the RBC and plasma, they 
recognised that the 1:1:1 balanced ratio may not be achieved until about 20 
units of RBC had been given. There was a risk of dilutional coagulopathy due 
to the use of RBC, as demonstrated by Seppo Hiippala.42 These early works 
refer to the dilution of coagulation factors and fibrinogen following total blood 
volume replacements.  However, more recent mathematical work by 
Hirshberg and colleagues had shown that initial resuscitation with as little as 
five or more units of RBC led to dilutional coagulopathy.43  Smaller ‘Acute 
Transfusion Packages’ (ATP) would be required.  
 
A commentary paper by Holcomb in 2007 24 described an MTP based on 6 
units of plasma, 6 units of packed RBCs, 6 packs of platelets and 10 units of 
cryoprecipitate, each stored in individual coolers.  The protocol was similar to 
the Copenhagen concept in which the transfusion protocols were combined 
with ongoing monitoring during surgery and the post-operative phase.44 A 
paradigm shift was required in which plasma, platelets and cryoprecipitate 
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would be used proactively.  In addition, military practitioners were successfully 
using fresh whole blood (FWB)45 as an adjunct to component therapy. It is 
noted that this was a controversial practice but FWB provided fresh red cells 
and platelets and delivered good results.  The underpinning theory was that 
protocols that reduced coagulopathy through restoration of an intact 
coagulation system should reduce overall blood use46 and improve survival.47 
 
UK Massive transfusion policy 
 
The UK policy for the management of massive haemorrhage on operations 
was developed during 2006 and first issued as a UK military Surgeon 
General’s Operational Policy Letter (SGPL) in July 2007.  Further editions 
were released to incorporate pharmaceutical adjuncts such as tranexamic 
acid.48;49  The policy maker’s challenge was to agree on a simple, safe and 
standardised protocol based on opinion and emerging practice rather than 
high-grade evidence.  The policy provided a brief rationale for the proactive 
use of blood and a new MTP. The policy recognised the limitation of the 
prevailing definition of massive transfusion, such as 10 units of RBC in 24 
hr.38  Therefore, it incorporated more practical criteria for the initiation of 
transfusion support based on rates of blood loss, mechanism of wounding, 
and physiology to identify the casualty at risk.  The key elements of the 
military policy, including the definitions and principles, are shown in Box 1. 
Close monitoring was required to optimise transfusion support and to 
minimise the potential complications.  
 
Practicalities.  The MTP was designed to be initiated by clinical staff who were 
concerned that the patient has had, or may be at risk, from the effects of 
massive or rapid haemorrhage.  Ordinarily, this was the medically qualified 
trauma team leader.  However, any hospital based triage officer or pre-
hospital teams could trigger the request. Speed, security and systems were 
essential.  Roles were assigned, as per updated Advanced Trauma Life 
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Support (ATLS) algorithms to staff members with the appropriate expertise, 
e.g. anaesthesiology for securing airway, emergency medicine for intravenous 
access. A new development was the redeployment of laboratory staff to the 
Emergency Department (ED)50  to receive baseline blood samples and to 
hand over the ‘Shock pack’.  The Shock Pack was 4 units each of Group O 
RhD negative red cells and thawed Group AB Fresh Frozen Plasma (FFP).  
Later, this practice was modified to deliver mini-Shock Packs of 2+2, 
especially for small patients and pre-hospital work.  Blood components were 
initially released as ‘universal’ blood, i.e. group O RhD negative RBC and 
group AB FFP. The red cells were issued as less than 14 days old to minimise 
the risk of the red cell storage lesion. 51 This had a considerable implication for 
managing the supply chain. 52 53 
 
   













Box 1. Key elements of military massive transfusion policy 
Definitions: Massive transfusion was defined as: 
1. The replacement of an equivalent amount of blood to an entire circulating blood volume of the 
patient with 24 h; or 
2. Administration of more than 10 units of red cell concentrate within 24 h (whichever comes first). 
Criteria: In the acute military operational setting, additional criteria include: 
1. The transfusion of over 4 units of red cells in 1 h; or 
2. The replacement of 50% of the total blood volume in 3h; or 
3. A rate of loss of >150mLmin−1. 
 
Principles of the Defence Medical Services (DMS) Operational Massive Transfusion Protocol 
The DMS operational MTP adopted an aggressive resuscitation approach in which the primary aim is to  
avoid a significant degree of coagulopathy. This approach required: 
1. Active avoidance of hypothermia using fluid warmers and rapid infusion devices. 
2. Maintain the haematocrit at 35%. 
3. Use of FFP to RCC in a 1:1 ratio as soon as practicable. 
4. Early use of cryoprecipitate to maintain the level of fibrinogen above 1.0 g L−1. 
5. Early intervention with platelet support to maintain the platelet count above 100 × 109 L−1.   
6. Frequent measurement of FBC and coagulation studies to confirm successful application of the 
MTP. 
7. Frequent measurement of potassium and calcium levels to identify the development or presence 
of hyperkalaemia or hypocalcaemia so that appropriate therapy can be started. 
8. Appropriate intervention with rFVIIa in accordance with current military guidelines. 
9. Regular assessments of the base deficit to monitor, along with hypothermia and coagulopathy, 
the lethal triad associated with massive trauma. 
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An overview of the staged approach to the delivery of the UK MTP is shown in 
Figure 3.  The UK protocol did not include platelets (PLT) or a source of 
fibrinogen in the initial pack, in contrast to the emerging military24 and civilian 
protocols.24 54-56  This was due in part to a perceived need to carefully manage 
scarce resources as there was limited access to these components.  This 
staged approach was consistent with the Canadian National Advisory 
Committee on Blood and Blood Products – Massive Transfusion Consensus 
Conference 2011.57   The evidence at the time for the use of a 1:1:1 RBC: 
FFP: PLT protocol was limited to retrospective and historical case-control 
series with no prospective randomised trials addressing ratio-based blood 
support. The influential consensus argued that the published data exhibited 
potential survivorship bias and the poor generalisability of single site studies.  
 
 
Figure 3.  An overview of the Massive Transfusion Protocol.   
Adapted from JSP 999.49 
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The counter argument for a phased use of haemostatic components was the 
developing evidence base for the role of fibrinogen in major haemorrhage.  
Fibrinogen levels fall following traumatic haemorrhage.  The CRYOSTAT 
study showed that the mean blood fibrinogen level in all trauma patients at 
admission was 1.55 g/L.58  Further resuscitation may dilute this.42  A 
prospective observational study of 517 patients had reported that admission 
fibrinogen levels are an independent predictor of mortality in trauma patients.  
There was a good rationale for fibrinogen replacement using either 
cryoprecipitate or fibrinogen.59 Recent guidelines60-62 recommend that if 
fibrinogen remains low (<1.5 g/l) despite the use of plasma, then 
cryoprecipitate or fibrinogen concentrate should be administered.  In 
summary, the UK approach started with a foundation ratio of red cells and 
plasma followed by individualised or ‘goal directed therapy’ guided by 
coagulation monitoring.  However, during the study period of this thesis there 
was an increasing trend for the inclusion of platelets and cryoprecipitate 




Goal directed therapy required diagnostic support to guide the use of blood 
components, especially the use of platelets and cryoprecipitate. In 2006, the 
UK Field Hospital laboratory could only provide the conventional coagulation 
tests and did not have access to the whole blood Viscoelastic Haemostatic 
Assays (VHA) used in civilian practice.56  The available conventional 
coagulation tests were the Activated Partial Thromboplastin Time (APTT), the 
Prothrombin Time (PT) and the fibrinogen assay.  However, these tests were 
designed to diagnose factor deficiencies and have limitations when used for 
guiding treatment in acquired coagulopathies such as TIC.63  In contrast, 
VHAs determine the functional coagulation status of whole blood.  The 
relative contribution of fibrinogen and platelets to clot strength can be tested 
through the use of specific inhibitors.  The viscoelastic properties of unspun 
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whole blood samples are recorded under low shear conditions and can be 
displayed as a visual profile of clot formation and breakdown over time.  VHAs 
may be performed as a point of care test to provide clinically relevant 
information at 5-10 minutes.  The tests have traditionally been used in major 
surgery leading to massive transfusion (MT) but are currently not approved in 
the UK for routine use in trauma.64 Further guidance is required for trauma.  
The currently recruiting iTACTIC trial is a randomised controlled trial designed 
to compare VHA guided resuscitation versus optimised conventional 




Factor Seven.  The new UK military massive haemorrhage policy in 2007 
introduced the use of activated recombinant Factor Seven (rFVIIa).  rFVIIa is 
a manufactured version of Factor VIIa and is licensed to control bleeding in 
patients with haemophilia and those with clotting factor inhibitors. The drug 
was also available off-licence for the use of acquired coagulopathy.   A 
multicentre randomised controlled trial (RCT) had examined the efficacy of 
rFVIIa,65 and found that treatment with rFVIIa in blunt trauma produced a 
significant reduction in the massive transfusion requirement of patients 
surviving for more than 48 hours. The first recorded UK military use of the 
drug was described in 2005.66 UK military guidance for use was provided in 
200767 and the drug was incorporated into policy.  Recombinant FVIIa was to 
be considered only after first line therapy had failed.  When used, it was to be 
given alongside haemostatic substrate and normalisation of physiology 
including core temperature. Later, a Cochrane review concluded that the use 
of rFVIIa as a haemostatic drug remained unproven.68 In addition, Levi et al.69 
reviewed the safety of rFVIIa and found an increased rate of arterial 
thromboembolism, which increased with patient age.  In practice, the drug 
was rarely used in military hospital practice after the development of the 
 32
military Massive Transfusion Capability and the evolution of Damage Control 
Resuscitation.  
 
Tranexamic acid.  Tranexamic acid (TXA) had long been shown to reduce 
blood loss in surgery without the risk of thrombotic complications.70  Renewed 
interest and experience in civilian practice had led to early informal adoption of 
TXA within battlefield resuscitation.71  However, it was the CRASH-2 trial,72 a 
huge global randomised controlled trial, that led to the wider adoption of TXA.  
The findings of the trial showed that TXA safely reduced the risk of death in 
bleeding trauma patients and that the all-cause mortality was reduced.  
However, the risk of death from bleeding was reduced by a modest 0.8%.  
Further sub-analysis of the CRASH data suggests that it was the early use of 
TXA, within 3hr, which delivers benefit. 73  Despite some reservations about 
the CRASH study there was emerging evidence for the use of TXA in combat 
related haemorrhage. The MATTERs study published in 2012 demonstrated 
the synergistic effects of TXA and fibrinogen in military practice.74  TXA was 
added to the MTP within the Clinical Guidelines for Operations (CGOs)49 and 
a supportive commentary was provided by the North Atlantic Treaty 
Organization (NATO) Blood Advisory Team.75   
 
Damage control resuscitation 
 
The concept of Damage control resuscitation (DCR) was formally introduced 
into the UK Defence Medical Services in 2007 to draw the range of advances 
in pre-hospital and hospital-based trauma care together into a coherent 
doctrine. 25  DCR was developed with a similar goal to that of DCS, i.e. to 
prioritise those interventions that address life-threatening bleeding and restore 
normal physiology. The authors note that the concept can also be used as a 
tool to assist military planning as in the tactical lay down of medical assets. 
The recognised framework for medical planning is the NATO 10-1-2 treatment 
timelines.76 In summary, enhanced first aid should be delivered within 10 min 
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of wounding with access to DCR within 1 hour.  Damage control surgery 
should be provided no later than 2 hours from wounding. 
 
The UK definition of DCR was ‘a systematic approach to major trauma 
combining the catastrophic bleeding, airway breathing and circulation 
(<C>ABC) paradigm with a series of clinical techniques from point of 
wounding to definitive treatment to minimise blood loss, maximise tissue 
oxygenation and optimise outcome’.25  It should be noted that this definition 
differed from the US military definition in which DCR starts from arrival in the 
ED and continues through to the Intensive Treatment Unit (ITU).24  The US 
definition continues to exclude pre-hospital interventions.  It is perhaps this 
definition which subsequently led to the perceived need for a ‘Remote’ or pre-
hospital DCR.  The haemostatic elements of the mature UK doctrine of DCR 
included: 
 Haemorrhage control techniques from the point of wounding  
 Battlefield Advanced Trauma Life Systems interventions 
 Advanced in-flight intervention by a primary retrieval team which later 
included the administration of blood and plasma 
 Consultant-based trauma team at the field hospital 
 An aggressive approach to coagulopathy, hypothermia and acidosis 
using early blood component support referred to as haemostatic 
resuscitation 
 Diagnostic imaging support 
 Damage control surgery  
 
Changing Injury Patterns.  In 2006, the mechanism of injury was largely 
ballistic.  By 2010 this had changed to blast trauma with a more proximal 
injury pattern. The signature injury became bilateral high transfemoral 
amputations and associated pelvic and perineal injury. This small cohort of 
critically injured patients required extraordinary surgery and massive 
resuscitative effort.  77  Whereas the concepts of DCR and DCS were initially 
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described as separate activities in a linear sequence of resuscitation, surgery 
and critical care, the elements were increasingly combined.  Midwinter and 
Woolley elegantly described the emergence of integrated DCR/DCS shown in 
figure 4.78 The speed of translation from theory to practice was extraordinary - 
Battlefield Medicine was ‘Transforming in Contact’ and would require 
considerable support from the transfusion community. 
 
Figure 4.  The evolution of damage control resuscitation adapted from 
Midwinter and Woolley 2011 78 
 
1.2 Developing the British military Massive Transfusion Capability  
 
The Massive Transfusion Capability 
 
Introduction. The Massive Transfusion Capability (MTC) was the wider defence 
programme developed in response to both the new haemorrhage policy and the 
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requirement for a greater transfusion capacity and capability. Capability is 
defined as the combination of equipment, trained personnel and support that 
gives the armed forces the capacity to achieve the tasks they are given.79  The 
purpose of the MTC was to deliver transfusion support, as an integrated part of 
resuscitation, delivered as far forward as possible.  The programme was co-
ordinated within the Defence Medical Services (DMS) 
 
Organisation of military healthcare. The organisation of military medical support 
is important for understanding the delivery of haemorrhage control and 
transfusion-based resuscitation. The organisational framework provides the 
context for the introduction of the MTC and the subsequent developments in 
pre-hospital transfusion.  The care of the patient outside of the UK is termed the 
operational care pathway.  Care is organised in echelons or roles with 
increasing medical capability.  Current NATO doctrine recognises 4 roles from 
the basic first medical treatment facility (MTF) to the sophisticated home base 
hospitals.76   The details for each Role are provided in Appendix 1.  The focus 
for this section is the Role 3 field hospital whereas the next section is focused 
on Roles 1 and 2. 
 
Transfusion logistics.  The supply of blood for the armed forces within this 
framework may be a function within logistic or medical commands. It is a 
considerable logistic challenge to deliver short shelf-life products with 
demanding storage criteria within a military ‘Line of Communication’.  
Therefore, blood supply and distribution has historically been the role of 
specialised units.  In the UK, both models of command have been used, 
however, during the period of study, transfusion was a defence logistics 
responsibility. Organisational restructuring had led to the creation of the 
Medical Supplies Integrated Project Team (Med S IPT) on 1 April 2005. The 
Blood Supply Team (BST), a sub-unit comprising of 3 biomedical scientists 
(BMS), was established in Birmingham. The team was charged with the co-
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ordination of global military blood supply compliant with the new European 
Directive.80  
 
Regulatory framework.  The assumptions underpinning the capability 
recognised the new transfusion regulatory framework and the need for 
appropriate clinical use of blood (Doughty and Walker, internal briefing 
papers).  The European Directive 2002/98/EC81  set standards of quality and 
safety for the collection, testing, processing, storage and distribution of blood. 
Directive 2004/33/EC82 provided further technical guidance and required 
member states to bring into force the necessary laws, regulations and 
administrative provisions by 8 February 2005.  The UK Blood Safety and 
Quality Regulations 2005 (BSQR)83 were laid before Parliament on 18th 
January.  The regulations designated the Medicines and Healthcare 
Regulatory Authority (MHRA) as the competent authority.  Designated Blood 
Establishments were authorised to collect, test, manufacture and distribute 
blood.  BST was to hold limited Blood Establishment status for blood 
distribution and storage. However, blood collection and military donor testing 
was contracted out to the civilian English blood service, NHS Blood and 
Transplant (NHSBT).  Blood components from Birmingham were shipped 
using the military assets and logistics chain.  The principle framework for 
blood component specifications are the Guidelines for the UK Blood 
Transfusion Services.84  Blood components were sourced from other 
countries, agencies and field programmes as required.  An overview of the 
transfusion process from the donor to the hospital is shown in Appendix 2. 
 
Delivery of the MTC programme.   
 
Defence Lines of Development. The MTC was an extraordinarily ambitious 
programme which covered many aspects of the logistics, laboratory and 
clinical capability.  An overview is outlined in Appendix 3.  The main MTC was 
delivered from 2010 within the framework of Defence Lines of Development 
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(DLOD).85 The British Ministry of Defence’s (MoD) DLOD is an example of a 
best-practice paradigms or frameworks where the interlinking functions and 
activities of the enterprise may be defined. A capability is typically managed 
and assessed using several dimensions or integrative elements.86  In addition, 
the UK Defence Medical Services (DMS) cites Interoperability and Clinical as 
overarching themes that must be considered when any DLOD is being 
addressed.  Such frameworks can take time to deliver as each dimension is 
developed by subject matter experts before integration. An overview of the 
key developments in military transfusion is shown in Appendix 3. 
 
Urgent Operational Requirements.  Several transfusion developments had 
started before the MTC as separate Urgent Operational Requirements 
(UORs).  Urgent Operational Requirement (UOR) is a system used by the 
British MoD to obtain urgent equipment for operations. UORs arise from the 
identification of previously un-provisioned and emerging capability gaps where 
there is increased urgency to bring the capability into service.87  The timeline 
for the key individual elements that were delivered rapidly as UORs were: 
operational platelet apheresis (2008), new transport and storage boxes based 
on phase change material (2008), a Laboratory Information Management 
System (2009) and the introduction of Rotational Thromboelastometry 
(ROTEM) (2009). The MTC programme continued through to October 2013. 
Some of the other elements in this program, especially the laboratory 
modernisation items were delivered as part of a later project.   
 
Concept of Employment.  The ‘Concept of Employment’ for the Massive 
Transfusion capability was described as 4 sub-capabilities that together 
delivered the Massive Transfusion Capability.  These are listed below and 
considered in turn:  
a) Blood product transport and storage 
b) Blood product delivery, including blood warmers and rapid infusers.  
c) Blood testing: Laboratory and Near Patient Testing,  
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d) Blood product generation including platelet apheresis and microbiology 
testing 
 
Table 1   An overview of the recent developments in military transfusion 
practice 
Year Month Development Notes Ref 
2007  Massive Haemorrhage Policy Including the Massive 
Transfusion Protocol. Updated in 
2009. 
48 
2007 May Regular supply of platelets 
from the UK 
Validation of phase change 
material technology 
 
2008 April Operational platelet apheresis Generation of platelets in plasma 53 
2008 June Blood for helicopter based 
Medical Emergency Response 
Team 
Use of Golden Hour Box 88 
2009 May Expansion of Emergency 
Donor Panel 
Resilience measure for 
Pandemic Flu 
 
2009 June LIMS (Laboratory Information 
Management System) 
Blood component issue and 
accounting  
53 
2009 Jan ROTEM (Rotational 
Thromboelastometry 
Point of Care Test for 
haemostasis 
89;90 
2009 Jan Evaluation of point of care 
testing for Blood Borne Viruses 
Commissioned civilian evaluation  
2009 Jul Role 2 Transfusion policy Designed initially for the Navy  
2010  Paediatric transfusion 
guidelines 
Clinical Guidance for Operations 
and training 
91 
2011 Jan Lyoplas-N Lyophilised plasma 92 
2011 Nov Defence Medical Services 
Transfusion Committee 
Reports to DMS Clinical 
Committee 
 




Blood product transport and storage 
 
Cold chain management. Blood components are a valuable temperature-
sensitive licensed resource that requires carefully controlled and monitored 
transport and storage.83 A summary of the storage requirements and shelf-life 
is shown in Table 2.   All storage equipment is calibrated, maintained and 
temperature mapped in accordance with Blood Safety and Quality Regulations 
200583 and the Guidelines for the Blood Transfusion Services in the United 
Kingdom.84   
 





Post reconstitution or 
post-thaw shelf-life 
Whole Blood           
(in CPD-A) 
4oC + 2 28 days NA 
Red cells 4oC + 2 
35 days (can be 







1-day 4oC + 2 
5 days if dry thawed 






24 hr at room 
temperature.  Do not 
refrigerate. 
Platelets 
22oC + 2 (with 
agitation) 
5 days 
7 days with bacterial 
testing or pathogen 
inactivation 
 
Phase change material.  One of the most significant advances in cold chain 
capability was the introduction of a new generation of passive transport 
containers which could maintain temperature without power.53  These were 
sealed containers consisting of a fabric outer case and a vacuum insulated 
chamber with an inner, removable thermal isolation compartment. The product 
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used was the Golden Hour Box® (GHB) (Minnesota sciences and Credo) 
which offered products with a range of both sizes and temperature range. The 
two litre model selected for the Medical Emergency Response Team (MERT) 
maintained storage temperatures of 2-8°C for up to 72 hours in external 
temperatures of 45°C. The storage temperature was continuously monitored 
using the TempIT® tag, temperature indicator together with single-use time-
temperature indicators WarmMark® and ColdMark®.  The platelet version of 
the box was introduced to maintain a similar temperature control chain but 
optimised at 22oC (+/- 2).  
 
Op Vampire. The new capability revolutionised the transport and storage of 
blood components and enabled blood to be projected as part of the airborne 
capabilities and later for ground based troops.94  However, the need to 
recondition the thermal isolation compartment in freezers tied the forward 
units to the field hospital.88  The GHBs were used for the pre-hospital delivery 
of blood and plasma for the UK enhanced Medical Emergency Response 
Team (MERT) co-located with the Field Hospital.  The MERT is a multi-
disciplinary advanced medical retrieval team working in the back of a Chinook 
helicopter. Pre-hospital transfusion was considered for patients without a 
palpable radial pulse or who had a non-invasive systolic blood pressure of 
less than 80mmHg. The aim was to restore these parameters, rather than to 
resuscitate to normotension, unless a traumatic brain injury was suspected, or 
time to definitive care was anticipated to exceed one hour. If more than one 
unit of RBC was required, plasma was co-administered, to achieve a ratio of 
1:1. A loading dose of 1g of tranexamic acid (TXA) was given to all transfused 
patients. A fuller description of the organisation and capability is provided in 
paper 2 of this thesis.  The call for MERT blood was affectionately termed Op 
VAMPIRE.  The call led to the rapid issue of blood from the laboratory directly 
to the MERT team and also alerted hospital staff that critically ill patients 
would be arriving soon.   
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Blood Product Delivery  
 
Blood warmers and rapid infusers.  Critically ill patients were being delivered 
alive to the hospital.  Many were hypovolaemic and hypothermic despite the 
extraordinary efforts of the pre-hospital team.  Traditional pressure infusion 
devices exert pressure through the inflation of a bag in which a blood product 
bag has been placed.  They have the advantages of being lightweight, easily 
stowed and manual rather than electronic.  However, they do not warm blood 
products or deliver specified volumes, or deliver at the speeds required to 
resuscitate the severely hypovolemic patient, whereas, modern rapid infusers 
can support the rapid replacement of blood products and simultaneously warm 
blood products from a low initial temperature (4°C) to 37.5°C.  In addition, any 
such system should be able to maintain a high flow rate without either 
inadvertently introducing cold fluid or air embolism.  The Belmont FMS 2000® 
Rapid Infuser System was selected with use of the 3.0 litre reservoir or 
‘Bucket’.  The use of this reservoir enabled red cells and thawed FFP to be 
pre-mixed in a 1:1 ratio.  The resulting mixture was fondly referred to as 
‘Bastion Pink’.  The Belmont could deliver controlled flow rates of up to 
750mls/min of fluid at 37oC and was brought into service in November 2011.   
 
Other initiatives.  Other initiatives included a feasibility study of Intra-operative 
cell salvage (IOBS).  In November 2011, a small study demonstrated the 
feasibility of IOBS in a military field hospital within the combat environment.95  
However, the red cell savings were modest at the cost of logistic burden. A 
paediatric massive haemorrhage protocol was  published in 2010.91  The 
paediatric workload in the military environment during recent conflicts was 
estimated at 4% during Op TELIC (Iraq) and 8% for Op HERRICK 
(Afghanistan).91 The figure for admissions to US Combat Support Hospitals 
(CASH) was 10%.96  The military Massive Transfusion Policy was adult-based 
and needed to be translated for paediatric practice.   
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Blood testing: Laboratory and Near Patient Testing 
 
Close monitoring was essential to guide transfusion therapy and minimise the 
potential complications of rapid and massive transfusion.  Pathology 
monitoring may be via the laboratory or using Point of Care Testing (PoCT).  
PoCT supports rapid clinical decision-making but requires a quality framework 
and good record keeping.   
 
Electrolyte disturbance.  The two most significant biochemical disturbances 
complicating massive transfusion are hyperkalaemia and hypocalcaemia.  
Hyperkalaemia during massive transfusion is not uncommon and may prove 
fatal.97  Postulated mechanisms include shock, older stored RBC, mechanical 
cell lysis due to high flow pressure bag type infusers, cell damage from blast, 
dehydration and massive fluid shifts from rapid whole-body reperfusion.   
Donated blood is collected in a citrate containing anticoagulant which chelates 
both ionised calcium98 and magnesium.53  Rapid transfusion of citrate may 
overcome the liver’s ability to metabolise citrate with resulting citrate toxicity.  
Hypocalcaemia may cause death99  due to a decrease in cardiac contractility 
and a predisposition to arrhythmia.100  Calcium is also critical for coagulation, 
and platelet activity.101  
 
Coagulation.   ‘Goal directed therapy’ to guide component use followed the 
initial pre-designated Shock packs. The challenge was whether to use 
standard laboratory diagnostic testing or to re-explore visco-elastic 
methodology.  One of the drivers for introduction of VHA technology was that 
appropriate blood component use should reduce the demand.47 ROTEM® was 
deployed to Afghanistan as a field trial in 2009 to determine its usefulness and 
reliability.90 The investigators concluded that the machine was robust enough 
to be used in a field environment, and was useful in detecting coagulopathy 
and improved outcomes.102 The field trials demonstrated that the early A5 and 
A10 values could predict hypocoagulation, with sensitivities and specificities of 
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0.98/0.69 (A5) and 0.97/0.78 (A10).89  Goal directed therapy was 
subsequently incorporated into the Military Operational Surgical Training 
(MOST) course which provided DCR team training.   
 
Blood product generation 
 
The final sub-capability of the MTC was blood product generation including 
microbiology testing for the Emergency Donor Panel (EDP). 
 
Emergency Donor Panel.  The EDP is a group of pre-screened volunteer 
donors who may be called upon at short notice to give FWB or platelets by cell 
separator (apheresis).  The process is overseen by the military Blood Supply 
Team.103  Donors are normally screened in the UK before deployment and 
managed by the deployed BMS.  The donors are re-screened and tested by 
PoCT at the time of each donation. The donation will be used before the 
results are confirmed in a reference laboratory.  Therefore, there is a 
theoretical risk of transfusion transmitted infection. The most significant risks 
to donors  in civilian practice are delayed vaso-vagal reactions and 
neurovascular injury. 104  The benefits of the EDP must be weighed against 
those risks.53  Traditionally UK donor panels were only group O, designed for 
the provision of whole blood.  However, where there is a BMS present, policy 
permits the use of all blood groups, which has the advantage of expanding the 
panel and supporting platelet apheresis.  
 
Operational platelet apheresis. The increasing numbers of casualties and the 
severity of injury in 2006 and 2007 highlighted the need for a platelet supply. 
Early collaborative work between BST and NHSBT had enabled a supply of 
fresh platelets from May 2007.  In addition, there was access to supplies from 
the US at Kandahar. However, both relied on the air bridge from Kandahar Air 
Field to Bastion. Resilience necessitated the scoping of a local supply. The 
main options considered were a frozen program based on the Dutch model105 
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or a platelet apheresis program based on the US model.106;107  At the time, 
there were no reported clinical studies from the Dutch for their frozen platelet 
programs.  Therefore, platelet apheresis was selected as the best option for 
resilience despite the potential complexity.  Apheresis was introduced by the 
3-man team including the author in both Iraq and Afghanistan, with a full 
operating capacity declared in April 2008.53  The selected platform was the 
Haemonetics MCS® which was being successfully used by the deployed 
United States (US) program.107   
 
Platelet donors.  The characteristics of the platelet donor would need to be 
slightly different from those of the whole blood donor.  The main determinant 
of the ABO blood group selection would be the plasma rather than the red cell 
group. However, there was a risk of residual red cell stroma and therefore the 
RhD, or “D” group would need to be taken into consideration.  Theoretically, 
the universal donor was blood group A RhD negative. However the 
percentage of the donor panel that was 15%.108 The EDP was expanded to 
recruit group A donors of both RhD types.  Donors were invited to give repeat 
single donations at monthly intervals. The single dose was selected to reduce 
the time required for donation.  However, in May 2009 following the threat of a 
pandemic influenza in the UK, further resilience was required.  It was met by 
the expansion of the EDP and the introduction of double platelet doses.  
 
Blood safety. Blood safety starts with careful donor selection especially when 
they are from a closed community. Infections such as gastro-intestinal and 
upper respiratory tract disease are common especially after group movement 
of personnel.  Pre-screened donors should be well at the time of donation, 
have an acceptable medical and life-style history and be vaccinated against 
hepatitis B.109  In 2009, a study was commissioned from the UK’s Health 
Protection Agency (HPA) to evaluate a commercially available method for 
donor testing in the military environment. The challenge was to find CE 
marked tests with suitable sensitivity to detect infectious disease with a very 
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low prevalence in donor blood samples. However, high sensitivity may be 
associated with low specificity and give rise to false positives.  Any positives, 
true or false positive, require very careful counselling and management when 
the donor is deployed.  DMS introduced PoCT tests for syphilis, hepatitis B 
and HIV1/2. Access to a suitable CE marked Hepatitis C kit has been more 
challenging.  Platelets stored at 22oC are at risk of bacterial growth from skin 
commensals.  Options for assuring the microbiological safety of collected 
components include pathogen inactivation and bacterial testing. Bacterial 
testing had successfully been used by the US.  The BacT/ALERT system 
(BioMerieux, Durham, N.C.) was subsequently introduced into the UK MTF at 




Transfusion safety served as a unifying clinical dimension of the MTC 
programme.  The biggest risk in transfusion is the transfusion of ABO 
incompatible blood, rather than infection.  Transfusion of the wrong blood to 
the wrong patient can result from errors made anywhere in the transfusion 
process, from blood collection through to the administration of blood.110 Errors 
can arise within both the clinical and laboratory areas.  However, despite the 
large number of components used in these recent conflicts, there were 
remarkably few events, and no patient deaths due to transfusion.  Errors can 
be prevented by training.  Individual training and assessment was based upon 
the national competence programme.111  Team training was consolidated 
through pre-deployment group training and validation.112   
 
Throughout the period of study there was only one reported incident of 
incorrect blood transfused.  As a consequence, further patient safety 
measures was initiated in 2012 to further reduce the risk of error.  These 
included the establishment of a Defence Medical Services Transfusion 
Committee (DMSTC); formalisation of training requirements including access 
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to a national e-learning package,113 a transfusion aide-memoire49 and local 
clinical standard operating procedures (SOPs). Transfusion serious adverse 
event (SAE) reporting was computerised as part of the new defence electronic 
event reporting system in 2012.   Most events reported were minor and near 
misses, related to process rather than transfusion reactions or clinical events.  
A new CGO was introduced in 201349 to reflect recently issued national 
guidance for the recognition and management of Acute Transfusion Reactions 
(ATR).114  The number of transfusion events per annum fell from an estimated 
1 per 1900 components transfused in 2012, to 1 per 3625 in 2013.115    
 
The impact of the Massive Transfusion Capability 
 
Clinical impact.  The capability was designed to safely and swiftly deliver 
Massive Transfusion to the critically injured.  The first formal analysis of these 
clinical cases and the resources required took place during 2009. 116  During 
the 12-month period, 59 personnel received massive transfusion.  The median 
use of blood components was 45 (IQR 28.5-62) units.  Of note, seven cases 
received more than 100 units. Five of these personnel including the one that 
received 237-units, survived to be discharged from hospital.  The severity of 
the trauma was considerable with a median injury severity score (ISS) of 30 
(IQR 22.5-36) and a new ISS (NISS) of 44 (IQR 34-58.5).  Despite these 
injuries and the requirement for critical care, the overall survival was 86%.  
The Allcock paper compared the outcomes with Borgman et al., 2007117, 
McLaughlin et al., 2008118 and Perkins et al., 2007119 and demonstrated better 
survival despite higher injury severity scores.  The authors concluded that 
massive transfusion had become an integral part of combat care and that 
ultra-massive transfusion could be successfully delivered in an austere 
environment.   
 
Logistics support. The delivery of the MTC placed extraordinary demands on 
transfusion services and medical logisticians. Once the delivery systems were 
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mature, blood was packed, transported and delivered 3,500 miles within 24 
hours of request.  Operational statistics were collated monthly.  The total 
number of blood components transfused during the recent operations in 
Afghanistan is shown in Figure 5a. together with the number of boxes shipped 
by the military Blood Supply Team in the period of 2006 to 2014 (Figure 5b).  
The workload for the deployed laboratory services was considerable as they 
not only had to prepare blood for issue but also achieve a 100% traceability 
rate. The introduction of a deployed Laboratory Information Management 
System (LIMS) in 2009 together with the use of bar code readers, transformed 
the speed and accuracy of issue and accounting for large amounts of blood 
components. By 2011, the red cell used in Camp Bastion equated to that of a 
UK district general hospital but with the complexity of running a dual inventory 
with segregated US and UK components.  
 
 
Figure 5a. Total number of components transfused during 2006-2014 
RCC: Red cell concentrates, FFP: Fresh Frozen Plasma, Cryo: 
























Figure 5b. Number of boxes shipped by the Blood Supply Team during 2006-
2014.  The three temperature controlled transport systems are represented 
by: GHB for Red cells, ACE 6 for frozen, Plts for Platelet boxes 
 
1.3 Taking transfusion forward  
 
Doughty and other UK authors had proposed that military transfusion support 
should be taken further forward where appropriate and feasible.120  The 
success of the MTC at Role 3 and during en-route care had led to the 
question of whether the principles could be applied to forward damage control 
MTFs and the wider pre-hospital community.  The rationale is that the risk of 
death or permanent impairment is significantly reduced if injured or wounded 
personnel are treated as soon as possible after injury or wounding.  However, 
there remains a tension between two main approaches to early medical care; 
‘a Scoop and run’ versus ‘Stay and play’ i.e. rapid evacuation to MTFs or the 
projection of capability with the risk of delay and losing high priced assets.  An 
overview of the medical capabilities based on modular expansion together 
with the requirements for mobility is shown in figure 6. The flow of casualties 
usually follows the continuum of care.  However, MTFs may be bypassed due 




















to patients’ needs and/or the workload of MTFs. An example of this would be 
use of the helicopter response team with direct transfer from First Response 
to a Field Hospital. 
 
 
Figure 6.  The organisation of military healthcare. Figure adapted from AJP 
4.1, 2015.76  
 
Development of Role 2 transfusion 
 
The considerations for forward deployment of transfusion both on land and at 
sea include environmental control, weight, size, power, and re-supply. Some 
degree of environmental control is required for laboratory equipment and 
consumables, during both storage and transit. Equipment should be protected 
against a wide range of ambient temperatures, humidity and high levels of 
dust. Consideration must be given to a reliable power supply for automation 
and cold chain.  Examples of Role 2 units include Role 2 Light Manoeuvre 
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(LM) and the maritime equivalent, Role 2 Afloat.  The generic clinical 
requirements for forward transfusion support at Role 2 included: the early use 
of TXA; RBC holdings based on the casualty estimate and resupply; plasma; a 
source of fibrinogen; calcium and rFVIIa together with appropriate PoCT.  
Greater freedom from the logistic burden could be provided by freeze-dried or 
lyophilised products together with whole blood.120 In addition, consideration 
would be needed for resupply where appropriate.   
 
Anti-piracy operations in the mid-2000s had led to a request to revisit 
transfusion support at Role 2 Afloat. The shelf-life of red cells is 35 days and 
is therefore nearly always likely to be shorter than the planned time at sea. As 
a consequence, the resupply of red cells at sea necessitated regular trips 
ashore, removing the ship from mission.  The options were the use of an EDP, 
as used by the Norwegian during anti-piracy operations121 or exploration of re-
supply.  The feasibility of air-dropping a transfusion capability pack was 
examined by a UK group during 2012 and 2013. The pack included red cells, 
lyophilised plasma and essential equipment.  The challenge was not so much 
the mechanics of air-drop and sea-recovery, but demonstrating the integrity of 
the red cell membrane during post-drop storage for up to 35 days.   A 
literature search had identified work by the Canadians who had demonstrated 
that red cells remained intact soon after an airdrop and a forced march. 122  
However, the red cells had not been studied during the remaining shelf-life.  A 
study was required to confirm the suitability for clinical use following storage 
for at least 28 days.  A project was successfully conducted in partnership 
between Joint Air delivery and Training Evaluation Unit (JADTEU), the Blood 
Supply Team, the NHSBT and the thesis author to deliver an approved air 






Freedom from frozen  
 
Plasma and cryoprecipitate are conventionally presented as frozen 
components.  However, alternatives for plasma include liquid (never frozen) 
plasma and dried plasma.  A lyophilised fibrinogen concentrate is widely used 
in Europe. Lyophilised products promise a useful alternative to frozen 
components due to the ability to store them at ambient temperature for 1-2 
years.124 Whereas they do not need thawing, they do require reconstitution 
before use. A further disadvantage is that they are manufactured and 
presented in medicinal glass which  limits their use in the pre-hospital 
environment.92 A question is whether to use whole plasma or combinations of 
plasma fractions such as fibrinogen concentrate.   
 
Lyophilised plasma. Lyophilised plasma provides a balanced mix of clotting 
factors and fibrinogen in a volume of approximately 200ml when 
reconstituted.125;126  Commercial products vary in their clotting factors, 
solubility, donor exposures, pathogen inactivation and licencing maturity. 
However, in 2009, only LyoPlas-Nw, subsequently referred to as Lyoplas, 
made by the German Red Cross (DRK), was available for procurement.  
LyoPlas is a single donor whole plasma product, which has been fielded in 
both civilian and military German units. It is classed as an un-licenced drug in 
the UK. Lyoplas was introduced into UK service in January 2011 and the use 
was later documented in 2012.92   The Israeli Defence Force (IDF) 
implemented the use of Lyoplas soon after in 2013 but have used a much 
greater volume than the UK.  The context of use is the pre-hospital setting 
with delivery by advanced life support providers, both physicians and 
paramedics.127 The concept of operations is a plasma first policy where 
plasma is used as the initial resuscitation fluid in the critically injured. The 
valuable review of their 3-year experience in 2017128 concluded that the use of 
lyophilised plasma by trained soldiers was feasible.  However, they reported 
that there was only a 57% adherence with treatment protocols, despite the 
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training program.  In addition, they noted that the disadvantages of slow 
reconstitution in the pre-hospital environment and slow infusion progression in 
five out of the 109 cases.   
 
Further developments The French military have a much longer history of 
lyophilised plasma production.129 In addition, they have provided valuable 
contribution to the literature on the clinical use of French Lyophilised Plasma 
(FLYP) for military use 130 However, their product was developed for domestic 
military use and was not available for export until 2016.  French lyophilised 
plasma is an attractive product in that it is a pathogen inactivated, lyophilised 
product based on a mini-pool of plasma to provide a universal plasma.129 The 
US does not currently have lyophilised plasma but have worked closely with 
the French to develop a lyophilised plasma program. The development of a 
freeze dried or lyophilised plasma is now considered a developmental priority 
within NATO countries both for military and civilian emergency practice.131 132 
Lyophilised blood products in lightweight containers promise advantages in 
civilian pre-hospital practice and as a wider resilience measure in emergency 
planning.132   
 
Fibrinogen concentrate.  Fibrinogen concentrate is an alternative source of 
fibrinogen to cryoprecipitate, but it is not currently licenced for use in acquired 
coagulopathies in the UK. It is a plasma fraction which has been subject to 
pathogen inactivation and is used extensively within Europe.  Fibrinogen 
concentrate has the advantages of a pharmaceutical product and is usually 
given as an initial dose of 3 to 4 g.  There is excellent evidence for both the 
effectiveness and safety of fibrinogen concentrate.70-72  The Oxford group 
claims that current evidence does not support the superiority of fibrinogen 
over cryoprecipitate.133  It is assumed that fibrinogen supplementation of either 
source may be used together with an anti-fibrinolytic drug such as tranexamic 
acid.74  Fibrinogen concentrate was introduced into military service for Role 1 
and 2 units in 2016. 
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Factor concentrates.  Whilst there was increasing confidence in the 
rationale for the use of fibrinogen replacement, there was continued 
caution about the use of Prothrombin Complex Concentrates.  This 




Experience in Afghanistan and Iraq had enabled the DMS to refine field 
hospital transfusion support to enduring medium scale military operations. 
However, there was an increasing awareness that medical forces must be 
continually prepared for the entry phase of a military campaign. Such activities 
may require medical personnel to resuscitate and sustain patients for far 
longer than the doctrinal timeline of 2 hours.  In addition, selected medical 
personnel would continue to be required to support isolated troops as well as 
deployed conventional forces.  The variety of scenarios drove a clear 
requirement for MTF to be able to deploy at all scales of effort and 
concurrency. The delivery of transfusion support outside of the hospital 
presented challenges, chiefly relating to the logistic constraints.  Modified 
transfusion support was successfully applied to Role 2 units however they did 
not translate easily to Role 1 MTFs.  
 
The Role 1 MTF focuses on the provision of primary health care, specialised 
first aid, triage, resuscitation and stabilisation. The UK model is the use of a 
general practitioner with enhanced military medical skills. These practitioners 
must be able to sustain casualties for an extended period in isolated teams 
that frequently operate outside the NATO medical doctrine of 1 hour to a DCS 
capability.  The requirement to deliver prolonged field care led to the 
exploration of using RBC and lyophilised plasma within small mobile teams 
working both in vehicles and on foot.  Wild et al., 2013135 had described the 
equipment which enabled a Role 1 team to carry a vehicle-based blood 
capability on long-range mobility patrols.  Gohkale et al., 201692 described the 
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first use by the UK forces of LyoPlas carried and delivered by patrol medics.  
For most units, the evacuation times were short, however, increasingly Pre-
Hospital Emergency care (PHEC) needed to evolve to meet the need for 
prolonged evacuation times. 
 
The limitations of modified transfusion packages are well illustrated by the 
experiences of a UK Role 1 team published in 2016. 94 The context was a 
medical team supporting a helicopter assault force (HAF) based in southern 
Afghanistan. A Role 2 style transfusion package of tranexamic acid, red cells 
and Lyoplas was transported as a man-portable capability. During the two-
year audit, Aye Maung et al., 94 demonstrated that the Role 1 team, dislocated 
from a hospital laboratory, could maintain the cold chain required for forward 
blood products for prolonged periods. Considerable detail of the technical 
elements was included in this paper, including the use of the GHB.  The GHB 
system worked well within the austere environment; however, it was not 
designed as a man portable system.  The weight of the fully loaded box was 
4.5kg when loaded and even when carried within a modified back pack was 
both heavy and uncomfortable.  The authors concluded that a conventional 
transfusion capability at this point in the medical evacuation chain imposed a 
significant logistic, training and governance burden.  Only 2 casualties 
required transfusion during the period of audit, which suggests that carrying 
blood at Role 1 places a relatively large logistical burden for a low clinical 
output.  Alternatives to this approach included a plasma only policy as used by 
the IDF127  or the development of a whole blood programme designed for the 
pre-hospital community.136  
 
Fresh whole blood 
  
Whole blood may be the best resuscitation fluid for massive haemorrhage.137   
FWB not only addresses concerns about the red cell storage lesion, but also 
provides a supply of both fresh plasma and a small dose of platelets. Whereas 
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the use of multiple components results in higher volumes of infused 
anticoagulant during resuscitation, FWB provides a physiological replacement 
therapy with less anticoagulant.26  There is some evidence that the partial use 
of FWB, i.e. used together with components, is associated with survival 
advantage.138 Few mature civilian blood services provide FWB139 for either 
their military or civilian users.  The Bergen group in Norway is a notable 
exception and has led the way in the supply of whole blood (WB) to both 
military and civilian use.  Table 3 shows a comparison of reconstituted whole 
blood using a 1:1:1 mix of components, with a unit of whole blood, based on a 
paper from the group.140  However, this is simplistic summary and a more 
detailed appreciation of the interactions of the different components is 
required to determine the optimal storage conditions and duration for future 
whole blood preparations.  In addition, WB is initially collected into a citrate-
based anticoagulant at a volume ratio of 1:7 anticoagulant to WB.  In this 
sense, WB is already a diluted blood product from the outset.  
 
Table 3.  A comparison of reconstituted whole blood using a 1:1:1 mix of 
components with a unit of whole blood. Adapted from Murdock et al.140 























FWB collection and use developed in the latter part of World War I (1914 – 
1918).120;141 WB was the only blood product available for transfusion in the 
military and civilian settings through to the late-1960s.  However, by this time, 
the availability of plastic blood bag collection and storage systems enabled 
blood component development. The US military retained the capability and 
have considerable recent experience in the use of whole blood in combat 
conditions.  Nessen et al. have shown that the widespread collection of FWB 
from emergency donors can be done safely142 and that the risks are rare.143  
Whereas, the collection of whole blood  was increasingly deployed during the 
period of study as a resilience measure within the UK field hospitals, it has a 
greater potential to support Forward Transfusion.120 The major concern with 
the use of FWB from emergency donors is safety including the risks of 
infectious disease and ABO incompatibility. The risks can be mitigated 
through the use of pre-tested donors within an Emergency Donor Panel (EDP) 
together with a robust training in a whole blood programme designed for the 
pre-hospital community. 
 
The Trauma, Hemostasis and Oxygenation Research (THOR) Network  
 
The emerging expert collaborative for forward transfusion was the Bergen 
based Trauma, Hemostasis and Oxygenation Research (THOR) Network.  
The THOR Network is an international multidisciplinary network of civilian and 
military providers ranging from first responders and medics to critical care 
physicians, and from basic scientists to clinical trialists. THOR has promoted 
the concept of Remote Damage Control Resuscitation (RDCR) together with 
research priorities 26  RDCR is an evolving concept and the term is not yet 
accepted in UK military doctrine. The concept is further confused by the 
additional terms used by the THOR community such as remote and austere.  
The term forward is understood to mean the pre-hospital setting or phase of 
resuscitation. The use of transfusion in this environment has been well 
established with the increasing use of blood during air evacuation such as 
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MERT.88   The terms far-forward and austere can be defined as the 
environments where professional health care providers do not normally 
operate and where the basic equipment and capabilities necessary for 
resuscitation are often not available.  These are the conditions in which 
Special Forces might be operating.  The US Rangers have also used the term 
Tactical DCR.144  Whichever term is used, transfusion is traditionally not used 
in this environment.  It might be feasible but at the risk of a logistic burden.94  
Despite the apparent constraints in this environment, it is proposed that the 
concept is worth exploring because remote DCR may have application for 
many remote civilian or widely dispersed communities, as well as for disaster 
medicine.131  Developments require an academic underpinning coupled to 
translation into practice. THOR has embraced the Bergen based Blood Far 
Forward research program from Norway as an exemplar of operationally 
focussed research. 
 
Blood Far Forward 
 
The Blood Far Forward (BFF) research program was established to improve 
battlefield survival by developing a safe method for pre-hospital whole blood 
transfusions.145  The program was initiated by the Norwegian Naval Special 
Operation Command in 2010. Collaborators and participants today include: 
The department of Immunology and Transfusion Medicine at Haukeland 
University Hospital, The Norwegian Armed Forces Medical Services, 
Norwegian Special Operation Command, Norwegian Army Special Operation 
Commando and the US Army Institute of Surgical Research.  The aim of the 
program is to improve battlefield survival by developing a safe method for pre-
hospital whole blood transfusion. The three primary research strands of the 
program are 
 
1. Donor performance and safety 
2. Blood efficacy and safety 
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3. Training and educational requirements 
 
Module 1. Donor Performance and safety 
 
Donor care and performance are key considerations for command. Donor care 
emphasises not just careful donor selection but also measures taken to 
reduce the risk of adverse effects related to donation.  All care must be taken 
to minimise the risk of a second patient especially in small team work.  There 
have been few studies on extreme performance and donation; therefore, the 
studies from the BFF program are very valuable.  In one study, 25 Special 
Forces soldiers underwent Bruce Protocol treadmill stress testing, push-ups, 
pull-ups, a 50-round rapid pistol shoot and a 20kg uphill load carriage exercise 
as a baseline. The soldiers then repeated all tests two to six minutes after the 
withdrawal of 450ml of blood. No significant decrease in shooting or physical 
performance was seen.146  
 
Such studies demonstrate that blood donation can be tolerated by elite 
soldiers147 . Recent detailed studies have demonstrated that donation in fit 
civilians has a minimal effect on VO2 max and no adverse impact on cognition 
(Eliassen personal communication).  The findings are consistent with the 
recent large scale INTERVAL study designed to explore the safety of donation 
intervals.148  Both inform the safety of donation for EDPs used in both military 
and civilian practice. Donor safety is also delivered through well designed 
equipment packs.  A pack designed for RDCR blood donation has been 
developed by the BFF program.136  The Role 1 pack included all the materiel 
required for donation including PoCT.  The pack weighs 780g including a unit 
of freeze dried plasma and a small lactate analyser. A US version is described 
in Fisher’s paper on ‘Tactical’ DCR144.  The US pack now has a NATO Stock 




Module 2. Blood Efficacy and Safety   
 
The advantages of whole blood have been actively promoted by members of 
THOR137;149 and considered by others.150 151 The efficacy and characteristics 
of both warm fresh and cold stored121 whole blood have been described. The 
blood donor model in the BFF program is based both on the field blood bank 
and “buddy transfusion” where blood is collected and used immediately in the 
tactical situation.  Donor selection is key to blood safety in the context of 
RDCR. Two papers are presented in this thesis which related to this research 
strand.  One is related to the selection of donor by blood group serology and 
the other is the selection of the untested donor. 
 
Haemolysin studies. The biggest risk in transfusion is the transfusion of ABO 
incompatible blood.152 Whole blood is plasma rich and may pose a risk due to 
the naturally occurring haemolysins, anti-A and anti-B.153  The use of group O 
blood from donors with low titers of anti-A/B blood group antibodies has been 
proposed as the safe universal whole blood for the emergency situation.154  
The UK has undertaken antibody screening for both whole blood and platelet 
donors since 2002. The primary purpose was the selection of safe group O 
platelet donors however, it provided a useful basis for the study of whole blood 
donors.  The author concluded that a UK study was required to determine the 
feasibility of restricting whole blood donors to Group O Low titre in small 
groups.  The work would be undertaken within a high readiness unit providing 
close support as a Role 2 (Light Manoeuvre).   
 
The unknown donor.  The provision of transfusion support to isolated military 
or civilian projects may require the use of an EDP for immediate Warm Fresh 
Whole Blood (WFWB). The number of screened personnel may not be large 
enough and isolated practitioners may be asked to collect blood from 
uncharacterised donors. Cordova et al., 2014 graphically describe such an 
event where 5 units of fresh whole blood were transfused following a 12-hour 
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battle, during which building fires threatened the isolated aid station.155 In 
2017, a shark attack on Ascension Island led to emergency collection of blood 
from islanders and contractor staff highlighting the need for civilian access to 
emergency donation.156 Training sessions conducted by the BFF teams had 
highlighted that practitioners need guidance for the selection of donors.   
 
Module 3. Training and Education 
 
The BFF programme espoused by the Norwegian Naval Special Operations 
Commandos136;145 has supported high fidelity training for an international 
community. The principles have been exported to the US and the UK but are 
not routinely delivered outside of the Special Forces community.   
 
Warm blood for GHOST-Ts.  Benavides et al. 2017157 described the 
development of an emergency didactic educational program based on the 
BFF program for a US forward surgical team sub-unit known as a Golden 
Hour Offset Surgical Trauma Team (GHOST-T).  They demonstrated that 
confidence improved in all members of the team but especially the clinical 
staff.  The Benavides paper is interesting in that it describes medical support 
to the withdrawal phase of war fighting which is rarely published. Withdrawing 
forces from the Iraqi operational theatre challenged the delivery of high quality 
combat casualty care.158  Withdrawal from Afghanistan presented similar 
challenges, with relevant lessons for the military’s return to “contingency 
operations” in contrast to the enduring activities in Iraq and Afghanistan.  
Contingency operations are military activities whose characteristics include 
the rapid deployment of forces, typically without the benefit of established 
medical facilities.  The emergency collection of blood is becoming a key 
medical resilience measure for any isolated community.   
 
Implications for UK military practice.   As transfusion moves geographically 
and technically forward the requirement for staff training will change.  Blood 
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collection is not a core clinical skill. Training is currently provided only to 
selected personnel who are considered to need it for their mission. The 
Benavides paper by US and UK authors concluded that training in all aspects 
of RDCR, including the use of whole blood, is essential for teams providing 
medical and surgical support to Special Operations personnel and other 
operations in austere environments.  In the UK, this training has been 
restricted to doctors and nurses.  However, experience from the US,144 
forward surgical teams157 and the Norwegian Blood Far Forward 
programme159 have demonstrated that a much wider range of staff can be 
successfully trained. Perhaps now is the time to consider the introduction of 
non-medical authorisation in the UK military and to extend the collection and 
administration of blood to a wider range of medical providers. This would a 
require a revised governance framework but afford battle space commanders 
much greater Freedom of Action.120 
 
Pre-hospital transfusion governance  
 
The increased complexity of transfusion services and the potential risks 
associated with pre-hospital transfusion had highlighted the requirements for 
governance. The format for the Defence Medical Services Transfusion 
Committee (DMSTC) mirrored the civilian structures160 with a multi-disciplinary 
committee answerable to the DMS Medical Director through the DMS Clinical 
Committee. However, the Terms of Reference for the committee were unique 
in the UK in that its remit covered all aspects of clinical transfusion practice, 
including pre-hospital and donor care.  The DMSTC benefits from having both 
military and civilian members and actively supports participation in the national 
Serious Hazards of Transfusion hemovigilance scheme (SHOT).  SHOT is the 
United Kingdom’s independent, professionally-led hemovigilances 
scheme.  SHOT has collated anonymised information on adverse events and 
reactions in blood transfusion in the United Kingdom since 1996.161 The 2016 
report continues to show that human error remains the biggest risk for ABO 
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incompatible transfusions.  The Key SHOT message was that all staff 
participating in transfusion must have the knowledge and training to undertake 
their role.152  The 2016 report included a chapter on donor haemovigilance for 
the first time.  The report quantified the rate of Serious Adverse Events of 
Donation (SAED) as 0.21 per 10,000 in the UK.   42 SAED were reported, 
most were in repeat donors with equal rates between men and women. Ten 
donors had problems related to needle insertion lasting for more than a year.   
Thirteen donors required hospital admission.  Most of these were due to vaso-
vagal events including 10 with delayed faints.  The findings have implications 
for the development of military and civilian emergency donor programmes and 
haemovigiliance.156 
 
1.4 Implications for civilian practice 
 
Overview.  Massive trauma including ballistic trauma is a global healthcare 
problem.162 The lessons identified during conflict offer the opportunity to 
optimise the survival for all traumatised patients.  An emerging concept was 
that the outcome in survivable major trauma was determined very early on by 
physiological factors, and by the initial responses of the trauma teams.  The 
doctrine of Damage Control Resuscitation carefully balanced haemostatic and 
hypotensive resuscitation.163 The emerging opinion was that massive blood 
loss should be managed with blood replacement.25 Should, and could, the 
philosophy of haemostatic resuscitation be applied to civilian trauma? Moor et 
al., in their 2009 review suggested – Yes – but caution should be applied to 
the civilian use of individual military protocols.163 They argued that the context, 
injury type and patients were different.  Above all, the military medical system 
was different. The military MTP was nested within the paradigm of 
institutionalised Damage Control Resuscitation.  It was institutionalised in that 
the system was optimised for trauma management of the individual from the 
point of wounding through to rehabilitation.  
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Transfusion support for the London bombings.  The large scale use of the 
emerging concepts were first tested in the UK when, on 7th July 2005 the 
London transport network was subjected to a series of terrorist attacks.  The 
bombings led to 700 injured and 56 fatalities.  Glasgow et al. reviewed the 
blood for the event.164  Approximately, 360 casualties were received in 
Emergency Departments and 110 were admitted to five hospitals during the 
morning.  The estimated distribution of casualties by treatment priority was P1: 
P2: P3 ratio of 5:10:85%. By midnight, 23 patients, i.e. 3% of the total injured, 
had required transfusion.  The initial mean use of red cells was 14 units in the 
first 24hr with a ratio of RBC: FFP of 3:2 in the most severely injured. The 
mean total use of RBC during the hospital stay was 17 (2-91) units.  The 
requirement for blood continued over several weeks with small peaks of 
demand at days 5 and 7.  The ongoing demand for blood due to repeat 
surgery was a relatively new concept that was reported for the first time 
following the London bombings.165;166 A number of lessons were identified 
from this event which are pertinent to this thesis.  These include: the 
organisation of transfusion support in mass casualty events (MCE), the benefit 
of structured guidelines for massive transfusion, the importance of good data 
collection and governance, and finally the importance of an integrated trauma 
system.   
 
Massive Transfusion Guidelines. UK civilian massive transfusion guidelines 
were re-issued in 2006,32 which coincided with the beginning of this study.  
The guidelines were based on sound traditional transfusion practice based on 
the review of laboratory results before the use of haemostatic components.  
The perceived limitations of this for military practice were the delays in both 
the return of laboratory results and blood component delivery. The pre-
emptive use of plasma espoused by civilian ‘enthusiasts’ was acknowledged 
in 2007 within the European guidelines for the management of bleeding 
following major trauma.167  The earliest UK guidelines to adopt the plasma rich 
protocols were the guidelines produced by the Association of Anaesthetists in 
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2010.63  However, the haemostatic resuscitation philosophy was not adopted 
into mainstream UK haematology practice until 2015.61  The reticence was 
based on the perceived lack of quality evidence both for trauma and for the 
extrapolation of trauma transfusion practice to all causes of massive 
haemorrhage. In addition, the haemostatic resuscitation strategy had been 
logistically challenging and had required considerable support from both the 
National Blood Service and laboratories.53 Considerable planning would be 
required for the resources, training and organisation of civilian laboratory 
support.168 In contrast, the military MTC had been well resourced.  However, it 
was unlikely that similar developments would be forthcoming in civilian 
practice without further evidence and endorsement from the wider trauma and 
transfusion communities.  
 
Civilian Trauma Services.  The design and delivery of the military medical 
system was under the auspices of a single ‘Defence Medical Service’.2  In 
contrast, the delivery of civilian trauma service was, and remains, fragmented.  
Pre-hospital care, which had been shown to be essential in mitigating the 
impact of military injury, is delivered by organisations separate from the 
hospitals.  In turn, civilian pre-hospital care is further divided with ground-
based pre-hospital care delivered by Ambulance Trusts whereas UK air 
ambulances are normally charities.  Any changes in civilian transfusion 
practice would be, in part, dependent on the demand for transfusion trauma 
services.  The changes in civilian trauma practice would require reorganisation 
and the better use of data registries. The Trauma Audit and Research 
Network (TARN) had been established in late 1989. The TARN database was 
an important development, but its use was inconsistent; in 2007 only 
approximately 50% of trauma hospitals submitted data.  The poor data 
submission and other failings of the trauma system were described in the UK 
National Confidential Enquiry into patient Outcome and Death (NCEPOD) 
2007, Trauma: Who cares?169  The NCEPOD study explored the organisation 
in trauma from the perspective of the patient journey.  There were nine key 
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recommendations including the development of designated level 1 trauma 
centres within a robust assurance system.  All agencies involved in trauma 
management, including pre-hospital care, should be integrated into the clinical 
governance programmes of a regional trauma service.  A considerable 
change in the organisation of civilian trauma services would be required to 
leverage the lessons learnt from the developments in military transfusion.   
 
Summary of introduction  
 
Massive haemorrhage is the most immediate threat to the injured service 
person.  The mortality rate after massive haemorrhage in trauma is high, 
unless actively managed from the point of wounding. Trauma also results in a 
complex disturbance of coagulation. Treatment requires early haemorrhage 
control and prevention of shock together with appropriate transfusion support. 
The introduction has provided an overview of recent development of UK 
military transfusion practice and indicates the potential for civilian healthcare.  
Four areas for exploration have been identified which will be developed into 
the aims of the thesis.  
 
1. The Massive Transfusion Capability was developed to deliver both the 
laboratory and clinical elements of haemostatic resuscitation.  The principles 
of the military hospital model were then applied to physician led pre-hospital 
care. The implementation and impact of both hospital and MERT practice 
require formal description to assist future military planning and developments. 
2. The key considerations for RDCR are reducing the logistic burden and 
optimising training. International networking in Norway has contributed to 
knowledge exchange and practical solutions.  Further developments are 
required, especially for emergency donor selection.  
3. The lessons identified during conflict offer the opportunity to optimise 
the survival for all traumatised patients.  Early adopters in England and 
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Norway have now had a decade of experience and offer an opportunity to 
study the impact of MTPs in civilian practice.  
4. Finally, ballistic trauma is a global healthcare problem. Recent terrorist 
events have led to MCE with a renewed interest in emergency resilience, 
including transfusion.   Studies are required to assess the implication of 
military transfusion practice for Transfusion Emergency Preparedness in both 
England and Norway.  
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2: AIMS OF THE STUDY 
 
2.1 The overall objective of this study is to evaluate the recent 
developments in military transfusion practice and to assess the impact on 
civilian practice.    The study describes the changes in transfusion support in a 
linear sequence during the period of 2006 – 2016. The early adoption of 
military principles is then explored in the context of civilian hospital practice 
and national emergency transfusion preparedness for Major Incidents leading 
to Mass Casualty Events. 
 
2.2 The study aims to demonstrate the contribution to military and civilian 
trauma transfusion attributable to the author through the analysis of published 
work.  Seven papers are presented here.  A list of associated publications is 
included in Appendix 4. The thesis is that the recent developments in military 
transfusion practice are significant and that they have impacted on civilian 
healthcare.  The thesis is explored through the following four aims: 
 
1. To describe the implementation and impact of recent UK military 
blood transfusion practice  
2. To further develop donor selection for Remote Damage Control 
Resuscitation 
3. To study the introduction and impact of Massive Transfusion 
Protocols in UK and Norwegian civilian centres 
4. To assess the application of military transfusion practice on Mass 





































The methodology for the seven papers is grouped according to the aims, 1-4, 
followed by some general methodological considerations.  
 
3.1 Developing Military blood transfusion practice  
 
Overview. The setting and source data for the principal defence study; Paper 
1 is similar for the associated descriptive paper, Paper 2.  Paper 1 is a 
retrospective analysis of blood component used in a single combat support 
hospital. The study was approved by the Royal Centre for Defence Medicine 
(RCDM/Res/Audit/1036/12/0175).  Paper 2 is a special report which covers 
the practical and clinical aspects of prehospital transfusion as practiced by the 
UK Armed Forces in Afghanistan and describes a cohort of patients who 
received treatment.   
 
Setting. The retrieval of casualties in Helmand Province was almost invariably 
by helicopter, usually directly to the UK Medical Treatment Facility (MTF) at 
Camp Bastion. In-flight care was provided by paramedics or doctors. For 
casualties who are in extremis, transfusion with red blood cells (RBC) and 
plasma may be initiated en-route by the Medical Emergency Retrieval Team 
(MERT), but was more commonly administered at the hospital at Camp 
Bastion.   
 
Source data. Data were extracted from the Joint Theatre Trauma Registry 
(JTTR), which records details of all casualties who receive treatment in 
deployed UK military MTFs. Since 2007, the JTTR has included all injured 
service casualties treated at Birmingham.  
 
Data management and statistical analysis.  Injury extent was quantified by 
three different injury severity scoring systems.  The three were; the injury 
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severity score (ISS), stratified into mild (ISS 1-8), moderate (ISS 9-15) and 
severe (ISS≥16); new injury severity score (NISS); and by body region, using 
the abbreviated injury scales (AIS).  Demographic characteristics were 
compared using Kruskall-Wallis tests for continuous data and Chi2 tests for 
proportions. The number of units of individual blood components transfused 
were analysed by calendar year and injury severity strata and compared using 
Kruskall-Wallis tests. Transfused patients were also analysed by volume of 
red cells transfused before being dichotomised into massive and non-massive 
transfusion. The ratios of plasma to red cell concentrate and platelet to red cell 
concentrate are presented as three-month moving averages. Analyses were 
performed using Microsoft Excel (Microsoft, Redmond, Washington, USA). 
 
3.2 Donor selection for Remote Damage Control Resuscitation 
 
Overview.  The context for papers 3 and 4 is the austere medical environment 
where evacuation to surgical support may be delayed.  Individuals or small 
teams may be required to sustain prolonged field care with minimal medical 
assets.  Transfusion support will require the use of Emergency Donors.   
 
Paper 3 describes a retrospective review of routine volunteer blood donor 
samples performed at 6 monthly intervals during a 2-year period.  The donor 
testing protocol was the UK standard for donation84 which included transfusion 
microbiology, blood grouping (ABO, Rh and K) and screening for atypical 
antibodies. All results were processed through the NHS Blood and 
Transplant’s (NHSBT) Laboratory Information Management System (LIMS) 
(Pulse Blood Transfusion System, Savant Ltd, Cumbria, UK). Plasma of all 
group O donors was screened for anti-A/B IgM using the Olympus PK7300® 
(Beckman Coulter) with a dilution of 1/85 against A2B cells.  Anti-A/B was 
defined as high titre (HT) positive if reactive at 1/128 (or equivalent dilution) by 
haemagglutination techniques and negative if reactive 
at 1:64 dilution.170 Results were electronically transferred to the military Blood 
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Supply Team (BST).  Data collation and analyses were performed using 
Microsoft Excel (Microsoft, Redmond, Washington, USA). 
 
Paper 4.  The initiative for this work follows the pre–conference exercise for 
the 2015 meeting of the Trauma, Hemostasis, Oxygenation and Research 
(THOR) Network, which took place in Norway.  The work forms part of the 
‘Blood Far Forward’ program - a whole blood-based research and training 
program for austere environments.   Staff and participants identified that there 
was little guidance for the rapid assessment and triage of blood donors for the 
non-expert.  The principal author attended the field teaching and exercise 
during which she consulted practitioners before reviewing the literature. The 
draft Field Emergency Donor Panel (EDP) Questionnaire and Triage Tool was 
then refined using a modified Delphi method with the writing group and then a 
wider group of experienced military and civilian practitioners. 
 
Literature review.  The following donor screening guidelines were reviewed.  
Military:  US Special Operations Command, Tactical Trauma protocols (TTP) 
2013171 and the Journal of Special Operations Medicine Training supplement 
2012.172 Civilian:  Standard Operating Procedures for the collection of whole 
blood, United Kingdom,173 THOR guidance,136 United Kingdom Blood 
Transfusion Services,84 American Association of Blood Banks (AABB)174 and 
the World Health Organisation (WHO).175 A search was performed of PubMed 
and CINAHL using the search terms:  Emergency Donor Panels, collection of 
whole blood, austere medical environment, and Special Forces medicine.  The 
search covered articles published up until September 2015. 
 
3.3 Introduction of Massive Transfusion Protocols in civilian centres 
 
Overview.  The setting and source data for Paper 5, the principal UK hospital-
based study presented here is similar to paper 6 from Bergen.  Both are 
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retrospective observational reviews of practice in a single institution, closely 
associated with military practice.   
 
Birmingham study design 
Paper 5 was a quality improvement initiative from the Queen Elizabeth 
University Hospital Birmingham, UK. The purpose of this before-and-after study 
was to determine the impact of modifying a Massive Transfusion Protocol (MTP) 
to include emergency red cells.  The usage study was a retrospective study of 
sequential MTP activations over three years, before and after protocol revision.  
The study was approved as a clinical audit.   
 
Setting.  The Queen Elizabeth University Hospital Birmingham, UK is the 
receiving facility for UK military trauma patients and is equivalent to a US level 
1 trauma centre. It serves a population of 1.2 million UK civilians. Following the 
UK wide reconfiguration of major trauma networks, the institution was 
designated a regional Major Trauma Centre in 2012. Blood is provided by a 
separate organisation, the centralised blood service, NHSBT. 
 
Source data.  All consecutive MTP activations throughout both periods were 
prospectively recorded by the transfusion laboratory manager using an audit 
template as part of ongoing quality management. Clinical outcome data were 
retrospectively collated from patients’ electronic clinical record and the Trauma 
Audit and Research Network (TARN) database.176  
 
Analysis.  All analyses were performed with version 6 of the Graph-Pad Prism 
statistical software package, GraphPad Software, Inc. San Diego, California. 
Data were presented as mean with standard deviation or median and 
interquartile range as appropriate. The unpaired t-test with Welch's correction 
was used for parametric data comparison. The Mann–Whitney U test was 
utilised for non-parametric comparisons. Frequency comparison of categorical 
data was undertaken with either the Chi square test or the Fishers exact test. 
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Statistical significance was set at p value ≤0.05.  The association between the 
trauma associated severe haemorrhage (TASH) and ABC score and the 
number of red blood cell (RBC) units used was tested with linear regression 
analysis and the R2 statistic. The Area Under the Receiver Operating 
Characteristic (AUROC) analysis was undertaken to test the accuracy with 
which the need for >6 RBC could be predicted. This number of RBC units was 
chosen as it represents progression to MTP pack 2 in both our and others’ 
protocol. 
 
Bergen study design 
Paper 6 was a study of the impact of a Massive Transfusion (MT) programme 
in a single Norwegian centre throughout the period 2002–2015.  Haukeland 
University Hospital (HUS) introduced a MT programme during 2007 including 
education, an Acute Transfusion Package (ATP) and point-of-care 
measurements using thromboelastography (TEG 5000, Haemonetics 
Corporation; Braintree, MA, USA).   
 
Methodology. A retrospective review was conducted of all episodes of patients 
receiving a massive transfusion during the period of Jan 1st, 2002 and Dec 
31st, 2015, i.e. 13 years.  Massive transfusions were defined as 10 or more red 
cell concentrates (RCC) given during the first 24 hours after insult. 38  An initial 
search was made using the ProSang laboratory information system (LIMS) 
(Databyrån AB, Stockholm, Sweden).  Patient records were then reviewed 
manually for demographics, transfusion support, principal indication for 
transfusion, haemostatic drugs and mortality.  The principal indication for 
transfusion was encoded using ICD-10. 
 
Statistical analysis. Statistical analysis was performed using IBM SPSS 
Statistics for Windows, Version 24.0 (IBM Corp., Armonk, NY, USA). 
Descriptive statistics were used to summarize the number of components by 
year, speciality, and patient demographics. The Student’s t-test was used to 
 74
compare the mean number of RCC, plasma and platelet concentrates 
transfused per episode pre-2007 and post-2007. Differences in platelet 
inhibitor and anticoagulant use between cardiac and non-cardiac episodes 
were tested using Chi-squared tests. A p-value <0.05 was considered 
statistically significant. Excel 2010 (Microsoft Corp., Redmond, WA) was used 
to produce graphs. 
 
3.4 Transfusion Emergency Preparedness  
 
Overview.  Paper 7 contrasted the planning approaches used for Transfusion 
Emergency Preparedness by NHSBT and Norway.  The paper included a 
review of UK and Norwegian methodology.   The UK methodology was a 
strategy based on component therapy.  Planning was based on the response 
to Major Incidents such as the London bombings164 together with the lessons 
identified from the preparation for the London Olympic Games.177  The 
methodology for the Bergen planning was based on developments from the 
military whole blood programme in Bergen.154 
 
London bombings. The transfusion response to the London bombings was 
analysed based on data from a variety of IT systems.  Data was collated from 
the National Blood Service’s LIMS (Pulse Blood Transfusion System).  Pulse 
is a core software system that powers the blood donation lifecycle of NHSBT 
in England (formed by the merger of the National Blood Service & UK 
Transplant in 2005).  The hospital data was derived from the respective 
hospital LIMS.   All data was collected immediately following the event and 
included: all blood components requested, issued and transfused in relation to 
the bombings, blood stock levels at the time and the injury profiles of the 
casualties transfused.   
 
Olympic planning. Glasgow et al. have described the blood service 
preparation methodology for the 2012 Olympics.177  As part of the preparation, 
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a new civilian literature review was commissioned from the Blizard Institute, 
London to further inform blood demand per patient.178  The potential demand 
was based on the average between past civilian demand,178 demand from the 
London bombings164 and recent military demand figures as in Paper 1.179  
 
Blood demand per patient. Severely injured casualties or Priority One (P1) 
were estimated to require 10 units of RBC, i.e. a traditional massive 
transfusion.  The ratio of red cells to haemostatic components was as outlined 
by a regionally agreed massive haemorrhage protocol.180 The less severely 
injured patients/Priority Two (P2) casualties were assumed not to routinely 
require haemostatic component support and the walking wounded Priority 
Three (P3) casualties were deemed not to require any blood at all.  A 
summary of the blood component requirement assigned for each triage 
category is shown in table 4.  
 













= pool of 4) 
Cryoprecipitate 
(Pool of 5) 
Priority 1* 10 8 2 1-2 
Priority 2 4 0 0 0 
Priority 3 0 0 0 0 
#Saline-adenine-glucose-mannitol 
 
UK emergency planning.  The planning approach developed for the UK was 
based on the number of casualties, potential red cell demand based on the 
priority and a demand factor of three.181  A stock plan for red cells was modelled 
using the following equation together with the background seasonal and daily 
variations in demand.  Similar modelling was done for platelets.  
 
 
Red cell demand = Number of casualties x Demand per patient x Demand factor 
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The final blood component stock plan was based on a compromise between 
potential component demand, shelf-life and an appreciation of logistically 
achieving and maintaining the required stock level for the Games.  In addition, 
the risk of stock build was considered against the risk of wastage.  As a result, 
a decision was made to increase the blood-stock slightly but also to develop 
high readiness donor panels for both group O whole blood and group A platelet 
donors. Plans were widely communicated with key stakeholders and exercised 
using a table-top exercise.   
 
Bergen emergency planning. The surge supply plans for Bergen was based on 
a novel approach proposed by HUS. HUS is in the process of implementing 
contingency plans that will involve the use of pre-screened military and civilian 
Group O low titre emergency donors. The donors will be recruited from three 
locations; a local naval base, from amongst the regional hospital employees 
and from city suburbs; they will be called to donate whole blood, to be fully 
tested and utilised as whole blood. Such as plan removes the necessity of 
detailed planning, component production and unnecessary stock build. 
 
3.5 Methodological considerations and research governance 
 
One of the main challenges to conducting research in a deployed setting is the 
obvious logistical difficulty of working many thousands of miles away from the 
UK and in a potentially hostile environment. In addition, there is a manpower 
limit imposed on numbers of personnel serving in a defined area of operations 
or theatre. Such difficulties can limit the potential to perform research, 
especially prospective randomised controlled trials (RCT).  Most initial 
research and feasibility studies during this period of study were carried out by 
deployed clinicians who collected data when not fulfilling their primary 
tasks.182 Examples supported by the author include CRYOSTAT58 and 
evaluation of cell salvage.95   However, many of the recent military studies are 
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retrospective studies using the Joint Theatre Trauma Registry (JTTR) housed 
by the RCDM. 
 
The JTTR records details of all casualties who receive treatment in deployed 
UK military MTFs. Since 2007, the JTTR has included all injured service 
casualties treated at Birmingham.183  The author has been closely involved in 
developing the data fields for both hospital and pre-hospital transfusion and 
has confidence that this data is complete.  The use of the JTTR restricts the 
eligibility to patients studied who were British and coalition (non-Afghan) 
service personnel.  Mortality for UK personnel was defined as in-hospital 
mortality which occurred within 30 days either in Afghanistan or in the UK.  For 
other coalition patients, in-hospital mortality included only that which occurred 
at the treatment facility in Afghanistan. This approach is pragmatic but has 
been employed for other studies as it is very difficult to track the progress of 
casualties from other countries through their respective evacuation chains. 
 
The issue of patient consent requires attention in circumstances such as 
severe trauma.  Novel consultation methods have been devised by the 
NHSBT Clinical Trials Unit in a manner consistent with the Mental Capacity 
(England) Act (2005).   The construct for patients with severe injury lacking 
capacity to consent, and without a Personal Consultee, is to use an 
independent clinician.  Patients or their relatives are subsequently consulted 
at the first opportunity. Non-interventional studies do not require these 
procedures however all studies, including audit and service improvement, 
must be approved by the Royal Centre for Defence Medicine or the equivalent 
civilian sponsor.   
 
All the studies presented in this thesis have been subject to the relevant 
research governance frameworks.  In principal, where appropriate, trials are 
conducted in compliance with the approved protocol, the Declaration of 
Helsinki (2008), the Principles of Good Clinical Practice (GCP) and the UK 
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Data Protection Act and the NHS Research Governance Framework for 
Health and Social Care.  Blood components are provided in compliance with 
European Commission Directive 2005/28/EC.  Authority from the Medicines 
and Healthcare Products Regulatory Agency (MHRA) and approval by higher 
military committees such as AGoMM (Advisory Group on Military Medicine) 
were secured where drugs were used outside of current licence, such a 
Fibrinogen Concentrate, or as an un-licenced medicine such as LyoPlas-N.    
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4: SYNOPSIS OF RESULTS  
 
4.1 Changes in UK blood transfusion practices in Afghanistan, 2008-
2011 
 
The aim of this paper was to document blood component usage in the UK 
medical treatment facility (MTF) at Camp Bastion, Afghanistan, over a period 
of four years; and to examine the relationship with changes in transfusion 
capability, injury pattern and survival.  In the paper we analysed the period 
after the introduction of the new massive haemorrhage protocol in 2007 
followed by pre-hospital transfusion in 2008.  This was a retrospective study of 
all blood component use in service personnel admitted for trauma. The data 
variables were extracted from the UK Joint Theatre Trauma Registry (JTTR).  
 
2618 patients were treated for trauma; 791 received blood components. The 
proportion of patients receiving blood components increased from 13% to 32% 
per annum.  417 (52.7% of all casualties transfused) received massive 
transfusion (≥10 units of red blood cells (RBC)), the proportion increasing from 
40% to 62% during the period of study. Use of all blood components 
increased significantly in severely injured casualties, to a median (IQR) of 16 
(9-25) units of RBC (p=0.006), 15 (8-24) of plasma (p=0.002), 2 (0-5) of 
platelets (p<0.001), and 1 (0-3) of cryoprecipitate (p<0.001). Cryoprecipitate 
(p=0.009) and platelet use (p=0.005) also increased in moderately injured 
casualties.  Survival increased from 76% to 84%. 
 
The number of blood components transfused to individual combat casualties 
increased during the 4-year period.  Survival also increased despite no 
change in injury severity score or injury pattern. Combat casualties requiring 
massive transfusion had a significantly higher chance of survival (93.1%) than 
civilian patients receiving the same amount of RBC (59.7%).  Survival is the 
product of the entire system of care, and transfusion was now available 
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throughout the evacuation chain.  We proposed that the changes in military 
transfusion practice and capability contributed to increased combat trauma 
survival. 
 
4.2 Initial UK experience of Pre-hospital Blood Transfusion in Combat 
Casualties 
 
This report presents the UK Defence Medical Services’ (DMS) initial experience 
of military pre-hospital transfusion. Experience derived from the field hospital 
resuscitation of severely injured patients had led to the development of damage 
control resuscitation (DCR). Pre-hospital transfusion was adopted by the UK 
armed forces as an extension of the resuscitation strategy.  
 
Pre-hospital transfusion was considered for patients without a palpable radial 
pulse or who had a non-invasive systolic blood pressure of less than 
80mmHg. The aim was to restore these parameters, rather than to resuscitate 
to normotension. Exceptions included; suspect traumatic brain injury (TBI) or if 
time to definitive care was anticipated to exceed one hour. If more than one 
unit of packed red blood cells (PBRC) was required, plasma was administered 
to achieve a RBC: Fresh Frozen Plasma (FFP) ratio of 1:1. A loading dose of 
1g of tranexamic acid (TXA) was given to all transfused patients during initial 
resuscitation.   
 
In the period from July 2008 to March 2011, 1153 casualties were retrieved 
from point of wounding to the MTF at Camp Bastion by the Medical 
Emergency Retrieval Team (Enhanced) (MERT-E); 310 casualties received a 
pre-hospital transfusion. 76.7% of recipients were severely injured (Injury 
Severity Score (ISS) of 16 or more), of which 48% of patients received pre-
hospital transfusion.  Almost one-half of patients required intra-osseous 
circulatory access and/or advanced airway management. The median (IQR) 
number of units of PRBC and FFP transfused pre-hospital was 2 (1-2).  The 
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median (IQR) total transfusion volume was 8 units (range 3-18) of packed 
RBC (PRBC) and 7 units (range 2-16) of FFP.  Nearly one-half of these 
patients required a massive transfusion (>10 units while at Camp Bastion), 
although one-fifth required no further transfusion after admission.  The crude 
mortality of casualties who required pre-hospital transfusion was 20%.  
 
Pre-hospital transfusion is an intuitively appealing intervention with 
considerable potential.  The UK Armed Forces have successfully and safely 
implemented pre-hospital transfusion.  Evidence for its use is currently limited 
although the first retrospective study suggests that DCR, including pre-
hospital transfusion has a significant mortality benefit. The implications are 
important not only for future military practice but also for the wider civilian 
community. 
 
4.3 The feasibility of group O LOw titre panels for small combat teams  
 
Military elements increasingly operate in small teams in remote areas with no 
immediate blood product support. In this situation, planners may endorse the 
collection of whole blood from pretested donors in emergency situations. The 
biggest risk of this arrangement is the accidental use of ABO incompatible 
blood, which can be fatal.  The risk may be mitigated by using only group O 
donors with plasma containing low levels of the naturally occurring antibody to 
group A and B red cells. This paper studies the ABO blood group distribution 
in potential blood donors from a high readiness UK medical regiment and 
explores the feasibility of using only Group O LOw titre (OLO) donors in very 
small teams.   
 
We performed a retrospective review of routine volunteer blood donor 
samples at 6 monthly intervals during a 2-year period.  Personnel were tested 
in random groups when available during training to create multiple donor 
panels to simulate small teams. 206 donation samples were collected from 
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157 potential donors. The testing protocol was the UK standard for donation 
which included transfusion microbiology, blood grouping (ABO, Rh and K) and 
screening for atypical antibodies. Plasma of all group O donors was screened 
for anti-A/B IgM using the Olympus PK7300® (Beckman Coulter) with a 
dilution of 1/85 against A2B cells.  Anti-A/B was defined as high titre (HT) 
positive if reactive at 1/128 (or equivalent dilution) by haemagglutination 
techniques and negative if reactive at 1:64 dilution.  
 
All donors were acceptable based on the lifestyle questionnaire, serology and 
microbiology screen.  Of the 206 samples reviewed, 85 (41%) were Group O 
(RhD positive and RhD negative). 14 Group O donors (16.5%) were shown to 
have a high titre of Anti-A or Anti-B. Therefore 71 donors, i.e. 34% overall 
were suitable as OLO donors.   The individual donor ‘panel’ size varied from 
15-44.  The absolute number of OLO donors in each panel ranged from 4-17 
and the number of group O RhD negative donors was 0-3. We concluded that 
a third of samples were suitable as group O low titre donors however, there 
were insufficient ‘universal’ donors within smaller subgroups (<10). In this 
situation, we recommend the careful use of both group O and group A donors 
or the use of a buddy-buddy blood group matrix.  
 
4.4 A proposed field emergency donor panel questionnaire and triage 
tool 
 
The aim of this short discussion paper was to raise and resolve some of the 
practical aspects for the non-specialist faced with the emergency collection of 
fresh whole blood (FWB) in the austere medical environment (AME).  
Examples include Military Special Operations, Humanitarian Missions, 
Remote Industry, the Cruise Industry and Scientific Exploration.  Healthcare 
providers are not traditionally taught donor selection and care.  We present a 
proposed Field Emergency Donor Panel Questionnaire and Triage Tool 
(QTT).  It is designed for an isolated medical provider for use in a hostile, 
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remote or austere environment that falls outside normal regulated supply of 
cold stored blood products.  
 
The initiative for this work followed the finding from a pre–conference exercise 
for the 2015 meeting of the Trauma, Hemostasis and Oxygenation Research 
(THOR) Network, which took place in Norway in June 2015.  The work forms 
part of the ‘Blood Far Forward’ program - a whole blood research and training 
program for austere environments.  The principal author reviewed various 
national and international, military and civilian donor screening guidelines to 
draft a generic Field Emergency Donor Panel (EDP) Questionnaire.  A Triage 
Tool was developed to rapidly select donors, prioritising those that were 
previous donors.  The tool and questionnaire were then refined by a group of 
practitioners with experience gained through responding to military and civilian 
events.   
 
The tool serves as a point of reference for local guidelines and has been 
shown to be feasible to apply.  In addition, the paper provides many useful top 
tips for the AME practitioner that may not be readily available in the general 
transfusion literature.  We acknowledge that although the use of the EDP is 
associated with risk it may be the only local method of providing timely 
transfusion support.  The best way to manage the risk is to brief and pre-
select potential blood donors before overseas travel.  An abbreviated donor 
questionnaire and triage tool can then be used as an aide to decision-making 
by the non-expert at the time of emergency donation. The tool should be 







4.5 The evolution of a massive transfusion protocol for trauma in a 
single UK centre 
 
Death from massive haemorrhage due to traumatic injury is potentially 
preventable after hospital admission using haemorrhage control and improved 
resuscitation techniques including Massive Transfusion Protocols (MTP).  The 
introduction of MTPs was designed to provide a rapid response, however, the 
preparation of plasma may delay delivery of the initial pack.  Emergency red 
cells are normally available in most hospitals and could be used to provide 
immediate blood-based resuscitation while waiting for a MTP.  The purpose of 
this before-and-after study was to determine the impact of modifying a civilian 
protocol originally introduced in August 2008. The amendment was to include 
emergency red cells rather than delaying transfusion whilst waiting for plasma.  
In addition, we investigated whether massive transfusion prediction models 
could have been used to guide ongoing transfusion support.   
 
We analysed all sequential MTP activations over three years, before and after 
the protocol revision. The percentage of MTP activation, component usage, 
and outcome data were compared. Trauma Associated Severe Haemorrhage 
(TASH) and Assessment of Blood Consumption (ABC) scores were derived 
and Receiver Operating Characteristic (ROC) analysis undertaken for an 
outcome defined as the use of > 6 red cell units. 52 and 66 MTP activations 
arose from the 216 and 495 major trauma cases, respectively. The protocol 
changes significantly reduced the MTP activation rate (p=0.0006) from 24% to 
13%, and the number of activations requiring >10 RBC increased from 13% to 
36% (p=0.006). However, the average emergency red cells usage in the 
second cohort increased from 0 to 4 units.  The time to MTP pack issue and 
the outcome measures such as survival and coagulation parameters were 
unaffected by the protocol revision. The TASH score showed an area under 
ROC (AUROC) of 0.88 for ongoing transfusion requirements.   
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We concluded that the change in protocol improved the predictive value of 
starting the MTP without causing a delay or ‘speed bump’.  However, we 
suggested that methods should be developed to rapidly provide plasma and 
prevent a plasma deficit.  In addition, we proposed that it was better to start 
the MTP early and then to step down once the patient was stabilised.  The 
TASH score appeared to provide a useful predictive tool for ongoing 
transfusion support.   
 
4.6 Massive Transfusion: changing practice in a single Norwegian 
centre 2002 – 2016   
 
In this paper, we described the epidemiology of massive transfusion and the 
impact of a transfusion programme in a single Norwegian centre throughout 
the period 2002–2016.  In 2007, Haukeland University Hospital introduced a 
massive transfusion (MT) programme incorporating education, 
thromboelastography and an Acute Transfusion Package (ATP). The ATP 
consisted of 6 units of RBC, 6 units of Octaplas solvent/detergent treated 
plasma (Octapharma AG) and 2 platelet concentrates (PC).  A retrospective 
review was made of all MT episodes defined as >10 RBC in 24 hours.  
Searches were made using the laboratory information system (ProSang).  
Patient records were reviewed manually for: demographics, indication for 
transfusion, haemostatic drugs and mortality.  Data was collated and analysed 
in SPSS.   
 
410 MT episodes were identified in 410 patients.  These episodes accounted 
for 2.8% of RBCs and 3.4% of PCs issued during the study period. The mean 
patient age was 60 (9-94) years, with a male predominance (64%).  87.1% of 
episodes were in support of surgery (cardiac services 42.7%; trauma 17.6%).  
29.8% of all MT involved platelet inhibitors with 82.6% of these patients 
undergoing cardiac procedures.   25.1% of MT involved anticoagulants.  The 
mean ratio of blood components RBC: plasma: platelets changed from 
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1.0:0.37:0.39 in 2002-2006 (n=149) to 1.0:0.79:0.85 in 2008-2015 (n=241, 
p<0,001). A sub-analysis showed that cardiac specialities used proportionally 
more plasma and platelets than other specialties. Survival appeared to be 
more improved in groups receiving 20 or more units. A sub-analysis of 
patients receiving >30 blood components within 24 hours showed that 30-day 
survival improved from 32.3% before 2007 to 54.9% after 2008 (p=0.027). 
 
MT was primarily used in major surgery.  The findings contrast with other 
studies showing that most red cells are used in medical specialities. The 
programme in 2007 successfully changed massive transfusion practice in that 
it delivered a more balanced treatment.  The greater use of haemostatic 
components in cardiac surgery may reflect changes in anti-platelet medication 
or local management. These findings should inform future studies, demand 
planning and patient blood management programs. 
 
4.7 MCEs: transfusion emergency preparedness across the continuum 
of care 
 
The purpose of this descriptive study was to compare the support of two 
transfusion service systems to MCEs; one in Bergen, Norway and one in the 
UK. Traditionally, transfusion services have not been involved as part of the 
healthcare response. However, recent developments in haemostatic 
resuscitation have highlighted the importance of transfusion support in the 
care of the critically injured. In addition, the frequency of terror attacks in 
Europe has re-energised an interest in preparedness using lessons identified 
from recent military experience. 
 
We reviewed the planning approaches used for MCEs such as the London 
bombings and mass gathering such as the Olympic Games.  We summarised 
the recent military and civilian data and described the potential for computer 
modelling.  We acknowledged the impact of military practice on pre-hospital 
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care, especially the early management of massive haemorrhage, which is key 
to controlling demand for blood. Demand is based on the supply of either 
multiple component therapy or whole blood, as both countries have introduced 
Massive Haemorrhage Protocols (MHPs) within their civilian hospital sectors.  
The challenge for the blood services is meeting the surge in demand for labile 
‘universal components’ such as group O red cells and group A platelets, or 
whole blood.  Supply options must be developed.  It was this aspect of 
planning that was the focus for the study. 
 
The English blood service has a network of manufacturing sites and stock 
holding units within a small but crowded geographical area.  In contrast, 
Norway has hospital-based blood collection and preparation. Transport within 
Norway may be limited by geography and weather conditions.  Therefore, 
different options may be considered for the emergency supply of blood.  In the 
UK, preparedness has included appropriate stock management including 
repositioning and re-supply from other centres.  In addition, integrated 
shortage plans exist with the hospitals to triage the use of blood components.  
However, the geography of Bergen is such that mutual aid from other 
Norwegian centres may not be immediately available.  Bergen has recently 
established pre-tested emergency donor panels together with military aid.  In 
addition, the manufacturing has been simplified to provide whole blood rather 
than component therapy. 
 
In this paper we illustrated that transfusion demand and capability planning 
can be an integrated part of the wider medical planning process for 
emergency preparedness. We concluded that the chosen solutions should be 




































Conflict continues to be a potent stimulus to innovation.163   The multiple 
injuries sustained in recent warfare by combatants on all sides, as in Iraq and 
Afghanistan, have been horrific.  However, the developments in military 
medicine have been extraordinary and have been presented as a revolution in 
military medical affairs.1;2 Haemorrhage control and haemostatic resuscitation 
have been cited as critical determinants of outcome in the seriously injured.8  
Should and could the military philosophy of Damage Control Resuscitation 
doctrine be adopted by civilian healthcare? In this discussion, I address the 
four aims using the results of the papers presented in this thesis to describe 
the implementation and impact of the recent changes in military transfusion 
and explore the significance for civilian practice. 
 
5.1 Implementation and impact of recent changes in UK military blood 
transfusion practice 
 
Overview.  The UK military Massive Transfusion Protocol (MTP) was 
introduced in 2007.  The military transfusion capability was developed to 
rapidly resuscitate critically injured young people. The volume of blood 
required, and the survival have been extraordinary.  Figure 5 in Chapter 1 
illustrates the rapid rise in blood component demand from 2008 onwards 
peaking in 2011 before tailing off in 2014. Papers 1 and 2 explore the impact 
of changing policy and practice during this period.  
 
The recent changes in UK military blood transfusion practice. Paper 1 
described the blood use per patients admitted to the UK role 3 Medical 
Treatment Facility (MTF) during the period of 2008 – 2011.  The paper 
included all patients presenting to the MTF and not just those arriving by 
helicopter.  A total of 2618 patients was identified.  Most patients were male 
(99%) and the median age was 22 years (range19-25). In broad planning 
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terms, one third of casualties received blood and fifty percent of these were 
Massive Transfusion (MT) i.e. ten or more units of red cell concentrates 
(RCC).  The percentage transfused increased from 13 to 32%.  The median 
blood component use per patient was 16 units of red blood cells (RBC), 15 
units of Fresh Frozen Plasma (FFP), 2 adult therapeutic doses (ATD) of 
platelets and 1 pool (5 doses) of cryoprecipitate. The most striking changes in 
military practice, i.e. the increase in the use of haemostatic components, was 
seen for the more severely injured group.  The findings are consistent with a 
US database analysis of multiple traumatic amputations published in 2017.184 
The US paper found that the average transfusion requirements in the period of 
2009- 2012 were RBC 18.6 (0–142), FFP 17.3 (0–128), platelets 3.6 (0–26), 
and cryoprecipitate 5.6 (0–130). Godfrey et al. correlates the degree of injury 
and demand for transfusion with the change in the technology of improvised 
explosive devices (IED) from 2009 onwards.   
 
Massive transfusion.  In the period of 2008-2011, 13.7% of UK hospitalised 
military trauma patients received a MT. The proportion of military patients who 
received a MT doubled during the period of study increasing from 9% to 20%.  
Paper 1 does not convey the enormity of resuscitating these combat injuries. 
However, Allcock had highlighted that 7 out of 59, i.e.11.8% of massive 
transfusions during 2009 involved more than 100 components.  Such cases 
not only required blood but also placed an enormous demand on all aspects of 
military healthcare.  Allcock showed that 51 (86%) survived to be discharged 
from hospital in the UK.116  It is difficult to compare this result directly with 
civilian healthcare practice and outcomes. An analysis of UK trauma registry 
data from 2005-2009 showed that only 0.4% of civilian casualties received 
massive transfusion.  Such patients received on average 11 units of RBC but 
only 4 units of FFP and 2 single units each of platelets and cryoprecipitate.  
The mortality rate for civilian patients with MT was 40.3%176 in contrast to the 
military survival rate of 93.1%.   The improved survival of military patients may 
be related to the patient population which is almost exclusively male, younger, 
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assumed fitter with access to body armour. However, 74% of military patients 
had an injury severity score (ISS) > 15.  The mean new injury severity score 
(NISS) of 22 hides the injury severity of patients with multiple amputations.   
 
Changes in capability.  Survival studies require careful consideration. The 
better survival of massively transfused casualties, compared with non-
massively transfused casualties shown in paper 1 is probably explained by 
survival benefit – i.e. casualties had to survive long enough to receive a 
massive transfusion. Pre-hospital transfusion was introduced during 2008.  
Paper 2 suggests that the developments in pre-hospital rescue and en-route 
care led to more severely injured casualties being rescued which may account 
for the apparent fall in survival following arrival at the field hospital.  The more 
severely injured casualties received proportionally more plasma, platelets and 
cryoprecipitate.  Paper 1 proposes that the increased use of platelets from 
2008 may be explained by the improved availability of this product following 
the development of a deployed apheresis capability.53   The deployment of 
rotational thromboelastometry (ROTEM) in 2009 may explain the increased 
use of both platelets and cryoprecipitate.  These findings are consistent with 
those reported by US colleagues, who also demonstrated that the introduction 
of ROTEM was associated with an increased use of all blood components 
other than RBC, and particularly cryoprecipitate (Cap, 2012 Personal 
Communication).  Paper 1 also highlights the changes in the use of 
pharmaceutical adjuncts to transfusion. Tranexamic acid (TXA) was not used 
before 2009, but is now given to most patients requiring transfusion, and 
almost all patients requiring massive transfusion. In contrast, recombinant 
factor VIIa (rFVIIa) was used during the early years of the war, but not later. 
This change may reflect an increasing recognition of the limited effectiveness 
of rFVIIa and risks of thrombosis.69 On reflection, the influence of the 
governance systems and pre-deployment training should also be recognised.  
The delivery of the massive transfusion capability (MTC) had a significant 
impact on all members of the clinical team, especially the nursing cadre.  The 
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delivery of emergency transfusion was integrated into pre-deployment training 
designed to provide high fidelity mission specific training leading to well-
orchestrated team-work. 50 
 
The development of pre-hospital transfusion for the MERT.  The introduction 
of phase change materials revolutionised air-borne transfusion logistics for 
both pre-hospital emergency care and medical evacuation. Intra-osseous 
devices enabled vital circulatory access as part of the blood delivery systems.  
The Medical Emergency Retrieval Team (MERT) transfusion capability was 
developed in the context of severely injured patients recovered by physician-
led helicopter borne medical teams with transfer times of 1-2 hours.  Paper 2 
by O’Reilly et al. in 201488 was the first of a pair of papers describing military 
pre-hospital blood transfusion.  This Special Report covers the practical and 
clinical aspects of prehospital transfusion as practiced by the UK Armed 
Forces in Afghanistan and describes a cohort of patients who received pre-
hospital transfusion.  O’Reilly, in an additional paper, presented a matched 
cohort study of mortality outcomes after pre-hospital transfusion.185  This was 
the first comparative study of military pre-hospital transfusion in a modern 
context.   There are acknowledged confounders but, in the context of 
particularly accurate matching of injury profiles, that paper showed a halving 
of mortality among recipients.  Paper 2 ends with a discussion of the rationale 
for pre-hospital transfusion and an exploration of future directions, especially 
for civilian practice.   
 
Pre-hospital transfusion.  The civilian context for the air ambulance may be 
different from that of the military. The transit times for most UK air ambulance 
transfers are shorter and the clinical capability en-route is restricted by the 
smaller airframes.  The value of pre-hospital transfusion for short transfers is 
debated however; early blood product resuscitation is intuitively attractive. 
Several air ambulances have described their early experience.185-188  These 
papers confirm feasibility and safe practice but do not confirm the survival 
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benefit suggested in military practice.  The Midwinter group’s systematic 
review of pre-hospital blood products (PHBP) resuscitation for trauma 
identified only low and very low-quality evidence and argued the case for 
prospective studies.186 Other investigators in the field have stressed the 
importance of “high-quality prospective data collection”.187 In 2016, the 
Midwinter group, including this author, started the pilot phase of RePHILL. 
RePHILL is a two arm, open-label, parallel group randomised controlled trial 
(RCT), investigating the role of PHBP resuscitation using up to two units each 
of red blood cells and Lyoplas-N.  The endpoint includes tissue perfusion as 
measured by lactate clearance. The pilot phase is finishing at the time of 
writing in 2017 and the methodology has been published.188 The experience of 
the pilot phase has highlighted the feasibility of delivering combined 
component therapy in the civilian pre-hospital environment. However, they 
have also highlighted the importance of close collaboration with laboratory 
services.189 
 
Impact on survival. Papers 1 and 2 have described the recent developments 
in military transfusion practice.  Others have claimed that these developments 
have had a significant impact on survival.1;8 Figure 7 shows the improved 
survival in UK combat casualties from Iraq and Afghanistan during the period 
2003–2012.8  Survival is the product of the entire system of care, which – in 
this setting of combat, the system of care incorporates the early control of 
external haemorrhage, hybrid resuscitation; rapid and physician-led recovery 
from the battlefield, early limited initial surgery including haemorrhage control, 
transfusion support and expert critical care. It is thus not possible to ascertain 
the individual contribution of the transfusion strategy employed, however, in 
Papers 1 and 2 we propose that it has been an important element.  
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Figure 7. Plot of predicted probability of survival by NISS value for each year. 
Shaded regions indicate the 95% CIs for the predicted values obtained from 
the logistic regression model.  Figure used with permission from the Journal of 
trauma and Acute Care Surgery.8 
 
 
5.2 The development of donor selection for forward transfusion 
 
Overview.  The current use of whole blood in trauma is primarily motivated by 
the need for a resuscitative solution that treats both shock and coagulopathy 
for patients with life-threatening hemorrhagic shock.137 In addition, whole 
blood offers simplified logistics, reduced donor exposure, reduced dilution by 
additive solutions and anticoagulants.  It is an ideal candidate for the military 
and civilian pre-hospital environment and possibly for Mass Casualty Events 
(MCE).   Whole blood collection as part of Remote Damage Control 
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Resuscitation (RDCR) is in the process of being developed in the UK.  Papers 
3 and 4 were studies designed to inform the selection of donors.  
 
Group O Low titre whole blood donors.  The Trauma Hemostasis and 
Oxygenation Research (THOR) network has advocated the use of group O 
donors who have been pre-tested, and shown to be negative, for low titre or 
clinically significant levels of anti-A/B antibodies.154 The approach is pertinent 
to both military and civilian practice but is particularly important when there are 
risks associated with both emergency collection and administration.  This 
approach was adopted and developed on a larger scale by the US 75th 
Ranger Regiment (Special Forces) as part of their ‘Rangers O Low titre’ or the 
ROLO initiative.144  Paper 3 describes the feasibility of using this approach for 
the smaller UK airborne medical regiment to create a POLO (Parachute O 
Low titre) panel.  We demonstrated in Paper 3 that for planning purposes, 
approximately one third of a military unit were suitable for a POLO panel.  The 
findings were similar to those of the US.144  However, we also demonstrated 
that the use of a group O donor only policy may need to be modified for small 
team work, i.e. less than 10 persons.190  The UK medical doctrinal notes157 
were updated to reflect the optional use of a ‘Blood Buddy’ system for small 
groups.  In this situation, planners are now advised to consider the use of both 
group O and group A donors (A to A and low-titre O for all others) or to use a 
prepared blood group matrix of donors and recipients (buddy-buddy blood 
group matrix).   However, Group O whole blood with low anti-A/B titres should 
be used where the blood group of the recipient is unknown or there is 
uncertainty.154  
 
Civilian use of plasma rich components.  In civilian medical service, the 
problems related to the transfusion of group O whole blood to non-group O 
recipients disappeared with the introduction of component therapy, (RBC, 
plasma and platelet units) and the virtual elimination of whole blood 
transfusion in adults. However, platelet transfusions with ABO-incompatible 
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plasma continue to occur routinely in hospitals in the US and Europe due to 
inventory constraints. Each unit of apheresis platelets contains about 200-300 
mL of plasma, which is similar to that of whole blood. A previous study by the 
Biomedical Excellence for Safer Transfusion (BEST) collaborative in 2010 
concluded that there was considerable variation in the transfusion practice 
and testing of minor ABO-incompatible platelet concentrates.191 In addition, 
few centres performed routine monitoring following such transfusions. 
Transfusion reactions are commonly reported and collated via hemovigilance 
systems. A total of 25 reports (mostly case reports) of haemolytic reactions in 
connection with platelet transfusions from 1975 to 2009 were evaluated in 
detail.192  From 30 patient cases, of which 25 were malignancies, mostly 
leukaemia, there were only two fatalities that could be linked to a haemolytic 
transfusion reaction due to incompatible platelets in otherwise very sick 
cancer patients. The risk of haemolysis associated with platelets has been 
reduced through the introduction of Platelet Additive Solution (PAS).  
However, guidance for haemolysin testing will be required if whole blood is to 
be reintroduced into the civilian inventory.   
 
The unscreened emergency donor.  The context of Paper 4 by Doughty et al., 
2016109 is access to blood for isolated military or civilian projects with 
extended lines of supply or limited logistical support, i.e. the austere medical 
environment (AME).   The medical planning for remote activity should consider 
the requirements for resuscitation, including transfusion support. The 
emergency use of fresh whole blood (FWB) should be considered if medical 
evacuation is delayed and there is no capacity to provide cold stored blood 
products. Ideally, team members and staff should be pre-screened as 
members of an Emergency Donor Panel (EDP). However, the emergency 
screening and management of unknown additional blood donors may also be 
required.  The aim of Paper 4 was to introduce a generic Field EDP 
Questionnaire and Triage Tool (QTT).109  A review of the literature 
demonstrated that there was very little published about the assessment of 
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blood donors in the AME.  The context and urgency may necessitate a rapid 
or focussed donor screen.  However, relaxing donor acceptance criteria will 
introduce risk.  Risks may need to be further managed using ‘donor triage’ and 
appropriate use of blood.  The paper also addressed some of the practical 
aspects for the non-specialist faced with the donor selection in the austere 
medical environment.  One of the novel considerations is the implication of 
donor selection and rejection within a close community.109  
 
Implications for civilian practice.  Transfusion is moving forward within the 
battlespace. Knowledge sharing from the THOR network has enabled new 
planning guidance to be developed for UK policy and practice as illustrated by 
Papers 2 and 3.  However, the concept of the safe group O donor has also 
informed the wider transfusion community leading to the acceptance of group 
O Low titre by the American Association of Blood Banks in 2017.193 
 
5.3 Introduction of Massive Transfusion Protocols in UK and 
Norwegian civilian centres  
 
Overview.    The theory of an acute coagulopathy of trauma together with 
retrospective evidence from analysis of military and civilian trauma databases 
led to new transfusion guidelines, including massive haemorrhage guidelines 
in Europe166;197 and trauma guidelines in Scandinavia.194 Early adopters in 
England and Scandinavia now have a decade of experience of using MTPs for 
massive haemorrhage.  Papers 5 and 6 study different, but complementary, 
aspects of the introduction of MTPs.   
 
The evolution of MTPs in Birmingham.  The Birmingham massive 
haemorrhage protocol introduced in August 2008 was identical to the UK 
military protocol based on transfusion shock packs of four RBC and FFP 
followed by the early use of platelets and cryoprecipitate.  The clinical 
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guideline is shown below in Figure 8.  Features include pre-hospital 
notification, haemorrhage control and cell salvage. 
 
 
Figure 8.  The 2008 version of the Massive Haemorrhage guidelines from the 
University Hospital Birmingham by Doughty and Billington. 
 
The first audit of MT activations in Birmingham had highlighted concerns 
about delays due to the availability of thawed plasma.  The average time from 
activation to issue of the packs was 30 min and this did not include transport 
time.  The study tested the hypothesis that immediate access to red cells in 
the Emergency Department (ED) may reduce demand for Shock Packs and 
the waste of unused thawed plasma. The primary aim of this study was to 
study the impact of protocol change together with education. The study 
showed that the mean age of the patients was 40 years and 73 -80% were 
male.  The main mechanism of injury was road traffic collision.  The mean ISS 
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was similar in the two study periods, 25 and 30 and the mortality was 13% and 
15%, i.e. unchanged. The use of emergency RBC reduced the MTP activation 
rate from 24 to 13% of all major trauma cases and the positive predictive rate 
for the use of Shock Packs improved from 13 to 36%.  The main finding was 
that many patients only needed 4 units of red cells and did not require further 
blood-based resuscitation.  However, this approach increased the use of 
group O RhD negative red cells and perhaps placed some patients at risk of 
plasma deficit.   
 
Predictive scoring systems.  Birmingham was an early adopter of MTPs and 
this audit was performed during the early days of practice.  Over-activation of 
the MTP was common and perhaps desirable if there are perceived delays in 
transport of samples and blood. Over-activation provides patient safety but 
impacts on staffing and use of resources.  Paper 5 attempts a retrospective 
application of massive transfusion predictive tools.  Predictive modelling for 
massive haemorrhage has been designed for MTP activation and may support 
decision making.195;196 However, Paper 5 argues that this is a limiting concept 
as the predictors are often not available at the time of admission. We 
proposed that if the scoring systems are applied later they can be used to 
determine the continued requirement for MT support.  Using a prediction 
model in this novel way permits the use of data gathered during resuscitation 
and removes the gatekeeper effect.   Greater accuracy can be gained through 
education, mentored clinical exposure197 and ongoing audit.    
 
Quality monitoring.  A recent quality management audit of a mature system in 
a US level 1 trauma system during 2016 was described recently by Hess et 
al.198  The MTP was activated 309 times during 2016 for a variety of 
conditions but mainly (77%) for trauma.  The mean ISS was 32 and the 
mortality 15%.  Over triage was minimal with 93% of all activations receiving 
blood and 83% receiving 3 or more units of red cell concentrates (RCC).  Of 
note, only 19% of all activations fulfilled the traditional criteria of at least 10 
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units of RCC.  The mode RCC use was 2 units, the median, 4 units and the 
mean 6.6 due to a small number of individuals requiring 20 or more units.  The 
system in Harbourview Medical Centre in Seattle is unusual in that it operates 
a transfusion support system very similar to military field hospitals.  The MTP 
activation results in a blood technician moving with components into ED to 
work closely with the clinical team.  The target response time is 3 minutes.  
Such a model would be very attractive for MCEs. 
 
Changing practice massive transfusion in a single Norwegian centre.  Paper 6 
is an early example of how the new transfusion paradigm has changed 
transfusion practice in relation to all patients with massive haemorrhage. The 
programme was based on established civilian practice in Copenhagen, and 
introduced as an integrated programme, including thromboelastography and 
education. More significantly, it was championed by the key stakeholder i.e. 
the Department of Anaesthesia and closely supported by the Department of 
Immunology and Transfusion Medicine. Only 410 MT episodes were identified 
in 410 patients during a 13-year period.  This was due to the selection criteria 
of > 10 units RCC.  The mean ratio of blood components RCC: plasma: 
platelets used in massive transfusion changed in 2002-2006 from a red cell 
predominant mix of 1.0:0.37:0.39 (n=149) to a more balanced ratio of 
1.0:0.79:0.85 (n=241) in 2008-2015 (p<0.001). The use of platelet 
concentrates, and plasma increased significantly after the introduction of the 
massive transfusion package in 2007, as seen in other studies.199-203 The 
survival figures did not change, other than for those patients transfused 
greater than 30 components.  The Halmin epidemiological study of 92,057 
massive transfusions during a similar period showed a slight increase in the 
median plasma: RBC ratio over time but no marked changes in mortality.204  
 
Patient demographics.  The mean patient age in the Bergen study was 60, like 
other civilian MT studies204;205 and more recent general trauma studies.206   
More importantly, it demonstrated that most (87.1%) episodes were in support 
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of surgery especially cardiac services (42.7%). Trauma accounted for only 
17.6%.   The figures may reflect the case-mix in an institution with a regional 
specialist unit in cardiac services.  However, the findings are similar to other 
teaching hospitals.205  Although the study numbers are small, there is a signal 
from the sub analysis that cardiac specialities used a greater proportion of 
plasma and platelets.  We propose that this may be related to changes in 
pharmaceutical practice in this group especially anti-platelet medication.  The 
paper concludes that MT remains an uncommon but serious complication of 
major surgery.  The findings contrast with the general transfusion use studies 
from the UK, which show that most red cells (65%) are used for medical 
specialties, especially haemato-oncology and gastroenterology.207;208   The 
findings are important for Patient Blood Management programmes and civilian 
blood component demand planning. 
 
5.4 Transfusion support to Mass Casualty Events 
 
Overview.  Recent terrorist events remind us again that the UK and Norway 
are not immune from the traumatic injuries seen in military medicine. The care 
of the patient with traumatic haemorrhage is demanding, and this is further 
complicated in the mass casualty situation. Mass casualties may result in a 
demand for blood that cannot be immediately met.  Paper 7 by Doughty et al. 
compared the UK and the Bergen systems and highlighted the need to work 
across the continuum of care, from the pre-hospital community to the blood 
providers.   
 
Definitions.  The terminology in Major Incident planning is complex; and 
civilian and military terminology differs. A Major Incident is any occurrence that 
presents a serious threat to the health of the community in such numbers or 
types of casualties to require special arrangements.  The exact scale of an 
event and the resources required are often unknown when initially declared by 
the emergency services.  For the purposes of this discussion, I have used the 
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term Mass Casualty Event (MCE) rather than Major Incident or Disaster.  An 
MCE may be defined as a ‘single or simultaneous event(s) or other 
circumstances where the normal major incident response of one or several 
health organisations must be augmented by extraordinary measures to 
maintain an efficient, suitable and sustainable response’.209  Glasgow argues 
that MCE is an appropriate term in the context of transfusion planning 
because it is healthcare specific and addresses healthcare load.  I suggest it 
is a good fit because Blood Services commonly support several healthcare 
organisations and planning must address the requirement for sustainability.   
 
Transfusion planning for the Olympics.  Glasgow et al. described how the 
military concepts of pre-hospital care, registry reviews, standardised MTPs 
and emergency donor planning principles were successfully integrated into 
NHS Blood and Transplant’s (NHSBT) planning for the 2012 Olympic 
Games.177  Demand planning for the Olympic Games was based on a 
compromise between the available civilian and military data combined with the 
feasibility of achieving and maintaining the required stock level. Military 
experience had shown that a third of patients needed blood with a 
requirement for 15 units of RCC and FFP.  In contrast, reviews of civilian 
MCEs with military type trauma suggested that few people need blood and the 
RBC demand was 2-3 units.  The notable exception was the demand for blood 
following the London bombings described by Glasgow et al.164  The mean 
RBC demand was 17 and the mode was 12. It is difficult to explain why the 
London bombing figures are so much greater than the civilian norm.  Blood 
use after the Boston Marathon bombing of April 15, 2013 was summarised by 
Quillen and Luckey in 2014.210  Thirteen percent of patients brought to the ED 
were transfused.  The mean blood use per patient (24 hr) was 6.15 units.  
Only 1 patient of the 58 (2%) received >10 units.  Quillen reflected on the 
greater blood use per patient transfused in London and suggested it was due 
to lack of tourniquets.210  The point is well made and demonstrates the 
importance of early haemorrhage control.  
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Transfusion requirements for MCEs. Paper 7 highlights the requirement to 
estimate the proportion of casualties requiring blood following MCEs.  
Traditional planning by the North Atlantic Treaty Organisation (NATO) is 
based on a P1: P2: P3 ratio of 25:25:50 however, this does correlate well with 
civilian events and transfusion planning.  A past Israeli survey of 1645 attacks 
involving 7497 casualties suggested 13% death at scene with 8% severe (P1) 
and 12% (P2) moderate casualties, i.e. a total of 20% who may need blood.  
Most blood is required within 6 hours.  Current Israeli planning assumes early 
notice of the MCE and the provision of 3 RBC per casualty and 7 units for 
more severely injured. 211 These planning principles would have worked well 
for the Manchester bombing in 2017 where 20% were transfused with a 
median use of 3 units. However, the Manchester incident was characterised 
by many girls and young women. It is noted that one third of the blood used 
(31/89) was group O RhD negative, of which 90% was used as emergency 
group O RhD negative.  The demand:use ratio was 3.5 for all red cells, which 
is similar to past attacks.  However, the demand factor for group O RhD 
negative blood was 5.25.212 The experience following the Manchester 
bombings, together with a recent review of blood use in civilian major 
incidents by Ramsey213 has led to revised UK planning figures of 3 units per 
admitted casualty. However, if the methods and devices used in MCEs 
change, as noted by Godfrey, than these figures may require amendment.   
Quality data and reviews following each event are required to inform future 
planning.   
 
Transfusion Emergency Preparedness in Norway.  Planning in Norway has 
been shaped by their own tragedy of MCE.  The paper from Gaarder et al., 
2012214 following the twin terrorist attacks in Norway in 2011 describes the 
impact of MCE using two different mechanisms.  The IED explosion in Oslo 
caused 8 deaths (8.1%) at the scene where 98 casualties were injured.  Ten 
(11%) of the survivors were triaged to the major  trauma centre.  In contrast, 
the shooting on the island caused 68 dead (52%) at the scene and 61 
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survivors.  21 of these were triaged to trauma, i.e. 34%.  The MTP was 
initiated in 7/149  injured cases (4.7%).  The mean MTP blood use: RBC 7.6 
units, Octaplas 5.6, platelets 2 ATD (pools of 4).  The authors comment that 
the provision of blood was easily met though existing stocks.  Despite this 
reassurance, the Norwegian Red Cross has engaged the author to advise on 
managing the donor response. 
 
Transfusion resilience.  Haukeland University Hospital has worked closely with 
the blood donor communities to develop a novel resilience plan based on the 
lessons identified from the Blood Far Forward (BFF) program.  Transfusion 
support is based on an agile whole blood program using military and civilian 
donors.  The demand planning for specific events has been developed further 
using more detailed modelling.  An example would be the planning for the 
Bergen World Cycling Championships.  The initial response is based on the 
use of existing stock however the urgent local donor panels are designed to 
replenish these.  All blood is fully tested however it is not subject to separation 
into components.  Irrespective of whether countries use blood components 
(UK) or whole blood (Bergen), transfusion must be part of an integrated 
healthcare plan.  Pre-hospital care and haemorrhage control should be 
optimised and the use of blood in MCEs may need to be triaged and 
simplified.  Most blood will be required within the first six hours but there may 
be an ongoing requirement .  Paper 7 contends that blood supply should be 
part of civilian transfusion emergency preparedness.  The author proposes 
that it is the principles of military planning and the resource constrained nature 
of RDCR that have the greatest potential to inform civilian practice. Bricknell, 
as one of the senior medical planners during this period argued that the 
absence of a mass casualty declaration is the best evidence for the 





5.5 The implications for civilian healthcare 
 
In the introduction, I reflected that the UK Trauma Services would require 
considerable re-organisation to leverage the lessons learnt from 
developments in military trauma and transfusion.  Trauma services are 
undergoing a transformation.  
 
Major Trauma Networks. The UK Major Trauma Networks were created in 
2010 and the regional Major Trauma Networks in 2012.  The networks have 
adopted many of the military trauma organisational practices.  Specific 
transfusion measures include the requirement to have a massive 
haemorrhage protocol (MHP) as in Paper 5.  Protocols alone do not make a 
difference, it requires leadership197 and local champions, as seen in Paper 6.  
Did these changes impact on survival?  Results from the Trauma Audit and 
Research Network (TARN) national audit in 2013 showed that 1 in 5 patients 
who would have died before the networks, are now surviving severe injuries. A 
more detailed evaluation of the London Trauma System was published in the 
2016 paper by Cole et al.206   The team used the same core methodology 
used by the National Confidential Enquiry into Patient Outcome and Death 
(NCEPOD) report described in Chapter 1.  344 severely injured patients were 
identified in a 3-month period and their outcome compared with the NCEPOD 
report. Survival had improved, with the greatest benefits seen in the most 
severely injured where the crude mortality rate reduced by 50% from 31% to 
11%.  The principle cause of death was Traumatic Brain Injury and not 
haemorrhage.  Patients were noted to have increased use of pre-hospital 
services and were older than in previous studies (NCEPOD).  The latter has 
also been demonstrated by Kehoe.216  The authors conclude that inclusive 
trauma systems seem to deliver quality through organisational change. 
However, I suggest that it is further evidence that the civilian population is not 
the same as the military population and that the future configuration and 
capability of trauma services should be different. 
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National Institute for Health and Care Excellence (NICE) Trauma Guidelines.217 
Rapid and efficient safe transfusion support is now considered an essential 
element in the management of major haemorrhage.218  Sadly, in 2015 a 
prospective UK observational study from 22 major hospitals showed that there 
were still delays in the delivery of blood.219 The authors concluded that only 2% 
of patients with massive haemorrhage received optimal, i.e. timely, 
resuscitation. Further direction was required for the wider trauma community.  
In 2016, the changes in transfusion practice that began in 2006, were formally 
adopted within the UK NICE guidelines for trauma.64  The early requirement for 
plasma had highlighted the delays in thawing FFP to order. The military had 
introduced pre-thawed plasma with an extended post thaw shelf-life in 2008. 
However, this was not introduced into UK civilian practice until after the NICE 
trauma guidelines in 2016.220  The introduction of pre-thawed plasma has 
reduced one of the practical barriers to the timely delivery of plasma identified 
in Paper 6.  It also appears to have reduced the wastage of plasma where there 
is a sufficient ongoing demand within the hospital. However, pre-thawed plasma 
may not be convenient for helicopter-based services deploying from airfields 
remote from their supporting blood banks as in Paper 2 and lyophilised plasma 
may be used.188  The demand for ‘plasma now’ has also resulted in the blood 
service reviewing the development of new components including liquid 
plasma221 and whole blood.150   
 
Patient Blood Management.  The civilian community has successfully reduced 
the demand for red cells through the Patient Blood Management (PBM) 
initiative.35 Whereas, the demand for blood appears to have increased in 
military practice despite haemorrhage control.  There is a perception that the 
opportunities for PBM are limited in the management of traumatic 
haemorrhage.  However, this paradox can be resolved.222 Patient Blood 
management is about optimising the care for patients rather than just reducing 
blood use.  Paper 1 suggests that the use of goal directed transfusion therapy 
increased the demand for haemostatic components.  However, these studies 
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also imply that some patients were under transfused in the past and that 
massive transfusion has contributed to the unexpected survival figures.8  
Classical PBM manoeuvres already being used by the military that reduced 
the demand for red cells included tourniquets, combat bandages and topical 
haemostats. The massive blood use after the London bombings may reflect 
the non-availability of these measures in civilian practice.  Damage control 
surgery is the definitive method of haemorrhage control.223 In addition, 
transfusion-sparing techniques can be learnt from civilian teams performing 
complex surgery without blood support, including cell salvage.224  There is 
also valuable guidance for transfusion planning from Coupland and others 
who have worked with the International Committee of the Red Cross (ICRC) in 
resource constrained environments. 225;226  
 
Transfusion demand planning. Studies in this thesis have considerable 
implications for civilian demand planning. Demand management of blood 
components is challenging. Challenges arise from the limited shelf-life of blood 
components combined with providing sufficient stock whilst minimising blood 
wastage. Most blood components in the UK, especially red cells, are used by 
non-surgical patients207;208 where it is harder to predict demand. In contrast, 
Doughty et al. and other investigators suggest that massive transfusion is 
associated with surgery204;205;227 which can be managed through PBM 
principles.  Whereas the use of red cells has fallen, the demand for other 
components has increased in the UK.  The drivers for the increase in platelet 
use may include haemato-oncology, gastroenterology and the wider use of anti-
platelet drugs as discussed in Paper 6.228 The requirements for plasma and 
fibrinogen replacement have also increased in most European countries. This 
may be due to the inappropriate use of plasma in non-bleeding patients229 but 
also in part to the wider use of MHPs as discussed in papers 1, 5 and 6. The 
wider use of pre-hospital transfusion in civilian practice is leading to an 
increased initial demand for ‘universal’ components such as Group O RhD 
negative RBC and Group AB FFP.  The recent paper by Naumann et al., has 
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quantified the potential demand. Most of the patients attended by the air 
ambulance are male.230  Consideration may need  be given to the carriage of 
group O RhD positive blood in addition to Group O RhD negative.  The trends 
for components use and the group mix should be factored into local and national 
demand planning as well as the planning for MCEs. Transfusion Emergency 
Preparedness for MCEs is underpinned by sound military planning principles 
together with the lessons learnt from taking transfusion forward. 
 
5.6 Limitations of study 
 
A general limitation of the study is the retrospective analysis of observational 
data collected during a period of considerable change.  The source data for 
Papers 1 and 2 were extracted from the military Joint Theatre Trauma 
Registry (JTTR), which records details of all casualties who receive treatment 
in deployed UK military MTFs. The data for both blood and other fluids is 
thought to be complete for military papers 1 and 2. In contrast, the study-
specific limitations for the civilian papers 5 and 6 include a lack of data on the 
volume of crystalloid and colloid solutions administered during resuscitation.  
The reason for lack of detail is that papers 3, 5 and 6 have used hospital LIMS 
data as a key source of primary data.  The author recognises that clinical 
information provided to hospital blood transfusion laboratories with requests 
for transfusion may be limited.  In addition, there may be difficulty in extracting 
the information required for retrospective studies from hospital IT systems. Of 
note, LIMS assumes that the time of blood administration equals that time of 
issue, which may not be correct.   
 
The definition of ‘massive transfusion’ used for all the studies (Papers 1, 5 and 
6) was ten units, or more, of RBC transfused in 24h. We recognise the 
limitation of this definition which has been used since the initial papers from 
the Holcomb team.38 Green et al.205 used several definitions including both MT 
>5 RBC units in 4 hours as well as the traditional >10 RBC units in 24 hours. 
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The former has been proposed by Mitra.231;232 When the two definitions are 
used together they should capture approximately 95% of all cases.  The MT 
>5 RBC units in 4 hours is a much more appropriate marker of active 
haemorrhage and resonates with the definitions used in the military protocols.  
In addition, it is useful for MI demand planning where it should be assumed 
that most blood will be required within the first 6 hours.  
 
Despite these issues, these studies add to our understanding of modern 
resuscitation strategies in both military and civilian practice. The military 
studies complement analyses from the US JTTR.233  The military studies in 
Papers 1 and 2 are based on a large and complete database collating 
contemporaneously collected data.  The conclusions are applicable to similar 
military trauma systems.  Likewise, the laboratory data from paper 3 is 
complete, being underpinned by both military and civilian LIMS.  The civilian 
studies in papers 5 and 6 are subject to the limitations of retrospective studies 
at a single centre and the numbers are relatively small.  Cardiac cases are 
over-represented in paper 6 and trauma is possibly underrepresented.  The 
general observations from both would be applicable to other large medical 
centres dealing with massive haemorrhage.  However, larger scale studies are 
needed from Norway. The Bergen team is currently designing these. 
 
Retrospective studies cannot prove causation. Papers 1 and 2 suggest a 
temporal association between increased component use and improved 
survival, in combat casualties requiring transfusion as part of Damage Control 
Resuscitation (DCR). The higher survival in the military severely injured may 
be accounted for in part by the younger age and greater fitness of the military 
patient group.  In addition, the military care system was optimised for trauma 
care with early care from point of wounding through to rehabilitation.4;234;235  
However, the small civilian studies in papers 5 and 6, have failed to 
demonstrate an improvement in 30-day mortality.  Similar observations, i.e. no 
significant improvement in mortality, have been made in other retrospective 
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civilian studies such as that by Green et al.205  The failure to demonstrate an 
improvement may be due to the sample size, the greater variance in co-
morbidities or the challenge in demonstrating incremental improvement in a 
more controlled environment.  The significance of these is considered in the 
future recommendations.  Finally, the body of published literature for 
transfusion in the austere environment and in support of mass casualties was, 
and remains, limited.   
 
The strength of the study is that it documents the entirety of a unique 








6.1   Summary of findings 
 
Aim 1.  The paradigm of military transfusion has changed in the last decade.  
The developments have been credited with contributing to survival of the 
critically injured. Survival is the product of the entire system of care, which – in 
this setting of combat, incorporates the early external haemorrhage control, 
hybrid resuscitation; rapid and physician-led recovery from the battlefield, 
damage control surgery, transfusion support and expert critical care. It is not 
possible to ascertain the individual contribution of transfusion however, it has 
been an important element.  
 
Aim 2.  Transfusion support is increasingly being considered in the Austere 
Medical Environment.  These are military and civilian environment where there 
is a risk of traumatic haemorrhage but minimal medical or logistic support.  
The collection of whole blood from a pre-tested Emergency Donor panel is a 
viable transfusion management option.   Knowledge sharing from the Bergen 
based Blood Far Forward program has enabled the further development of UK 
military practice.  In addition, the concept of the safe universal whole blood 
donor has informed the wider transfusion community leading to the 
acceptance of group O Low titre as a new standard. 
 
Aim 3.  Massive Transfusion Protocols have been successfully introduced into 
civilian practice for both trauma and other causes of massive haemorrhage.  
Massive Transfusion (MT) is a phenomenon of surgery not trauma and the 
organisational principles can be applied to all causes of haemorrhage.  MT is 
resource intensive and has implications for both hospital and blood service 
organisation. However, the civilian studies have not demonstrated a survival 
advantage and the definitions of MT require standardisation to allow 
comparison of practice and the design of further studies.  
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Aim 4.  The pattern of blood use in civilian Mass Casualty Events (MCE) 
differs from that seen in the recent military experience in Afghanistan and Iraq.  
Far fewer injured require blood and few require Massive Transfusion and 
haemostatic component support.  However, military style planning has added 
value to the preparation for MCEs and the response to Major Incidents.  
Elements of military planning have included the optimisation of pre-hospital 
care, haemorrhage control, transfusion triage, MTPs and emergency donors.  
Transfusion Emergency Preparedness should become an integrated part of 
healthcare emergency planning. 
 
6.2 Reflection on findings 
 
Returning to the opening vignette, the recent developments in military 
transfusion practice have had a direct impact on civilian transfusion practice, 
including the planning and response for MCEs.  Elements of new clinical 
practice include: pre-hospital control of haemorrhage, pre-hospital transfusion, 
trauma registries, standardised massive transfusion protocols and emergency 
donor planning. However, caution is required in extrapolating the blood 
demand for military trauma to current civilian hospital practice or emergency 
planning.  I suggest that the lessons learnt for MCEs from the military are 
related to planning rather than the direct comparison of transfusion 
requirements.  Military planning and transfusion practice together underpin the 
emerging discipline of Transfusion Emergency Preparedness.   
 
Transfusion has emerged as an essential and successful element of combat 
care. The success must be placed in the context of the whole healthcare 
system, especially pre-hospital care.  Combat has stimulated rapid innovation. 
Sometimes military developments have been based on emerging evidence 
together with pragmatism rather than randomised controlled trails.  However, 
the thesis has presented evidence that lessons identified from military medical 
and transfusion care have been intelligently adopted into civilian practice and 
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planning. In turn combat care has benefitted from civilian transfusion 
regulatory and governance expertise.  The continued military-civilian 
collaboration and international innovation in transfusion practice has the 
potential to benefit not only the armed forces, but also the wider healthcare 
community.   
 
6.3 Recommendations and future works 
 
The operations in Iraq and Afghanistan have been a stimulus to develop new 
paradigms of treatment.  Developments in planning have led to transfusion 
emergency preparedness. However, preparedness for the future requires 
constant horizon scanning.  A recent analysis of the implications of future 
operating environments for the defence medical services can be summarised 
as follows:236  
• Preparedness: High readiness, humanitarian assistance, disaster relief 
• Operations: Urban, distributed small mobile combat teams, sea basing 
• Technology:  Develop capability but reduce size and weight, 
telemedicine 
• Economic: Need for evidence base and collaboration with academia 
and industry 
The last statement is important.  It emphasises the need for an evidence base 
developed together through partnerships.  The North Atlantic Treaty 
Organization (NATO) Blood Panel exists to promote interoperability of 
transfusion practice between NATO partners.  It was started as an informal ad 
hoc working group in 2005.  In January 2011 it was formally integrated into the 
NATO Committee of Chiefs of Military Medical Services (COMEDS) structure 
as a permanent sub-element and expert panel under the Military Health Care 
Working Group (MHCWG).  More recently, it has advised the United Nations 
on deployed transfusion support.  The panel has served as an important forum 
for the development of pre-hospital transfusion and transfusion in the austere 
environment.  In doing so, there are synergies with the Trauma, Hemostasis 
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and Oxygenation Research (THOR) community, especially in the areas of 
innovation and research.131    
 
The collaborative work between Birmingham and Bergen has linked military 
and civilian teams from both organisations.  We have achieved significant 
changes in emergency transfusion support especially very early transfusion 
support.  Sometimes practice has preceded the evidence and has stretched 
regulatory and logistic constraints. Ethical and philosophical issues are also 
important and require us to question ‘should we’ and not just ‘could we’.  
Conducting research in military182 and civilian trauma, especially MCEs, is 
challenging especially where practice has become established and the 
numbers of patients required to power studies are great. In addition, this 
thesis has illustrated the caution required when extrapolating the lessons 
identified in one system to another.  The challenge is for the combined 
communities to continue to optimise transfusion support with intelligent 
application of best evidence.  To do this will require an ongoing commitment 
for data collection and management.  In addition, quality quantitative and 
qualitative research should be embedded into routine clinical and planning 
practice.   
 
Pilot and feasibility studies provide guidance for future studies.  For instance, 
the CRYOSTAT feasibility study58 signaled possible associations between 
higher fibrinogen levels following trauma and better outcomes and use of 
healthcare resources. The observations coupled with other reports59 led to the 
current CRYOSTAT-2 study to determine the clinical benefit of early fibrinogen 
supplementation.  Multi-centre randomised controlled trials are viewed as the 
gold standard however, such trials take a considerable time to prepare and 
are best done through clinical trials networks.197 Such trials may not show 
significant improvements in mortality.  An example is the PROPPR trial 
(Pragmatic, Randomized Optimal Platelets and Plasma Ratios Trial) published 
in 2015.237  The large trial of transfusion in traumatic haemorrhage trial did not 
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achieve the primary objective.  The use of a 1:1:1 ratio of RBC: FFP: platelets 
did not result in a significant reduction in mortality at 24hr or 30 days, however 
more patients achieved haemostasis and fewer experienced death by 
exsanguination.  Despite perceived limitations238 these trials appear to be the 
tipping point for the British Society of Haematologists61 formally supporting the 
early use of plasma in haemorrhage in ratios of 3:2 to 1:1 and the National 
Institute for Health and Care Excellence (NICE) trauma guidelines of 1:1.217   
 
Professor Hans Erik Heier from Oslo has suggested that a more philosophical 
approach should be applied to current and future development.131  Increasing 
the resources and skills available may not lead to a linear improvement of 
results. The general law of decreasing marginal efficiency suggests that where 
the effect of additional resources and skills is progressively reduced, the better 
results are those which are obtained early. When few resources and skills are 
available, as in the far forward environment or mass casualties then small 
changes are likely to make a bigger difference than under optimal Damage 
Control Resuscitation (DCR) conditions.131 For instance, the benefits of whole 
blood (WB) over component therapy may be of greater significance in Remote 
DCR and pre-hospital practice than within hospital conditions. New trials for 
whole blood are being introduced however, John Ioannidis warned that “the 
hotter the scientific field and with more scientific teams involved, the less likely 
the research findings are to be true”. 239 The clinical advantage of WB may 
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               Appendix 1 
Organisation of military healthcare 
 
All military medical treatment facilities (MTF) are categorised into response 
capabilities Role 1 – 4. A brief description based on current medical doctrine is 
provided below.76 
 
Role 1 MTF - Medical Response Capability.  The initial medical response 
capability (Role 1 MTF) is a national responsibility and focuses on provision of 
primary health care, specialised first aid, triage, resuscitation and stabilisation. 
NATO doctrine assumes this will be a physician.  The UK model is the use of 
a general practitioner with enhanced military medical skills. Transfusion is not 
traditionally offered in this Role.   
 
Role 2 MTF - Initial Surgery Response Capability. Initial surgery response 
capability (Role 2 MTF) is characterised by its ability to perform surgical 
interventions in addition to perform reception / triage of casualties; 
resuscitation and treatment of shock to a higher level than Role 1 facilities. 
There are two main types of Role 2 MTFs: basic and enhanced (E). Examples 
of the enhanced hospital would be the high readiness field hospitals and their 
maritime equivalent, the Primary Casualty Receiving Facility (PCRF).  
Examples of basic Role 2 medical units are the Air Manoeuvre Surgical Group 
(AMSG) and the Commando Forward Surgical Group (CFSG). In some 
circumstances, it may be necessary to provide a mission-tailored medical 
treatment facility including a surgical module, the so called Forward Surgical 
Element (FSE).   
 
Role 3 MTF - Hospital Response Capability. A hospital response capability 
provides secondary health care at theatre level.  A Role 3 MTF must provide all 
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the capabilities of the Role 2E MTF and be able to conduct specialised surgery, 
care and additional services as dictated by mission and theatre requirements.  
The Role 3 facility may also act as a hub for medical logistics providing blood 
resupply and platelets. The field hospital at Bastion was an example of a Role 
3 MTF which was subsequently stepped down to a Role 2E before closure. 
 
Role 4.  Role 4 is a base hospital capable of providing the full capability of a 
Major Trauma Centre.  The Role 4 facility for the UK is the University Hospital 
Birmingham.  The full care package from reception to rehabilitation is co-
ordinated by the Royal Centre for Defence Medicine.  
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                  Appendix 2 
Vein to vein: An overview of the transfusion process 
 
The figure provides an overview of the transfusion process from donor 
recruitment to administration of blood components to the patient. The process 
starts with the key step of donor selection before the collection by whole blood 
or apheresis. Testing of the samples and manufacturing of the collection are 
simultaneous activities. Whole blood is filtered before separation into 
components.  Blood components are issued to the hospitals after a final 
validation check of the manufactured product together with the results of 
microbiological and serological testing.  Source plasma may be used for 
clinical plasma or fractionation to produce plasma derivatives such as 
fibrinogen. 
 
An overview of the Development in Military Transfusion Capability 
The capability developments starts with the haemorrhage control tools for Role 1 and 
extends through to Role 4.  The MTC programme is focussed on the Role 3  field hospital 
with investment in both the clinical and laboratory spaces.  The cold chain requirements 
extends forward from NHS Blood and Transplant through to the MERT.  
 
 146
                Appendix 3 
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SUMMARY
Objective: To document blood component usage in the UK
medical treatment facility, Afghanistan, over a period of 4 years;
and to examine the relationship with transfusion capability,
injury pattern and survival.
Background: Haemostatic resuscitation is now firmly estab-
lished in military medical practice, despite the challenges of
providing such therapy in austere settings.
Materials and Methods: Retrospective study of blood compo-
nent use in service personnel admitted for trauma. Data were
extracted from the UK Joint Theatre Trauma Registry.
Results: A total of 2618 patients were identified. Survival
increased from 76 to 84% despite no change in injury severity.
The proportion of patients receiving blood components
increased from 13 to 32% per annum; 417 casualties received
massive transfusion (≥10 units of RCC), the proportion
increasing from 40 to 62%. Use of all blood components
increased significantly in severely injured casualties, to a median
(IQR) of 16 (9–25) units of red cell concentrate (P = 0·006), 15
(8–24) of plasma (P = 0·002), 2 (0–5) of platelets (P < 0·001)
and 1 (0–3) of cryoprecipitate (P < 0·001). Cryoprecipitate
(P = 0·009) and platelet use (P = 0·005) also increased in
moderately injured casualties.
Conclusions: The number of blood components transfused to
individual combat casualties increased during the 4-year period,
despite no change in injury severity or injury pattern. Survival
also increased. Combat casualties requiring massive transfusion
have a significantly higher chance of survival than civilian
patients. Survival is the product of the entire system of care.
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the Association of Surgeons of Great Britain and Ireland (2013), and
will be presented at BBTS (2013).
Correspondence: Mr Jan Jansen, Ward 505, Aberdeen Royal
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However, we propose that the changes in military transfusion
practice and capability have contributed to increased combat
trauma survival.
Key words: haemostatic resuscitation, military transfusion,
tranexamic acid, trauma resuscitation.
The past decade has seen remarkable changes in military trauma
transfusion practices, brought about by the recognition that
acute traumatic coagulopathy is associated with excess mortality
(Brohi et al., 2003; MacLeod et al., 2003; Brohi et al., 2007; Pid-
coke et al., 2012), and that combat casualties transfused with high
plasma to red cell unit ratios had dramatically improved survival
(Borgman et al., 2007; Pidcoke et al., 2012). Haemostatic resus-
citation, comprising the administration of predetermined ratios
of units of red cell concentrate (RCC), plasma (FFP) and platelets
(PLT), is now firmly established, despite the inevitable challenges
of providing such therapy on deployment, and in austere settings.
Two recent analyses from the United States have examined
changes in military blood use over time. Pidcoke et al. (2012)
have shown that the volume of blood transfused per casualty,
and the ratio of the units of plasma and platelets to red cell
concentrate has increased, and that these changes are correlated
with improved survival. Rentas et al. (2012) have demonstrated
similar trends. However, neither of these studies have examined
the impact of changes in injury pattern and severity on blood use.
The aim of this study is, first, to analyse blood component
usage in the UK medical treatment facility at Camp Bastion,
Afghanistan, over a period of 4 years; and second, to examine
the relationship between blood component usage, transfusion
capability, injury pattern and survival.
MATERIALS AND METHODS
Design
This is a retrospective analysis of blood component use in a
single combat support hospital. The study was approved by
the Royal Centre for Defence Medicine (RCDM/Res/Audit/
1036/12/0175). Eligible patients were British and coalition
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(non-Afghan) service personnel admitted following injury, and
transfused one or more units of blood components before and
during admission to the UK medical treatment facility (MTF)
at Camp Bastion, Helmand province, Afghanistan, between
1 January 2008 and 31 December 2011. Casualties who only
received transfusions after discharge or transfer from the hospital
were excluded.
Source data
Data were extracted from the Joint Theatre Trauma Registry
(JTTR), which records details of all casualties who receive
treatment in deployed UK military medical treatment facilities
(MTF). UK service personnel are followed up to discharge
from Queen Elizabeth Hospital, Birmingham. Coalition service
personnel are followed up to aeromedical evacuation from the
hospital at Camp Bastion. Extracted data included demographic
details, injury severity scores, and the number of units of red cell
concentrate, plasma, platelets, cryoprecipitate and fresh whole
blood transfused. In addition, data on adjuncts to haemostasis
management (recombinant factor VIIa and tranexamic acid)
was extracted.
Setting
The retrieval of casualties in Helmand Province is almost
invariably by helicopter, usually directly to the UK MTF at
Camp Bastion. In-flight care is provided by paramedics or
doctors. For casualties who are in extremis, transfusion with red
cell concentrate and plasma may be initiated en route, but is
more commonly administered at the hospital at Camp Bastion.
The MTF at Camp Bastion is a field hospital optimised for the
management of trauma. Staffing is multi-national but comprises
predominantly British and American military personnel. The
hospital has increased in size and complexity over the period
of this study, from a basic tented facility to a solid build. In
late 2011, it had 4 operating tables, 12 intensive care beds and
2 CT scanners. The laboratory provided a basic transfusion and
general pathology diagnostic service together with the ability to
receive and re-distribute blood components. Blood components
are provided by licensed blood services and imported by
military logisticians. All UK components were leucodepleted.
The principles of transfusion inventory management remained
largely unchanged during the period of study. Red cells provided
for resuscitation should be ‘fresh’. In 2009, the policy further
defined this as less than 14 days old where possible. Plasma
was provided as pre-thawed FFP with a maximum post thaw
shelf-life of 5 days. The laboratory also managed a pre-tested
Emergency Blood Donor panel. This capability permits the
donation of Fresh Whole Blood and the collection of platelets
by apheresis.
Transfusion policy
Transfusion support for the severely injured was guided by a
Massive Haemorrhage Policy, containing a Massive Transfusion
Box 1. Key components of the massive transfusion protocol
used by the Defence Medical Services (Surgeon General’s
Policy Letter, 2007).
Definition
Massive transfusion is defined as:
1. The replacement of an equivalent amount of blood to
an entire circulating blood volume of the patient with
24 h; or
2. Administration of more than 10 units of red cell
concentrate within 24 h (whichever comes first).
In the acute military operational setting, additional criteria
include:
1. The transfusion of over 4 units of red cells in 1 h; or
2. The replacement of 50% of the total blood volume in
3 h; or
3. A rate of loss of >150 mL min−1.
Principles of the DMS Operational Massive Transfusion Pro-
tocol (MTP).
The DMS operational MTP adopts an aggressive resuscita-
tion approach in which the primary aim is to avoid a sig-
nificant degree of coagulopathy. This approach requires:
1. Active avoidance of hypothermia by the use of fluid
warmers and rapid infusion devices.
2. Maintain the Hct at 35%.
3. Use of FFP to RCC in a 1 : 1 ratio as soon as practicable.
4. Early use of cryoprecipitate in order to maintain the
level of fibrinogen above 1·0 g L−1.
5. Early intervention with platelet support to maintain
the platelet count above 100 × 109 L−1 using
UK (or more local source if appropriate) derived
platelet components, or platelets donated using field
apheresis, both in preference to whole blood from the
Emergency Donor Panel (EDP).
6. Frequent measurement of FBC and coagulation
studies to confirm successful application of the MTP.
7. Frequent measurement of potassium and calcium lev-
els in order to identify the presence of hyperkalaemia
or hypocalcaemia so that appropriate therapy can be
commenced.
8. Appropriate intervention with rFVIIa in accordance
with current military guidelines.
9. Regular assessments of the base deficit in order to
monitor (along with hypothermia and coagulopathy)
the lethal triad associated with massive trauma.
Protocol (MTP) together with guidance for monitoring response
to treatment (Surgeon General’s Policy Letters, 2007, 2009). The
key elements of the policies are shown in Box 1. The MTP
may be initiated by clinical staff who are concerned that the
patient has had or may be at risk from the effects of massive or
rapid haemorrhage. Treatment is initially given as ‘Shock Packs’,
based on the use of pre-thawed plasma (4 units) and red cell
concentrate (4 units) in a 1 : 1 ratio. Shock packs may be used
© 2013 Crown copyright. Transfusion Medicine, 2014, 24, 154–161
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in both the hospital and pre-hospital setting (physician-staffed
retrieval helicopters carry 4 units of red cell concentrate and 4
units of plasma). Subsequent transfusion support including the
early use of cryoprecipitate and platelets is guided by the clinical
response together with the results of laboratory and point of
care testing. Pharmacological adjuncts have changed during the
period of study with the decreasing use of recombinant factor
VIIa (rFVIIa) and the increasing use of tranexamic acid (TXA)
since 2009. The transfusion protocol has recently been updated
to incorporate the evidence for the routine use of TXA (CRASH-
2 trial collaborators, 2010; Morrison et al., 2012) and a higher
target for fibrinogen.
Transfusion capability
Transfusion capability increased over the period of the study,
in line with operational requirements. The focus has been
on both the capacity and capability to support haemostatic
resuscitation. Plasma, cryoprecipitate and platelets have all
been available since before the period of study. However,
greater resilience was introduced in spring 2008 with the
introduction of an operational apheresis capability to collect
platelets (Doughty et al., 2011). Pre-hospital transfusion was
introduced in summer 2008, requiring investment in equipment
and manpower. Laboratory staffing was increased, and services
increasingly automated. The introduction of the Laboratory
Information Management System in 2009, together with full bar
coding, has transformed the speed and accuracy with which staff
can respond to the call for large amounts of blood components.
Walk away automated diagnostic technology has facilitated the
processing of large numbers of samples, required to monitor
resuscitation in critically injured patients. More recently,
rotational thromboelastometry (ROTEM) was introduced, as a
point-of-care test, to further optimise haemostasis management.
Data management and statistical analysis
Injury burden was quantified by injury severity score (ISS),
stratified into mild (ISS: 1–8), moderate (ISS: 9–15) and severe
(ISS ≥ 16); new injury severity score (NISS); and by body region,
using abbreviated injury scales (AIS).
Demographic characteristics were compared using
Kruskall–Wallis tests for continuous data and χ2 tests for pro-
portions. The number of units of individual blood components
transfused were analysed by calendar year and injury severity
strata, and compared using Kruskall–Wallis tests.
Transfused patients were furthermore analysed by volume
of red cell concentrate transfused, dichotomised into massive
and non-massive transfusion. For the purposes of this study,
massive transfusion was defined as the administration of 10
or more units of red cell concentrates while at Camp Bastion.
The definition was chosen due to ease of data collection and to
permit comparison with other studies.
Mortality for UK personnel was defined as in-hospital
mortality which occurred within 30 days either in Afghanistan
or in the UK. For other coalition patients, in-hospital mortality
included only that which occurred at the treatment facility in
Afghanistan. This approach is pragmatic, and has been employed
previously (Morrison et al., 2012), as it is very difficult to
track the progress of casualties from other countries through
their respective evacuation chains. Furthermore, although some
casualties succumb after transfer to role 4 care, this is unusual.
The ratios of plasma to red cell concentrate and platelet
to red cell concentrate are presented as three-month moving
averages. The frequency of use of tranexamic acid and FVIIa were
calculated in all transfused and massively transfused patients.
All analyses were performed using Microsoft Excel (Microsoft,
Redmond, Washington, DC, USA).
RESULTS
Between 1 January 2008 and 31 December 2011, 2618 coalition
service personnel were treated for trauma at the UK MTF Camp
Bastion. 791 (30·2%) required a transfusion. The characteristics
of this group are shown in Table 1. Nearly all (99%) were male.
The median age was 22 years (range: 19–25). The median injury
severity score and new injury severity score were 22 and 34,
respectively, indicating a high burden of injury. Analysis of ISS
strata reveals that 74·1% of transfused casualties were severely
injured (ISS 16+) (Table 1).
Number and proportion of casualties transfused
The number of trauma patients per year has increased from 303
in 2008 to 794 in 2011, peaking at 849 in 2010 (Fig. 1). The
number of trauma patients who required transfusion has also
increased, from 68 in 2008, to 257 in 2011 (Fig. 1). In addition to
an overall increase in the number of casualties, the proportions
that were transfused have also risen, from 22% in 2008 to 32%
in 2011 (Fig. 2). Four hundred and seventeen casualties (52·7%
of all patients transfused) received a massive transfusion (10
or more units of red cell concentrate). The proportion of all
trauma patients who received a massive transfusion (13·8% in
total) increased from 9% in 2008 to 20% in 2011. The proportion
of transfused patients who required a massive transfusion also
increased, from 40% in 2008 to 62% 2011 (Fig. 3).
Injury severity
There has been little change in injury severity, as measured by
ISS (P = 0·189) or NISS (P = 0·104) (Fig. 4). Similarly, there
has been little discernible change in the pattern of injury, as
measured by the proportion of casualties with a severe injury
(defined as an AIS ≥3) (Fig. 4).
Blood component use
In terms of injury severity, the median number of units of red cell
concentrate transfused to severely injured casualties increased
from 2008 to 2011 (P = 0·006). There was no corresponding
Transfusion Medicine, 2014, 24, 154–161 © 2013 Crown copyright.
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Total number 791 417 374
Male, n (%) 784 (99·1) 412 (98·8) 372 (99·5)
Age, years, median (IQR) 22 (19–25) 22 (19–25) 23 (20–26)
Injury severity
NISS, median (IQR) 34 (18–52) 42 (30–54) 23 (9–37)
ISS, median (IQR) 22 (14–31) 27 (19–35) 17 (7–27)
by ISS strata
ISS 1–8, n (%) 77 (9·7) 12 (2·9) 65 (17·4)
ISS 9–15, n (%) 113 (14·3) 30 (7·2) 83 (22·2)
ISS 16+, n (%) 586 (74·1) 368 (88·3) 218 (58·3)
Unknown, n (%) 15 (1·9) 7 (1·7) 8 (2·1)
NISS, new injury severity score; ISS, injury severity score.
Fig. 1. Number of trauma patients, and number of trauma patients
transfused, by year.
increase in casualties with mild and moderate injuries (P = 0·617
and P = 0·283, respectively) (Fig. 5). The median number
of units of plasma transfused to severely injured casualties
similarly increased over the same time period (P = 0·002).
Again, there was no corresponding increase in those with
mild and moderate injuries (P = 0·350 and P = 0·549). The
median number of units of cryoprecipitate and pools of platelets
transfused, in contrast, increased in severely (both P < 0·001)
and moderately (P = 0·009 and P = 0·005, respectively) injured
patients (Table 2).
In terms of total transfusion requirements, the median
number of units of red cell concentrate administered to massively
transfused casualties did not change (P = 0·699), but the median
Fig. 2. Proportion of trauma patients transfused, by year.
Fig. 3. Proportion of patients who received a massive transfusion, by
year.
Table 2. Median (interquartile range) units of cryoprecipitate
transfused, by year
Year ISS>16 ISS 9-15 ISS1-8
2008 0 (0–1) 0 (0–0) 0 (0–0)
2009 1 (0–3) 0 (0–0) 0 (0–0)
2010 1 (0–2) 0 (0–0) 0 (0–0)
2011 1 (0–3) 0 (0–2) 0 (0–0)
P* <0·001 0·009 0·551
*Kruskall–Wallis test.
number of units of plasma and platelets increased (P = 0·046
and P < 0·001, respectively) (Fig. 7).
The average moving ratio of units of plasma to red cell
concentrate and units of platelets to red cell concentrate
administered to massively transfused patients has progressively
increased (Fig. 8).
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Fig. 4. Injury pattern: Proportion of patients with AIS≥3, by region
and year.
Fig. 5. Median number of units of red cell concentrate transfused, by
injury severity and year.
Use of pharmaceutical adjuncts
Recombinant factor VIIa (rVIIa) was widely used until 2009,
when approximately one-quarter of casualties who required
red cell transfusions, and approximately one-half of those who
required massive transfusion, received this product. By 2011,
these proportions had decreased to 4·6 and 6·3%, respectively.
Conversely, tranexamic acid was not used until 2009, but is
now administered to two-thirds of casualties requiring blood
transfusion, and 80% of those requiring massive transfusions
(Fig. 9).
Survival
The overall survival of casualties who received any transfusion
was 78·8%, ranging from 76·9% in 2008 to 84·8% in 2011. For
casualties who received a massive transfusion, survival currently
stands at 93·1%. Survival was lower for non-massively transfused
than for massively transfused casualties (Fig. 10).
Fig. 6. Median number of units of plasma transfused, by injury severity
and year.
Fig. 7. Median number of units of red cell concentrate, plasma and
pools of platelets administered to massively transfused casualties, by
year.
DISCUSSION
This is the first comprehensive analysis of blood use by the UK
Defence Medical Services, in a mature operational theatre. It
provides an insight into current practice, its evolution, and the
impact of policy and capability.
Conventional resuscitation of the bleeding trauma patient,
as described in the 8th edition of the Advanced Trauma
Life Support course, relies on the initial administration of
large volumes of crystalloid solutions, followed by red cell
concentrate and further crystalloid (American College of
Surgeons, 2008). Products such as plasma, cryoprecipitate and
platelets would only be introduced at a later stage, and usually
once demonstrable abnormalities in coagulability or platelet
numbers were present. The contemporary treatment of combat
casualties differs: There is greater emphasis on controlling
haemorrhage (Hodgetts et al., 2006), hypotension during en-
route care is permissible, and the use of crystalloid solutions
Transfusion Medicine, 2014, 24, 154–161 © 2013 Crown copyright.
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Fig. 8. Average moving ratio of units of plasma to red cell concentrate,
and platelets (individual units) to red cell concentrate, by year.
Fig. 9. Tranexamic acid and recombinant factor VIIa use, by year.
is limited to maintaining a palpable radial pulse, and only
when blood is not available (Jansen et al., 2009). Lost blood is
replaced with a combination of products which approximate
whole blood, and where necessary, transfusion support can be
provided en route to definitive care.
As a result, the proportion of injured service personnel who
were transfused blood products has increased, year on year.
Approximately one-third of casualties now receive treatment
with blood components. The proportion of casualties who
received a massive transfusion has increased five-fold, to 20% of
all casualties. This proportion is markedly higher than reported
in civilian practice. A recent analysis of UK registry data has
shown that only 0·4% of civilian casualties require massive
transfusion (Fuller et al., 2012). The proportion of transfused
patients who received a massive transfusion has doubled. It is
tempting to ascribe these changes to increasing injury severity
or changing injury patterns, but this is not supported by our
data. The observed trends therefore seem to reflect changes in
practice.
Fig. 10. Survival, by year and volume of transfusion.
The most striking changes are the increase in the number
of units of red cell concentrate, plasma, cryoprecipitate and
platelets transfused to severely injured patients. These findings
suggest that severely injured patients may have been under-
resuscitated in the past.
Changes in blood product use may also be accounted for by
developments in policy and capability, which explain some of the
differences in the UK and US approaches to combat casualty care
in this setting. The Defence Medical Services employ physician-
led medical emergency retrieval teams (MERT), which have the
ability to transfuse up to 4 units of RCC and thawed plasma
during the en-route phase of care. This capability, which has
been shown to improve mortality in some groups of patients
(Morrison et al., 2013), results in earlier commencement of
transfusion support, and may also be responsible for some of
the overall increases in red cell concentrate and plasma seen over
the duration of the study period.
Increased platelet use can be explained by the improved
availability of this product, following the development of a
deployed apheresis capability, in 2008 (Doughty et al., 2011),
and perhaps also the greater use of near-patient haemostatic
testing. Point-of-care ROTEM has been available since 2009,
and has facilitated the recognition of both coagulation factor
deficiencies and platelet function abnormalities. Detection of
these defects may explain the increased use of both platelets
and cryoprecipitate, facilitating ‘bespoke’ component therapy.
These findings are consistent with those recently reported by
US colleagues, which demonstrated that the introduction of
ROTEM was associated with an increase in the use of all blood
components other than red cell concentrate, and particularly
cryoprecipitate (Cap et al., 2012).
There has also been a marked change in the use of
pharmaceutical adjuncts to transfusion. Tranexamic acid was
not used before 2009, but is now given to most patients
requiring transfusion, and almost all patients requiring massive
transfusion. Recombinant factor VIIa, in contrast, was widely
used during the early years of the war, but is now only
© 2013 Crown copyright. Transfusion Medicine, 2014, 24, 154–161
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infrequently administered. This latter change may reflect an
increasing recognition of the limited effectiveness of rVIIa, but
also points towards current strategies, including initial formula-
driven component use, subsequent tailored therapy based on
point-of-care-testing, and antifibrinolytic therapy, providing
adequate microvascular haemostasis.
The introduction of new strategies such as formula-driven
resuscitation and tranexamic acid, as well as capabilities such
as apheresis and thromboelastometry, is – to some extent – a
reflection of operational requirements. However, it also reflects
the successful dissemination of clinical guidelines, which have
been shown to change practice (Simmons et al., 2010).
The better survival of massively compared with non-
massively transfused casualties is perplexing at first, but probably
explained by survival benefit – casualties had to survive long
enough to receive a massive transfusion. Overall, the survival
of massively transfused casualties is high (93·1%) compared
with recent British civilian experience (59·7%) (Fuller et al.,
2012). The difference in survival may, in part, reflect variations
in injury types and severity (civilian patients are more likely
to have suffered blunt trauma, including neurological injury)
and underlying co-morbidity (combat casualties are almost
exclusively male, younger and fitter). Has transfusion practice
and capability improved survival? Survival is the product of the
entire system of care, which – in this setting – also incorporates
the early control of external haemorrhage with tourniquets, the
use of topical haemostatic agents, hypotensive resuscitation,
rapid and physician-led recovery from the battlefield, early
surgical haemorrhage control, limited initial surgery and expert
critical care. It is thus not possible to ascertain the individual
contribution of the transfusion strategy employed however; we
propose that it has been an important element.
This study has limitations. It is a retrospective analysis. Injury
severity scoring, and stratification into severe, moderate and
mild injury, is known to be less useful when applied to combat
casualties compared with civilian trauma victims. The definition
of ‘massive transfusion’ used for this study was 10 units, or
more, of red cell concentrate transfused in 24 h. We recognise
the limitations of this definition. The transfusion strategies
and outcomes employed in non-massively transfused patients
are of considerable interest, but difficult to analyse because
time-to-death data lacks granularity.
Despite these issues, this study adds to our understanding of
modern resuscitation strategies, and complements recent anal-
yses from the US Joint Theatre Trauma Registry. Retrospective
studies cannot prove causation, but there nevertheless seems
to be a temporal association between increased component
use and improved survival, in combat casualties requiring
transfusion as part of Damage Control Resuscitation. The
underlying principles may be of benefit to other populations.
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S U P P L E M E N T A R T I C L E
A proposed field emergency donor panel questionnaire
and triage tool
Heidi Doughty,1 Patrick Thompson,2 Andrew P. Cap,3 Philip C. Spinella,4 Elon Glassberg,5
Håkon Skogrand Eliassen,6 Marc De Pasquale,7 and Geir Strandenes6
BACKGROUND: The provision of transfusion support
to isolated military or civilian projects may require the use
of an emergency donor panel (EDP) for immediate warm
fresh whole blood (WFWB). The aim of this short
discussion article is to raise and resolve some of the
practical aspects for the nonspecialist faced with the
emergency collection of WFWB whole blood in the
austere medical environment (AME).
METHODS AND RESULTS: A proposed field EDP
questionnaire and triage tool (QTT) is presented. It is
designed for the hostile, remote, or austere environment
that falls outside normal regulated supply of cold-stored
blood products or removed from trained blood collection
personnel, where collection may fall to an isolated
medical provider. The tool has been drafted based on
review of existing guidelines and consultation with
practitioners. It serves as a point of reference for local
guidelines and has yet to be validated.
CONCLUSIONS: The use of the EDP is associated
with risk; however, it remains the simplest method of
providing rapid transfusion support. The best way to
manage the risk is to brief and prescreen blood donors
before deployment. An abbreviated donor QTT can be an
aide to decision making at the time of donation. The tool
should be tailored to requirements and underpinned by
policy and training.
M
assive hemorrhage is a medical emergency
and an immediate threat to life. The resus-
citation of patients with massive hemor-
rhage requires the early use of transfusion
support. Military and civilian guidelines promote the use
of transfusion strategies that recapitulate the functionality
of whole blood (so-called “balanced transfusion”) for both
trauma and nontraumatic hemorrhage such as bleeding
associated with childbirth and gastrointestinal bleeding.1-4
Whole blood or blood components may not be available in
a situation where they are required urgently. Team mem-
bers and supporting staff may be asked to donate whole
ABBREVIATIONS: AME 5 austere medical environment;
EDP 5 emergency donor panel; FWB 5 fresh whole blood;
PoCT 5 point-of-care testing; QTT(s) 5 questionnaire and
triage tool(s); WFWB 5 warm fresh whole blood.
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blood or collect blood from an otherwise uncharacterized
donor pool. Cordova and colleagues5 graphically describe
such an event where 5 units of fresh whole blood (FWB)
were transfused following a 12-hour battle during which
building fires threatened the isolated aid station.
The context of this article is access to blood for iso-
lated military or civilian projects with extended lines of
supply or limited logistical support, that is, the austere
medical environment (AME). Examples include military
special operations, humanitarian missions, remote islands
or industry, the cruise industry, and scientific exploration.
The medical planning for remote activity should consider
the requirements for resuscitation including transfusion
support. If medical evacuation is delayed or prolonged
and there is no capacity to provide cold stored blood
products, then the emergency use of FWB should be con-
sidered. Team members and staff should be prescreened
according to national standards for blood donation (e.g.,
transfusion-transmitted disease testing, blood typing,
hemolysis titer assessment) as members of an emergency
donor panel (EDP). However, the emergency screening
and management of unknown additional blood donors
may also be required. Blood donation for the healthy indi-
vidual is safe; however, there are risks.1,6 There may be a
challenge in balancing the safety and management of
both critically ill patients and their blood donors. Careful
donor screening and care is essential to optimize the
safety for both. However, the context may not support a
conventional donor assessment, and a more rapid or
focused donor screen may be required. Relaxing donor
acceptance criteria will introduce risk; the decision will
ultimately be one of risk–benefit analysis. Risks may need
to be further managed using “donor triage” and careful
consideration of the need for transfusion. The aim of this
short discussion article is to introduce a field EDP ques-
tionnaire and triage tool (QTT). The article also addresses
some of the practical aspects for the nonspecialist faced
with donor selection in the AME.
MATERIALS AND METHODS
Initiative
The initiative for this work follows the preconference exer-
cise of the Remote Damage Control Resuscitation Sympo-
sium, which took place in Norway in June 2015. The work
forms part of the “Blood Far Forward” program—a whole
blood–based research and training program for austere
environments. During training exercises, participants
were required to rapidly assess several potential blood
donors for emergency donation. Staff and participants
identified that there was little guidance for the rapid
assessment and triage of blood donors for the nonexpert.
Literature review
The following donor screening guidelines were reviewed.
 Military: US Special Operations Command, Tactical
Trauma protocols (TTP) 2013,7 and the Journal of
Special Operations Medicine Training supplement
2012.8 Standard operating procedures for the collec-
tion of whole blood, Centre of Defence Pathology, UK.
 THOR guidance.9
 Civilian: UK Blood Transfusion Services,10 American
Association of Blood Banks (AABB),11 and the World
health Organization (WHO).12
Literature searches: A search was performed of
PubMed and CINAHL using the search terms: emer-
gency donor panels, collection of whole blood, austere
medical environment, and special forces medicine.
The search covered articles published up until Sep-
tember 2015.
Development
The field EDP QTTs were developed on the basis of experi-
ence gained through responding to military and civilian
events. Members of the multinational exercise group were
invited to comment on the feasibility of applying the tools.
Scope
The scope of this article is to provide guidance for opera-
tional teams supporting the critically ill patient when work-
ing in an AME. The technical aspects of blood collection are
outside the scope of this paper but are well covered in pre-
viously published reviews9 and the Special Operations Com-
mand, Tactical Trauma protocols. Readers are also referred
to national guidelines for full donor selection and their own
standard operating procedures for emergency procedures.
PROPOSED FIELD EDP QTT
The proposed field emergency donor panel QTT is shown
in Fig. 1. The safest donors for warm FWB (WFWB) are
members of a team that have been questioned, screened,
and tested as conventional donors to national standards.
Such donors may have donor cards or other proof of sta-
tus. In the absence of preselected team members or the
presence of other prequalified donors who can verify their
status, the field EDP QTT may be used to help select the
most appropriate donors from a mixed donor pool. Past
donors are those that are not in date according to national
norms for the mandated testing; however, they are pre-
ferred over unknown donors because they are familiar
with the procedure and standards required.
Blood donor brief
The aim of the donor brief is to inform and identify poten-
tial donors. The donors can then be triaged into current,
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past, and new donors. An initial group brief should cover
the following:
 State that WFWB may be required;
 Outline the blood groups and amount of blood
required;
 Explain the process;
 The importance of the health check;
 The tests that will be performed and that these
might be positive;
 Donor deferral and confidentiality;
 Potential adverse donor reactions;
 Confirm that donors are volunteers and consented;
 Identify individuals who have previously given
blood and those that are in date.
At this point, current and past donors, if previously
accepted, can be directed for rapid assessment and dona-
tion if urgent. All donors must be well on the day of
donation.
Fig. 1. Field EDP QTT.
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The field EDP QTT
The QTT is a highly abbreviated version of a donor ques-
tionnaire. It is designed to be used after the group briefing
for all donors. Donated blood should be safe and, in par-
ticular, should not put the patient at risk of infectious dis-
ease. The question set may need to be tailored to the
situation. Some questions that are commonly asked such
as those about tattoo may be nondiscriminatory because
the behavior may be common to most or all donors. Like-
wise travel history may be nugatory in some communities.
Questions related to sexual behavior may initially need to
be simplified and then triage applied, that is, prepare to
accept all donors but use them in order of lowest risk first.
Infectious risk is commonly related to lifestyle and loca-
tion. However, in many parts of the world infectious dis-
ease may have been acquired at birth or after medical
treatment and individuals may not be aware and cannot
declare the risk when questioned. The risk of transfusion-
transmitted infection in screened blood donors in differ-
ent countries may be estimated using published national
data.
The QTT
The QTT is broken into three sections: primary triage, sec-
ondary triage, and risk triage. These three stages help to
rapidly identify the individuals that may participate in the
EDP and eliminate the individuals that may pose a rela-
tively less acceptable risk to the transfusion recipient. The
field EDP QTT is designed to assist and act as an aide
memoire. It is not designed to replace clinical judgement
and experience.
Primary triage
Primary triage identifies those who will consent to dona-
tion and those who may be regular donors who can be
rapidly progressed through screening as the optimum
candidates.
Secondary triage
Secondary triage seeks to disqualify candidates on the
grounds of high risk to either donor or recipient on the
grounds of current health, risk of disease, and pregnancy.
It must be remembered that in extremes these candidates
Fig. 1. Continued
DOUGHTY ET AL.
S122 TRANSFUSION Volume 56, April 2016
may be considered for donation if no other donors exist,
and while only the attending clinician can make this diffi-
cult decision they may also be able to obtain consent
from the injured.
Risk triage
Risk triage seeks to quantify the remaining risk, giving a
numerical value for the clinician to work with. It is an
abbreviated field expedient questionnaire and serves only
to guide and remind an isolated practitioner who will use
this in conjunction with clinical experience and advice
from telemedicine or other trusted sources. The numerical
value is not an absolute value of risk involved, but merely
an aid to quantifying the risk. The value is proportional to
the risk, so the lower the score the lower the risk. There is
no “cut point” of acceptable risk given the emergency set-
ting of the potential transfusion; the scoring is thus
relative.
The risk triage bases the scoring system on:
 Past blood donation history;
 Ease and safety of venipuncture;
 Lifestyle;
 Travel history;
 Veins and body weight;
 Occupation/role.
Individuals that are potentially suitable may be fur-
ther triaged based on nationality and blood group if
required.
Female donors
A number of the questions relate to female donors.
Women tend to have greater iron demands and lower total
blood volume and are more likely to faint especially if
young and at first donation.13 Women may also have
smaller or more deeply set veins—factors that may make
them less suitable donors in emergency situations where
speed is of the essence. Pregnancy is associated with
changes in blood volume, iron demand, and the develop-
ment of white blood cell antibodies. Women should not
donate when pregnant and are conventionally deferred
for a period of time after pregnancy and while breast-
feeding.
DISCUSSION
Transfusion support remains an important element of
medical planning for individuals traveling or working
remotely. The problems with transfusion support in the
AME include availability, transfusion-transmitted diseases,
accurate testing, and a secure cold chain. All efforts
should be made to ensure blood safety through the appro-
priate sourcing, supply, and storage of blood. Transfusion
support can be provided using stored blood components
projected from the home nation or provided by special-
ized commercial companies or host nation support. How-
ever, blood is a logistically challenging materiel to manage
and resupply especially where there is minimal medical
infrastructure.
The advent of commercially available storage systems
using phase change together with lightweight temperature
monitoring devices permits storage for dislocated teams
for extended periods of time.14 However, it imposes a
logistic and training burden. Alternative options include
the use of fluids, dried plasma, and early evacuation.
Where early evacuation is not an option, and blood is not
available, medical planners should consider emergency
whole blood donation as a resilience measure.1 FWB
offers the best physiological replacement fluid for major
blood loss and the emergency collection of whole blood
requires very little equipment.15 The remote damage con-
trol resuscitation pack designed for blood donation
described by Strandenes and coworkers9 includes all of
the materiel required for donation including point-of-care
testing (PoCT). The pack weighs 780 g including freeze-
dried plasma and a lactate analyzer.
Potential donor screening and consent
The key to safe blood is donor selection. A review of the
literature demonstrated that there was very little pub-
lished about the assessment of blood donors in the AME.
The small numbers of teams undertaking EDPs appear to
be using national donor questionnaires. The question-
naire takes time to deliver properly and may exclude a
large number of potential donors. The challenge is a rapid
assessment of donors to find the best available. Despite
the emergency, we still advise that donors should be vol-
unteers and give informed consent. A description of the
process is important for planning purposes. It should be
clear whether blood is to be taken immediately or whether
donors are to remain on standby to be called forward as
required.
The potential donors must also understand the pur-
pose of the health check and the reason for screening.
Caution must be exercised if language is a barrier and an
interpreter is used. Potential donors are asked about con-
fidential and sensitive aspects of their medical history and
lifestyle. Not all donors define “sex” or “sexual contact” in
the same way and local guidance may be required. There-
fore, potential donors should be consented in a way which
offers privacy to get an honest response. Donors should
be assured that the information they provide will be kept
confidential to the degree possible, recognizing that this
may be challenging in isolated and small-group settings.
Untested donors and screeners should be aware that
both screening and testing may reveal unexpected and
unwelcome results. “Rejecting” individuals in a small and
close community requires careful handling. Test results
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may include both false and true “positives” and the donor
may need psychological support if given unexpected news
and in possession of firearms. It is recommended that
potential donors consent for follow-up testing if required
and that pretransfusion blood samples be retained for
confirmatory testing if possible. Some countries may
require all “bled” donors to have formal testing through
either samples taken at the time of donation or samples
taken on return to base. This is often not feasible due to
tactical situations (ongoing combat, prolonged evacuation
on multiple platforms, etc.) and it may be easier to follow-
up the patients who have received emergency transfusion.
Abbreviated donor history questionnaires
The assessment of donor suitability aims to exclude dona-
tions from individuals at risk, particularly those who have
recently acquired infections, which may not be detected by
routine screening tests or with infections for which no
effective screening is available. Certain behaviors have been
shown by surveillance data to be associated with a high risk
of transmission of human immunodeficiency virus (HIV),
hepatitis B virus (HBV), and hepatitis C virus (HCV). These
include skin piercing, IV drug use, exposure to treatment
with blood and blood products, and unprotected sex espe-
cially with individuals in high-risk groups. High-risk groups
include men who have sex with men and sex workers.
Donor history questionnaires are designed to identify
risk and must be comprehensive. However, they need to
be pertinent to the country and context. Questionnaires
are constantly evolving and abbreviated questionnaires
have been introduced by a number of blood transfusion
services. Abbreviated questionnaires are designed to
speed up the process but are used for known or repeat
donors. An excellent civilian example of this is analysis of
the Food and Drug Administration–approved 34-question
abbreviated donor history questionnaire implemented in
2003 for repeat blood donors.16 The travel, medication,
and health history questions were decreased by 18 ques-
tions. Data were analyzed from more than 50,000 dona-
tions and showed that there was no significant difference
in reactive screening and/or confirmatory tests. However,
these results cannot readily be extrapolated to new
donors. New donors may have to be accepted at risk in
the AME with limited assessment tools.
Donor safety and performance
Blood donation should be a safe procedure in the healthy
donor. The donor assessment not only enables a review of
the donor’s medical history but also provides an opportu-
nity for a very basic health check, especially in unscreened
individuals.
Physical assessment
Many countries do not include a physical assessment;
however, it may add value in the context of a rapid ques-
tionnaire. Physical assessment on screening and before
donation should look for clinical signs to exclude current
infection, severe anemia, significant disease and intoxica-
tion such as temperature, rash, malnutrition, pallor, jaun-
dice, cyanosis, shortness of breath, and intoxication from
alcohol or drugs. The venipuncture site should be checked
to see that the donor’s veins are accessible and suitable
for easy venipuncture.
It is essential that commanders have confidence that
the operational performance of donors will not be com-
promised. Strandenes and coworkers17 have demon-
strated that the combat readiness skills of Special Forces
soldiers are maintained immediately after donation of a
single unit of whole blood. Despite this, caution must be
applied to the use of certain occupational groups as
donors. Avoid the use of donors operating key machinery
or those responsible for transporting others. Do not bleed
aircrew. Generally aircrew personnel should not fly within
4 days after blood donation. Flight personnel in combat or
performing shipboard duties should not donate blood for
4 weeks before flying.
The impact of blood donation may be greater on less
healthy individuals especially those with a smaller body
mass and malnutrition. Blood donation leads to loss of
iron. After whole blood donation, donors are required to
be excluded from further whole blood donation for up to
12 weeks to permit natural recovery of iron stores. How-
ever, this can be safely shortened if hemoglobin (Hb)
screening is available. Recommended satisfactory donor’s
Hb levels are more than 12.5 g/dL for females and more
than 13.5 g/dL for males. It should be noted that Hb may
not adequately characterize donor iron status, although
this may be the only available metric in the AME setting.
Recognized complications of donation include fainting
and venipuncture-associated complications. These can be
mitigated by predeployment training, selection of donors,
including veins, and good donor care.
Blood group selection
Blood group selection
Group O whole blood with low anti-A/B titers from pre-
screened donors should be used where the blood group of
the recipient is unknown or there is uncertainty.18 The val-
ues cited by Strandenes in this article from the THOR
group were an anti-A and -B titer less than 100 for IgM
and 400 for IgG type. However, there is no international
definition of high-titer hemolysin. The use of ABO-
identical or -compatible blood may need to be considered
if demand for group O/low titer exceeds supply or if no
donors have been prescreened. The preferred nationality
of donors may also be specified. The use of a
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multinational donor panel is a policy decision based on
preagreed standards. There are scientific and practical
reasons to select donors within national lines such as pop-
ulation disease prevalence and blood groups.
ABO group
The use of incompatible blood may result in a hemolytic
transfusion reaction and cause serious harm. It is essential
that the blood group of the donor is known. ABO grouping
is conventionally performed twice on new donors. In
addition, formal ABO testing consists of both a cell group
and a plasma group. Blood may need to be given on the
basis of a pretested donor blood group alone where tech-
nical support is not available to fully confirm the blood
group. Most teams using EDPs are using a PoCT (e.g.,
Eldon card for ABO and D). It should be noted that PoCT
will only provide a forward group or a cell group, although
this is acceptable in this setting. It is therefore recom-
mended that the results of locally determined ABO types
are compared with known results where available. The
results should be the same and the donor should not be
used until the group is confirmed. An additional safety
check is to test the collected unit itself to confirm labeling
and reduce the risk of error. If the donor pool is extended
to include donors of other ABO groups besides O, a practi-
cal approach is the use of group A blood for group A recip-
ients and group O for all others. If a preprepared donor
panel is used for a small team, a “blood-buddy” matrix of
ABO- and D-compatible personnel for small groups may
be considered.19
D group
The distribution of blood groups varies between popula-
tions and may affect the choice of blood donors. Garcia
Hejl and colleagues20 observed that blood type frequen-
cies in their “potential walking blood bank” were similar
to those observed in European or American countries.
However, they noted a low frequency of B blood group
and D– in the “potential walking blood bank.” Conven-
tionally, D– blood can be used for all patients; however, it
is often in short supply. The use of D– blood may need to
be prioritized for females of childbearing potential (under
the age of 50).
Disease screening
The risks to the patient associated with the emergency
collection of FWB include blood group error and the risk
of transfusion-transmitted disease and a rare risk of trans-
fusion associated graft-versus-host disease. The risk of
transfusion-transmitted disease is dependent on the prev-
alence of baseline blood-borne disease in the donor popu-
lation and the risks associated with the location, such as
malaria. In addition, donors should notify of any adverse
events of illness within a 14-day period after donation.
However, this may be impossible in the context of inde-
pendent movement of donors, patients, and staff. Risks
can be mitigated by vaccination, prophylaxis, vector expo-
sure control, and similar measures but may have to be tol-
erated. Consideration should be given to follow-up of
patients who have received emergency blood.
Prescreened donors are the safest donors in that they
have been screened based on national donor selection
guidelines and testing. WHO guidelines advise that all
blood components should be fully screened to standards
by an accredited blood service wherever possible. Manda-
tory tests include ABO and D blood group and tests for
HIV, HBV, HCV, and syphilis. Positive screening results
should ideally be forwarded to a specialist reference labo-
ratory for confirmatory testing. PoCT may be used to
screen locally collected units before release. However, the
PoCT should be selected with the appropriate sensitivity
and specificity for blood donation rather than disease
screening.
Some organizations may also choose to take blood
samples at the time of donation for later definitive testing.
Samples must be packed and transported in IATA 650
packaging; most samples for confirmatory testing must be
received within 5 days of sampling. Samples that cannot
be tested within in this timeline should be separated and
the plasma frozen until transport is available.
Training and recordkeeping
Training
Medical providers who anticipate the emergency collec-
tion of whole blood should consider the training of per-
sonnel. Personnel should know how to conduct an
emergency donor session, store, issue, and account for
any blood donated. Training should also address the indi-
cations for the collection of blood and the administration
of blood. Transfusion training should be incorporated into
predeployment training and include practical sessions in
a high-fidelity environment. Strandenes and coworkers21
demonstrated that nonmedic soldiers had a 100% success
rate in both blood collection and blood reinfusion on fel-
low soldiers after a short introduction to the procedures.
Recordkeeping
National and international guidance requires a record of
all blood donated and used. The standard of recordkeep-
ing may be a simple entry in the field medical notes. The
advantage of using a properly designed donor or resusci-
tation pack is that it should contain the paperwork for
donation. Recordkeeping is designed to permit recall of
donors and lookback exercises in the event of donors or
patients found to have viral markers. Source tracing of
infection across international boundaries and organiza-
tions may be challenging and consideration should be
given to a local Point of Contact who would be responsible
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for any donor follow-up. All procedures and the associated
records related to the conduct of a field collection should
be completed at the time of donation. It is recommended
that the fate of all donations is recorded, both transfused
and discarded. The use of EDP blood should also be
recorded in the clinical notes and included in the
handover.
DISCLAIMER
The discussion included in this article does not override
the responsibility of health care professionals overseeing
emergency donor programs to provide direction and
training appropriate to the operational situation. All activ-
ities related to blood transfusion should be subject to
appropriate legislation, quality, and clinical governance
regulations. It is also advised that there is policy or author-
ity for the use of emergency blood donation.
CONCLUSIONS
The use of the field EDP QTT is associated with risk; how-
ever, it remains the simplest local method of providing
rapid transfusion support. The biggest risks are those
associated with ABO mismatch and infection. It is very
difficult to produce a satisfactory generic abbreviated
donor history questionnaire. The best way to manage the
risk of donation is to brief and prescreen donors before
overseas travel. An abbreviated donor questionnaire can
then be used to rapidly screen donors when required.
Where donor selection is applied to a number of donors
including untested donors, then a triage approach to
donor management is recommended.
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Introduction
Rapid and efficient transfusion support is an essential compo-
nent in the management of major haemorrhage (MH) [1]. This has
been highlighted by the experiences gained during recent military
conflicts, and has led many civilian trauma centres to adopt ratio-
based major transfusion protocols (MTPs) within the framework of
a massive haemorrhage protocol [2]. The introduction of protocols
results in a better co-ordinated response, better outcomes and a
reduction in complications [3,4]. Although the optimal ratio of
blood product use is uncertain there has been a move in civilian
centres to adopt RCC:FFP ratios of 3:2 or 2:1 [5]. It is probable that
the early use of plasma and platelets should be even higher in the
severely injured. The recently published study by Holcombe et al.
showed that although that the use of a 1:1:1 ratio of RCC:FFP:Pla-
telets did not result in a significant reduction in mortality at 24 h or
30 days, more patients achieved haemostasis and fewer experi-
enced death by exsanguination.
Massive haemorrhage protocols including a massive transfu-
sion protocol have increasingly become an integral part of damage
control resuscitation (DCR) in order to prevent and manage
posttraumatic coagulopathy in the first hour and beyond. The
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A B S T R A C T
Background: Death from massive haemorrhage due to traumatic injury is potentially preventable after
hospital admission using haemorrhage control and improved resuscitation techniques including
massive transfusion protocols. Massive transfusion protocols (MTP) are an essential element of damage
control resuscitation and provide a coordinated clinical pathology response to massive haemorrhage
after hospital admission. The decision to activate and de-activate a MTP is based on a number of patient
and local factors. The purpose of this before-and-after study was to determine the impact of modifying a
protocol to include emergency red cells. In addition, we investigated whether massive transfusion
prediction models could have been used to guide on-going transfusion support.
Methods: Sequential MTP activations over three years, before and after protocol revision, were analysed.
Percentage of MTP activation, component usage and outcome data were compared. Trauma associated
severe haemorrhage (TASH) and assessment of blood consumption (ABC) scores were derived and
receiver operating characteristic (ROC) analysis undertaken for an outcome defined as the use of >6 red
cell units.
Results: 52 MTP1 and 66 MTP2 activations arose from 216 and 495 major trauma cases, respectively.
Protocol change significantly reduced the MTP activation rate (p = 0.0006) from 24% to 13%, and the
number of activations requiring >10 RCC increased from 13% to 36% (p = 0.006). Average emergency red
cells usage in the second cohort increased to 4 units. Survival, coagulation parameters, and time to MTP
pack issue were all unaffected by the protocol revision. The TASH score showed an area under ROC
(AUROC) of 0.88 ongoing transfusion requirements.
Conclusion: The change in protocol increased the use of emergency red cells but reduced MTP activation
and use of multiple blood components. The TASH score appears to provide a useful predictive tool for
ongoing transfusion support and may be of value for the trauma clinicians.
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massive haemorrhage protocol should include the clinical,
laboratory and logistic response [6]. Protocols should also address
the immediate availability of un-crossmatched group O red cells
for trauma patients with massive haemorrhage [7]. The decision to
activate the local massive transfusion protocol is complex, must be
made rapidly, and yet if not required may lead to unnecessary
treatment, waste of resources or harm [8]. Scoring systems have
been proposed to improve the prediction for massive transfusion
support [9,10].
We introduced a fixed-ratio massive transfusion protocol in
August 2008 based on transfusion shock packs of 1:1 red cell
concentrates (RCC):fresh frozen plasma (FFP) followed by the early
use of platelets and cryoprecipitate. The protocol included prompts
for activation of the protocol which could be done either in the pre-
hospital environment or on admission. Pre-hospital activation
requires additional training and has subsequently been shown to
be effective [11]. Transfusion packs were prepared when ordered
with a target response time of 30 min. Ongoing monitoring
established that packs were often ordered but not used [12]. In
addition, there were occasional incidents where there appeared to
be delay in emergency transfusion support despite reference to the
use of emergency red cells within the protocol. We proposed that
adding an additional step in the protocol prompting the use of
emergency red cells during initial resuscitation may improve the
emergency use of blood rather than crystalloids. Red cells could be
given either during the pre-hospital or hospital period. Where red
cells are given during the pre-hospital period then this step would
be omitted. The final ratio of RCC to FFP following the introduction
of the additional step of 2 RCC to the initial 4 plus 4 pack was
designed to be RCC:FFP = 6:4.
The primary aim of this study is to describe the impact of
changing the protocol. The secondary aim was to assess if existing
scoring systems for the prediction of massive transfusion, normally
used at the point of activation, could have been used to guide the
subsequent requirement for component support beyond the first
massive transfusion pack.
Materials and methods
Setting and MTP revisions
Setting
This study was a retrospective observational review of practice
in a single institution, the Queen Elizabeth University Hospital
Birmingham, UK. The hospital is the receiving facility for UK
military trauma patients and equivalent to a US level 1 trauma
centre. It serves a population of 1.2 million UK civilians.
Following the UK wide reconfiguration of major trauma net-
works, the institution was designated a regional Major Trauma
Centre during the period of study. Pre-hospital treatment for
trauma included a 24 h physician led emergency response
capability with day time helicopter support. Pre-hospital
transfusion was not available. Patients admitted to the trauma
unit who require trauma ward admission for 3 days, critical
care admission or whose injury led to their death (30 days) are
recorded in the UK Regional Trauma Audit Research Network
(TARN) database. The unit receives approximately 300–400 such
cases per annum, which satisfy this classification and are herein
referred to as major trauma cases.
Implementation
The hospital implemented the first massive haemorrhage
protocol containing a massive transfusion protocol (MTP) in
2008 following a review of the military experience, the literature
and consultation with key stake-holders. This protocol was based
on the UK military transfusion algorithm and is outlined in Fig. 1A.
Activation of the massive haemorrhage protocol and the MTP were
concurrent and was made at the discretion of the trauma team
leader, a senior clinician, with consensus from the trauma team.
MTP pack one consisted of 4 units of red cell concentrates (RCC)
and 4 units of fresh frozen plasma (FPP) (thawed from frozen on
request). The second, and all subsequent, transfusion packs also
contained an adult therapeutic dose (ATD) of platelets (PLT).
Cryoprecipitate was given as clinically directed on the basis of
laboratory fibrinogen and thrombo-elastography results.
Thrombo-elastography was available in theatres and the critical
care unit. Clinicians were informed that all MTP activations
would be prospectively recorded by the transfusion laboratory
and would be subsequently reviewed in multi-disciplinary
meetings.
Review
The first annual review of MTP1 activations highlighted a
number of concerns. Concerns included delays in transfusion,
despite access to emergency red cells, and the non-use of thawed
FFP when provided. The transfusion protocol was therefore
modified one year after implementation (Fig. 1B). The revised
(MTP2) protocol algorithm included a short initial evaluation
period during which clinicians were prompted to use emergency
RCC transfusion if immediate transfusion support was required.
The recommended maximum number of emergency RCC units was
two. This amendment was not designed to stop massive
haemorrhage protocol activation i.e. be a speed bump. It was
designed to provide a rapid red cell response during resuscitation
and assessment before proceeding to massive transfusion i.e.
multi-component transfusion support. The initial massive hae-
morrhage activation continued to alert the laboratory to thaw
frozen plasma just in case it was needed. However, a telephone call
confirming full MTP activation was required to release the massive
transfusion pack.
Change management
The roll-out of both MTPs was supported by specific training in
the emergency department. Copies of the algorithm were present
in all clinical areas for reference. The protocol also formed part of
the trust’s mandatory transfusion training for medical staff during
which the continued requirement for baseline blood samples was
emphasised. We anticipated that there would be a learning curve
associated with the introduction and change of protocol. To reduce
the impact of any learning curve associated with the introduction
of protocols we have not included MTP cases occurring in the first
100 days after implementation of either.
Blood components
All blood components met UK specifications including leuco-
depletion. The estimated age of all RCC provided for transfusion
packs was 18–21 days. Emergency RCC were group O RhD and Kell
negative. Fresh frozen plasma was single donor, quarantined
plasma from untransfused males. Plasma was thawed and issued
to order. Thawed plasma maintained within temperature control
was returned to stock and stored at 4 8C for 24 h before discard.
Platelets were either prepared by apheresis or derived from whole
blood (4 buffy coats). The adult therapeutic dose (ATD) of platelets
was >2.4  1011.
Predictive scoring systems
The trauma associated severe haemorrhage (TASH) score and
assessment of blood consumption (ABC) scores were both
calculated in accordance with their original publications and
subsequent validation [9,10,13]. (Appendix 1 outlines the consti-
tution and details of clinical parameters required to measure these
scores).
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Outcome data: Transfusion support and clinical data
Transfusion support
All consecutive MTP activations throughout both periods were
prospectively recorded. All timings in the following data, for both
MTP1 and MTP2, were recorded from the initial activation call
(rather than the confirmatory call in MTP2). Data registered at each
MTP activation included: patients’ demographics; the time and
date of MTP activation; the environment in which MTP activation
occurred (pre-hospital or emergency department); a summary of
the clinical indications; the time of issue of the first and
subsequent MTP packs; the total number of emergency RCC units
used prior to MTP pack 1 arrival; the number of RCC, FFP, PLT and
cryoprecipitate units requested; the proportion of requested blood
components utilised until stand-down; and finally the time that
the blood bank was contacted to de-activate the MTP.
Clinical outcome
Clinical outcome data were retrospectively collated from
patients’ electronic clinical record, laboratory results and TARN.
The TARN database has been described elsewhere [14]. Data
collected included: survival (60 min, 24 h and 30 days); Injury
severity score (ISS); mechanism of injury; presence or absence of
penetrating trauma; the presence of high-risk fractures (unstable
pelvic fracture and displaced and/or open femoral fractures);
baseline clinical observations; point of care haemoglobin; base
deficit on arterial blood gas sampling at the point of admission;
baseline and 24 h coagulation; and the presence of a positive focused
assessment with sonography for trauma (FAST) scan or free fluid on
trauma series computerised tomography (CT). All patients within
the prospectively collected data were accounted for.
Analysis
All analysis was performed with version 6 of the Graph-Pad
Prism statistical software package, GraphPad Software, Inc. San
Diego, California. Data are presented as mean with standard
deviation or median and interquartile range as appropriate. The
unpaired t-test with Welch’s correction was used for parametric
data comparison. The Mann–Whitney U test was utilised for non-
parametric comparisons. Frequency comparison of categorical
data was undertaken with either the Chi square test or the Fishers
exact test. Statistical significance was set at p value  0.05.
The association between the TASH and ABC score and the
number of RCC units used was tested with linear regression
analysis and the R2 statistic. The area under the receiver operating
characteristic (AUROC) analysis was undertaken to test the
accuracy with which the need for >6 RCC could be predicted.
This number of RCC units was chosen as it represents progression
to MTP pack 2 in both our and others’ protocol.
Fig. 1. MTP1 and MTP2 algorithm.
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Results
The two periods of study for the use of MTP1 and MTP2 were
259 and 536 days respectively. Fifty-two MTP1 and 66 MTP2
activations took place from a respective total of 216 and 495 major
trauma cases during these two periods. The key features of the two
cohorts are outlined in Table 1. No significant difference in the
demographic composition of the two cohorts was identified. The
mean ISS was moderately higher during the second period 30.65
vs. 25.50 (p = 0.14) however this was not significant. The injury
mechanism, baseline observations, point of care test results,
frequency of penetrating injury and incidence of high-risk fracture
(unstable pelvic fracture and displaced and/or open femoral
fractures) had also failed to show any statistically significant
differences.
MTP activation and blood component usage
MTP activation
The rate of massive transfusion protocol activation expressed as
a percentage of the major trauma calls, was 24% (95% confidence
interval [CI]: 19–30%) during the first period and then reduced to
13% (95% CI: 10–17%) following the change in protocol (p = 0.0006)
(Table 2). In neither cohort did we see an association between
‘unnecessary’ activation and the place of activation, addressing
concerns that pre-hospital activation may be ‘less accurate’.
Blood component use
Thirteen percent (95% CI: 6–26%) of those in the initial cohort
received  10 RCC in 24 h. Within the second cohort this increased
to 36% (95% CI: 25–49%) (p = 0.006). Patients in the second cohort
were significantly more likely to use the FFP supplied in MTP pack
1 and received more FFP throughout treatment (Table 2). The use of
emergency RCC increased in the second observation period as
expected. However, this increase was greater than that planned in
the revised protocol (Median 2 units, IQR 0–3.25). When adjusted
for the total number of trauma cases treated, the increase was from
0.26 units per major trauma in MTP1 to 0.34 units per major
trauma in MTP2. The total median use of emergency red cells per
case increased to a median of 4 (IQR 0–8).
Outcome data
Survival
Survival data before and after MTP revision was compared at
intervals of 60 min, 24 h and 30 days (Table 3). No difference was
identified both in crude mortality rates and mortality stratified by
time of death. Red cell use correlated positively with mortality.
Assessment of the group in whom 10 RCC were used in 24 h saw
crude mortality rates of 45% (95% CI: 27–64%) compared with 23%
(95% CI: 15–33%) in the group using <10 RCC in 24 h (p = 0.04). No
difference in the outcome of the group in which 10 RCC were used
was seen between the MTP1 and MTP2 cohorts. Two deaths
occurred beyond 30 days, one from sepsis at 94 days post injury
and the other, a 90 years old male, died from an acute coronary
syndrome 128 days following the initial injury.
Laboratory support
Coagulation parameters at baseline and 24 h did not differ
between cohorts. The introduction of the MTP2 protocol did not
significantly increase the time from the initial activation call to the
laboratory to the issue of the first MTP pack (Table 3).
Component ratio
In the present study, ratios of blood products are based on
averages transfused per patient and comparison was carried out
between the two groups. The aim of this analysis was to
demonstrate the variation in product delivery frequency with a
protocoled ratio based transfusion program rather than the
quantity usage of blood products. We compared the ratio (RCC:FFP
and RCC:PLT) transfused in MTP1 to those in MTP2 (Table 3). This
analysis was only undertaken in patients transfused at least two
units of RCC (total RCC including emergency group O RhD negative
red cells). This exclusion was undertaken to prevent the high
frequency of patients for whom MTP activation was followed by
little or no RCC transfusion (in the MTP1 cohort) from influencing
Table 1
Patient characteristics of the MTP1 and MTP2 cohorts.
MTP1 (n = 52) MTP2 (n = 66) p Value
Demographic data
Age (years) (mean, SD) 40.8, 16.4 41.3, 19.8 0.88
Male (% total) 38 (73%) 53 (80%) 0.38
Mechanism of injury 0.98
Fall > 3 m (n) 7 10
Stabbing (n) 8 11
Gunshot wound (n) 1 2
Road traffic collision (n) 36 43
Injury severity
ISS (mean, SD) 25.50, 13.03 30.65, 14.21 0.14
Unstable pelvic fracture (n) 9 17 0.37
Open/compound femur (n) 5 16 0.05
Penetrating mechanism (n) 10 13 >0.99
Table 2
Summary of MTP activation rates and blood components usage for MTP1 and MTP2
cohorts.
MTP1 MTP2 p Value
Total major trauma calls (MTC)
(n)
216 495
MTP activation (% total MTC) 52 (24%) 66 (13%) 0.0006
10 RCC (total) n, % 7 (13%) 24 (36%) 0.006
Group O RhD negative use pre
MTP pack 1 (median, IQR)
0 (0–2) 4 (2–5.25) <0.0001
Total FFP use per patient
(median units, IQR)
0 (0–4) 2.5 (0–8) 0.0004
Patients not transfused FFP
from MTP pack 1 (n, %)
33 (63%) 21 (32%) 0.001
Proportion of MTP pack 1 FFP
used (median, IQR)
0% (0–50%) 50% (0–76%) 0.0007
Table 3
Survival data, coagulation data, RCC:FFP ratio and time to MTP pack issue.
MTP1 MTP2 p Value
Mortality, n (%) 13 (25%) 15 (23%) >0.99
24 h – 30 day 4 3
60 min – <24 h 3 5
<60 min 6 7
Coagulation median (IQR)
Baseline PT 1 (1–1.2) 1 (1–1.2) 0.55
24 h PT 1 (0.9–1.1) 1 (0.9–1.1) 0.77
Baseline APTT ratio 1.2 (1–1.3) 1.2 (1–1.3) 0.91
24 h APTT ratio 1 (0.9–1.1) 1 (0.9–1.2) 0.78
Blood component ratiosa (mean, SD)
RCC:FFP 2.24, 1.18 2.22, 1.54 0.95
RCC:PLT 7.86, 3.02 9.38, 5.13 0.34
Time to MTP issueb
Minutes (mean, SD) 28, 10 25, 8 0.13
a Calculated (mean and SD) of products usage ratios:mean of ratio blood products
transfused per patient. This analysis was only undertaken in patients transfused at
least total two units of RCC and followed by blood components (FFP/PLT).
b Time to MTP issue is time taken to issue from the time of confirmatory call to
blood bank.
T. Boutefnouchet et al. / Injury, Int. J. Care Injured 46 (2015) 1772–1778 1775
Downloaded for Anonymous User (n/a) at University Hospital Birmingham NHS Foundation Trust JC from ClinicalKey.com by Elsevier on December 04, 2017.
For personal use only. No other uses without permission. Copyright ©2017. Elsevier Inc. All rights reserved.
the results. The mean RCC:FFP ratio was 2.2 with no significant
difference between the first and second cohorts. The ratio for both
groups was notable for its deviation from the ratio specified by the
protocol. Four patients in the MTP1 cohort and 10 in MTP2 were
given >2 RCC and received no FFP. The number was therefore
relatively higher in the second group and the median number of
RCC transfused for these patients was 4 and 4.5 respectively. These
14 patients were also excluded from the original analysis of
component ratios since their mean and SD becomes indefinable. Of
these patients, 1 in MTP1 and 5 in MTP2 had died within 60 min of
arrival at the ED. In order to determine whether the latter group of
patients had an impact on ratio deviation, the ratios of the mean
blood products transfused, all patients included were also
calculated for each group. The ratios of mean blood products
transfused were RCC:FFP 1:2 and RCC:PLT 1:10.5 in MTP1 and
RCC:FFP 1:2 and RCC:PLT 1:11 in MTP2. These results demonstrat-
ed analogous distribution of blood product ratios with the original
analysis. This can be explained by the fact that the group of
patients excluded represents the two extremities of the MT
spectrum i.e. patients at high risk of early death owing to sever
injuries and patients with minor injuries not requiring MT.
TASH and ABC score
Despite alteration of the pre-test probability, both the ABC and
TASH scores retained a correlation with the total number of RCC
used. In particular, the TASH score retained a good correlation with
the number of RCC used (R2 0.6) (Fig. 2). We tested the performance
of the ABC and TASH scores to discriminate the need for transfusion
of >6 units of RCC in other terms progress beyond the first massive
transfusion pack. At this cut-off point the TASH score had an
AUROC of 0.88 (95% CI: 0.81–0.93). The AUROC of the ABC score
was 0.81 (95% CI: 0.72–0.87) (Fig. 3).
Discussion
Massive transfusion protocols (MTP) provide a valuable
framework for the co-ordinated and timely response to massive
haemorrhage. The very nature of the context means that MTP are
activated in highly stressful circumstances. Under-treatment of
trauma casualties with MH, a group whose mortality approaches
40%, is catastrophic [15]. Confronted with a potential massive
haemorrhage, especially where there may be perceived delays in
transfusion support and conscious of the devastating conse-
quences of under-treatment, an inexperienced clinician may
justifiably apply a liberal approach to MTP activation. Whilst
proportionate MTP over-activation may mitigate the risk of under-
treatment, a low predictive accuracy for MT may challenge the
sustainable supply of ‘universal’ components and platelets. The
provision of blood in the emergency setting of a patient with
massive haemorrhage requires the use of a transfusion protocol
designed for the local situation taking into account pre-hospital
care and local constraints. We suggest that protocols and the
outcome should be subject to constant review and amended as
required. Amendment of our MTP protocol was associated with a
reduction in activations, a greater percentage use of plasma and
platelets when ordered and no adverse outcomes. However, it led
to a greater use of emergency red cells than expected. The risk of
this is plasma deficit and needs addressing. The results are not
surprising but demonstrate the impact of changing protocols.
MTP over-activations may reduce the risk of under-treatment
but has the inevitable consequence of exposing patients with non-
major haemorrhage to unnecessary blood components. The full
risks of using an MTP in this latter group remain unclear. The risk of
human error remains the greatest danger in any transfusion and
the risks may be greater in the emergency situation. Specific
concerns relate to the unnecessary use of plasma, with recent
reports of acute lung injury in non-massively transfused patients
exposed to high volumes of FFP exemplifying the need for caution
[16]. However, more recently the PROPPR trial has demonstrated
there was no increase in complications when higher blood product
ratios are used [17]. MTP over-activation is also unappealing when
one considers its potential impact on blood component stocks.
Achieving a safe and sustainable rate of MTP activation, which
balances both the risks of under-recognition of MH as well as those
of over-activation, will be highly desirable. Activation is inextrica-
bly linked with the ability of clinicians to accurately predict MH
and knowledge of the local logistic and laboratory response time.
Until now it has been difficult to discern from the literature how
accurately clinicians predict massive haemorrhage, target trans-
fusion use, and what factors influence these issues. This lack of
clarity has arisen from the practice of excluding cases where an
MTP has been activated for patients requiring little or no
transfusion [4,18] and a general paucity of information about
the size and composition of the denominator groups [3,19]. The
only brief insights into this issue have been provided by
Hendrickson et al. [20] Morse et al. [21] and Sinha et al. [22]
who, in their respective paediatric, adult non-trauma and mixed
MTP groups, have all noted MTP activation can be followed by little
or no transfusion.
In this present study we also found that massive transfusion
packs were called for patients who, although bleeding, did not have
‘massive haemorrhage’. This contention was supported by a
number of surrogate markers. For example, the mortality rate in
the initial cohort (MTP1) was 25%, far lower than the 40–50%
mortality rate which is widely reported for patients who require
MT [15,23]. Likewise, analysis of blood component use in this
group showed that over half (63%) of the initial group had notFig. 2. Correlation of TASH score with the total number of RCC used.
Fig. 3. Receiver operating characteristics curve for TASH and ABC scores.
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received emergency RCC and or plasma (63%). Only seven cases
(13%) from the first cohort ultimately met the definition of 10
units of RCC. Activation of the massive transfusion protocol during
the first period had a predictive accuracy (positive predictive
value) for MT of just 13%. The modification of the protocol resulted
in a reduction in the demand for massive transfusion packs from
24% of major trauma cases to 13% (p = 0.0006). The positive
prediction of MT improved, increasing from 13% to 36% (p = 0.006).
Analysis of blood component usage showed that a greater
percentage of the plasma was used and fewer of the MTP2 packs
were returned with the FFP unused. Any concerns that the protocol
may impede FFP delivery and impair outcomes proved unfounded.
Survival, coagulation parameters, time to transfusion pack issue
and final RCC:FFP ratio were all unaffected by the protocol revision.
It should be noted that the second period in this study overlapped
with the re-designation of the unit as a Major Trauma Centre. The
impact of this has led to an increase in patients with poly-trauma
and a moderately increased injury severity score (mean, SD 30.6,
14.2) in the second group. However, there was no significant
change in mortality among in the second group following
introduction of the amended protocol.
The use of emergency RCC Group O RhD negative in the second
cohort increased from a median of 0–4. The findings, although
greater than expected, were consistent with recent reports of pre-
MTP emergency RCC use [18]. A median of two additional
emergency RCC units was used i.e. a total of 4 units of RCC
(Table 1) resulting in a final RCC:FFP ratio of 2:1 rather than 3:2.
We appreciate that there is a debate with regards to a hierarchy of
resuscitation vs. the immediate use of plasma and that some
authors may be concerned that the initial use of RCC may lead to a
potential plasma deficit. Where practitioners would prefer early
access to plasma, a more rapid access to liquid plasma through the
use of pre-thawed or reconstituted lyophilised would address this
concern the reasons for the greater use of emergency red cells than
expected were not explained by injury severity or delay in plasma
provision. However, we subsequently introduced the use of pre-
thawed plasma which improved the mean initial laboratory
response time to 15 min for the initial pack. It is plausible that
there was improved ‘targeting’ and treatment of patients. The
mechanics of transfusion may have changed during this period
with the introduction of a new generation of rapid infusers, i.e.
blood was transfused more rapidly before the laboratory could
respond. It is also possible that the first (MTP1) cohort may have
been under-transfused. Under transfusion has been highlighted by
the UK haemovigilance Scheme [24] and the National Patient
Safety Agency [7]. Whatever the reasons for the increased use, the
increase in emergency red cell use is important for transfusion
service planning. Current practice in the UK is to use O RhD
negative cells for emergency transfusion although these should be
prioritised for women of child bearing age. There is a risk that
males may be alloimmunised however the risks are less than
expected [25]. Consideration should be given to further restricting
the emergency use of O RhD negative blood.
Aggressively pursuing further reductions in the rate of over-
activation increases the risk of under-treatment of massive
haemorrhage. It is better to start transfusion treatment early
followed by safe and rapid MTP de-escalation if not required. The
process becomes even more valuable in the context of multiple
casualties where blood component use may need to be prioritised
[26]. Some investigators have developed predictive models for
massive transfusion to aid clinical decision making [9,10,27,28].
Whilst conceptually attractive, these models have several limita-
tions. Importantly they all serve as a ‘gatekeeper’ at the point of
activation. This is a very limiting concept because, for many
clinicians, unless the sensitivity approaches 100% they represent
an unacceptably high risk to use in clinical practice [29]. Equally,
the parameters required for the accurate measurement of such
predictors are often unavailable at the point of activation. The
nature of our data has allowed us to explore the utility of MT
prediction models later in the course of a MH, beyond the point
of MTP activation. Our casualties were all clinically judged to be
at high risk of MH and had been commenced on MTP which
contrasts with the original development of these scores in large
unscreened trauma cohorts. Despite altering the pre-test
probability, the models we tested (and in particular the TASH
score) retained a positive correlation with RCC use. We therefore
tested the TASH score within a model designed to predict who,
after clinician-led MTP activation, may require continued MTP
support. We chose a cut point of >6 units RCC units for this
model, reflecting the need for MTP continuation beyond pack 1
in our (and others’) protocols. Using a MT prediction model in
this manner removes the ‘gatekeeper’ effect and places the
emphasis on objectively deciding if MTP support can be safely
de-escalated or stopped. It also addresses concerns that a
predictive score may take time to calculate. The time to TASH is
less than 8 min [30], and all the parameters required for the
TASH score calculation should already be available when scoring
is used later in the course of resuscitation. The TASH score
performed well in this new role (AUROC 0.88). We suggest
that such scoring systems may have a value in not only to predict
the individual’s probability for massive transfusion but also
in identifying patients with a continuing need for further
transfusion.
This study is subject to limitations of a retrospective before-
and-after study at a single UK centre and the numbers are
relatively small. However, the general observations would be
applicable to other centres dealing with trauma. Study-specific
limitations include a lack of data on the volume of crystalloid and
colloid solutions administered during resuscitation. We recognise
the limitations of the use of 10 units RCC as a definition of MT, a
definition which was chosen to allow comparison with other
studies. The authors assumed the impact of a learning curve on the
delivery of the protocols which reduced the numbers of activations
available for study. Despite these limitations our study confirms
the findings of others that massive transfusion protocol ‘over-
activation’ is common and perhaps desirable. Although an
independent analysis of individual operators of MTP is beyond
the scope of this study, we suggest that reflection of individual
practice, together with multi-disciplinary review, constitutes an
important element in optimising the use of MTPs.
Conclusions
The introduction of a step with emergency red cells first has
resulted in rapid response rather than a speed bump. We suggest
that a prompt for the early use of red cells in MTPs during
assessment may provide sufficient transfusion support for the less
severely injured and reduce the subsequent requirement for
additional blood components. However, measures should be taken
to ensure that the momentum to treat the severely injured is not
compromised and that the inappropriate use of O RhD negative red
cells is minimised. Finally, scoring systems traditionally used to
predict the individual’s probability for massive haemorrhage and
used to initiate massive transfusion may also have a role in
predicting the requirement for further transfusion support.
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Objectives: To describe the impact of a Massive Transfusion (MT) programme in a 
single Norwegian centre throughout the period 2002–2015.   
Background: Transfusion support for massive haemorrhage has changed since the 
mid-2000s, with protocolled use of haemostatic components.  Haukeland University 
Hospital (HUS) introduced a MT programme during 2007 including education, Acute 
Transfusion Package (ATP) and point-of-care measurements (thromboelastography).   
Methods/Materials: A retrospective review was made of all MT episodes defined as 
>10 red cell concentrates (RCC) in 24 hours. Episodes were identified using the 
laboratory information system.  Patient records were reviewed manually for 
demographics, transfusion indication, haemostatic drugs and mortality.  The ATPs 
contained 6 units RCC, 6 units Octaplas and 2 platelet concentrates (4 buffy coats/ 
apheresis in PAS).  
Results: 410 episodes were identified in 410 patients.  These accounted for 2.8% of 
all RCCs and 3.4% of PCs issued. The mean patient age was 60 (9-94) with a male 
predominance (64%).  87.1% of MT episodes were in support of surgery (cardiac 
services 42.7%; trauma 17.6%).  29.8% of MTs involved platelet inhibitors with 
82.6% of these undergoing cardiac procedures. The mean ratio of blood components 
RCC: plasma: platelets changed from 1.0:0.37:0.39 in 2002-2006 (n=149) to 
1.0:0.79:0.85 in 2008-2015 (n=241, p<0,001). A sub-analysis showed that cardiac 
specialities used proportionally more plasma and platelets.   
Conclusion: Massive transfusion was primarily used in major surgery.  The 
programme changed MT practice and delivered a more balanced use of components. 
The greater use of haemostatic components in cardiac surgery may reflect changes in 
anti-platelet medication.  
 
Key Words: Massive transfusion, blood component therapy, acute transfusion 
package, red cell: plasma: platelet ratio 
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Introduction 
Massive haemorrhage is a medical emergency requiring transfusion.  Epidemiological 
studies of massive transfusion show that this may occur in most acute medical and 
surgical specialities (Halmin, et al. 2016) .  Traditional practice was to use red cells 
only once 40 % of estimated blood volume was lost.  Haemostatic components were 
commonly considered if the transfusion was likely to be massive, i.e. 10 or more units 
in 24 hours.  However, since 2004 there has been increasing evidence that balanced 
transfusion support or Haemostatic Resuscitation should be introduced as soon as the 
risk of life-threatening uncompressible haemorrhage is identified (Holcomb, et al. 
2007).  Transfusion support has become an integrated part of resuscitation designed to 
provide haemostatic support in addition to red cell replacement.  This approach has 
led to the increasing initial use of standardised Acute Transfusion Packages (ATP) or 
‘Shock Packs’ which contain a fixed ratio of red cells, plasma and platelets (Malone, 
et al. 2006).  Subsequent management is commonly goal directed with tailored 
transfusion support in which the use of haemostatic components is guided by 
laboratory and point of care monitoring (Doran, et al. 2012, Rossaint, et al. 2016). The 
acceptance and introduction of haemostatic resuscitation has varied across the globe 
during the last decade.  However, there has been increasing refinement and 
endorsement of this approach to Massive Transfusion despite the continuing 
uncertainty and resource implications (Hunt, et al. 2015, Rossaint, et al. 2016).  Early 
adopters in Scandinavia now have a decade of experience.  Haukeland University 
Hospital (HUS) introduced a massive transfusion (MT) programme during 2007 
including education, Acute Transfusion Package (ATP), and point-of-care 
measurements (thromboelastography).  We describe the use and impact of the 
programme in a single Norwegian centre during the period of 2002 – 2015.  
 
Setting 
Bergen is a city on the Western Coast of Norway.  The city population is 
approximately 278,000 and the Bergen metropolitan region has about 420,000 
inhabitants. Although geographically isolated by road, it is a popular centre for 
tourism, giving rise to periods of expanded population.  The Haukeland University 
Hospital is a 790-bedded secondary care facility providing regional specialist 
cardiothoracic service.  It is also a regional trauma receiving hospital. The Department 
of Immunology and Transfusion Medicine provides the hospital transfusion and 
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regional diagnostic services.  In addition, the department collects and processes blood 
components for the local hospitals. 
 
Implementation   
The hospital implemented an ATP on 17 December 2007.  However, clinical practice 
had started to change following a visit to Copenhagen in Jan 2007 by representatives 
from the haematology and anaesthetic departments.  Thromboelastography (TEG 
5000, Haemonetics Corporation; Braintree, MA, USA) was introduced into clinical 
practice in April 2007.  The instruments were originally available in theatres and the 
critical care unit, and then later the blood bank.  There was an ongoing education 
programme throughout the year within the Department of Anaesthesia. The request 
for an ATP was made at the discretion of the senior anaesthetist. Transfusion packs 
were prepared on-demand with a target preparation time of 30 minutes. Each ATP 
consisted of 6 units of RCC and 6 units of Octaplas solvent/detergent treated plasma 
(Octapharma AG, Lachen, Switzerland), and two platelet concentrates (pool of 4 
buffy coats or apheresis collected in 65-70 % platelet additive solution).  The total 
plasma from the platelet concentrates, together with the plasma from Octaplas, 
provided a red cell to plasma ratio of 1:1.  Fibrinogen replacement, using 
cryoprecipitate until 2014 and then fibrinogen concentrate, was given as clinically 
directed guided by laboratory fibrinogen and thromboelastography results.  
 
Materials and Methods 
Methodology 
A retrospective review was conducted of all episodes of patients receiving a massive 
transfusion during the period of Jan 1st, 2002 and Dec 31st, 2015, i.e. 13 years.  
Massive transfusions were defined as 10 or more RCC given during the first 24 hours 
after insult (Malone et al., 2006). An initial search was made using the ProSang 
laboratory information system (LIMS) (Databyrån AB, Stockholm, Sweden).  Patient 
records were then reviewed manually for demographics, transfusion support, principal 
indication for transfusion, haemostatic drugs and mortality.  The principal indication 
for transfusion was encoded using ICD-10. The total RCC use for the period was 
calculated as a denominator. 
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Blood components 
All RCC were prepared from whole blood and processed in SAGM with a residual 
plasma volume of 10-30 ml.  Leucodepletion was introduced in 1996 and applied to 
all red cell and platelet concentrates.  The plasma used throughout this study was 
Octaplas solvent/detergent treated plasma (Octapharma AG, Lachen, Switzerland) 
with a standardised unit volume of 200 ml.   The production method for recovered 
platelets changed during the study period from manual preparation to automation 
using the OrbiSac, TACSI and Reveos systems (Terumo BCT, Inc., Lakewood, CO, 
USA). Most of the platelets included in the ATP were issued as a pool recovered from 
4 whole blood donations resuspended to give an average total volume of 309 ml in 
30-35% plasma and 65-70% platelet additive solution. In addition, during the years 
2003-10 40% of the platelet concentrates were pathogen inactivated by the Intercept 
psoralen-based technology (Cerus Corp., Concord, CA, USA) in 2003-2012. The 
routine use of tranexamic acid was advocated with the introduction of the ATP in 
2007.  Tranexamic acid was given as an initial bolus dose of 1 gm within 3 hours of 
insult, followed by a second dose as infusion. 
Statistical analyses  
The ratios for the number and volume of plasma and PCs to RCCs were calculated. 
Standardized volumes of 276 ml for RCCs and 309 ml for PCs were used. The total 
amount of plasma transfused was also calculated to include the 35% plasma in PCs. 
PC volume ratios were multiplied by 4 to account for the pooling of four donors per 
concentrate. 
Statistical analysis was performed using IBM SPSS Statistics for Windows, Version 
24.0 (IBM Corp., Armonk, NY, USA). Descriptive statistics were used to summarize 
the number of components by year, speciality, and patient demographics. The 
Student’s t-test was used to compare the mean number of RCC, plasma and platelet 
concentrates transfused per episode pre-2007 and post-2007. Differences in platelet 
inhibitor and anticoagulant use between cardiac and non-cardiac episodes were tested 
using Chi-squared tests. A p-value <0.05 was considered statistically significant. 




We identified 410 massive transfusion episodes in 410 patients during the 13-year 
period from 1 Jan 2002 to 31 Dec 2015.  
 
Overall blood component usage 
The total blood component use in this period was 225,455 RCCs, 84,101 plasma units 
and 28,885 PCs. Of these, 6,363 RCCs (2.8%), 992 PCs (3.4%) and 5,046 units of 
plasma (6.0%) were used for massive transfusions. The total number of units 
transfused per episode varied greatly, but most were closer to 10, with 80% of 
episodes using 18 or fewer. The summary of component use per transfusion episode is 
shown in table 1. The pattern of component use by year is shown in Figure 1. 
 
RCC usage remained essentially unchanged before and after 2007, whilst the number 
of plasma units and PCs doubled (p<0.001). Figure 1 shows the mean annual use of 
each component over the study period.  The mean total number of component units 
increased from 25 to 30.  The total volume of blood components used in resuscitation 
increased by 1887 ml with most of this accounted for by plasma.  
 
Patient characteristics 
The number of transfusion episodes by age and gender is shown in Figure 2.  262 
(64%) of the episodes involved males and 148 (36%) females. The mean age was 60 
(9-90) for males and 59 (17-94) for females with highest numbers in the age groups of 
60-79 for males and 70-79 for females. 
 
The blood use by specialty is shown in Table 2.  Most of the episodes (42.7%) were in 
support of cardiothoracic surgery.  In total, surgery accounted for 87.1% of all 
episodes including surgery for trauma.   
 
Full information on medication was available for 386 patients (94%). Of these, 115 
were on platelet inhibitors and 97 on anticoagulants. The majority of platelet inhibited 
patients were cardiac (82.6% vs 17.4% in the non-cardiac group, p<0.001). 
Anticoagulant use was more evenly distributed (55.7% cardiac, 44.3% non-cardiac, 
p=0.008). In the cardiac group, 55.9% of patients used platelet inhibitors, compared 
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with 9.3% of non-cardiac patients (n=170, p<0.001). Anticoagulant use was greater in 
the non-cardiac group (31.8 vs 19.9%, n=216, p=0.008).  
 
Blood component ratios 
The pattern of components use throughout the period of study is shown in figure 1. 
The aim of the programme was to move towards 1:1:1 ratio of RCC: plasma: PC.  The 
use of plasma and platelets rapidly increased during the period of 2007-2009.  The 
mean component ratio of RCC: plasma: PC changed from 1.0:0.37:0.39 (n=149) in 
the period 2002 – 2006 to 1.0:0.79:0.85 (n=241) during 2008 – 2015. In summary, 
there has been a more balanced use of haemostatic components since the 2007 
programme and this practice has endured.   
 
A sub analysis illustrated in Figure 3 showed that the cardiac patients have made 
greater use of haemostatic components compared to other patient groups. The volume 
use of plasma has increased from 2014 onwards and now exceeds the use of RCC. 
 
Survival  
Table 3 shows that both for 24 hours and 30 days registration points, the survival 
increased significantly in the 2008-2015 group receiving a total of 30 or more blood 
components. However, no apparent survival advantage is demonstrated in the groups 




Whole blood collection figures for Haukeland University Hospital fell slightly from 
20,991 in 2006 to 19,751 in 2015.  Platelet apheresis increased from 199 to 543.  Red 




The mortality rate after massive haemorrhage is high unless actively managed.  
Haemorrhagic shock also results in a complex disturbance of coagulation which may 
be further exacerbated by crystalloids and colloids (Holcomb, et al. 2007).  
Coagulopathy in shock is a marker of poor survival and must be addressed (Brohi, et 
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al. 2003).  The pathophysiology in traumatic haemorrhage has been actively explored. 
Hypoperfusion, hyperfibrinolysis, activation of protein C and upregulation of 
thrombomodulin pathways are all thought to contribute significantly to this early 
coagulopathy (Brohi, et al. 2003)  In addition the integrity of the vascular 
endothelium may be lost in hypoxia (Ganter, et al. 2008).  The theory of an acute 
coagulopathy of trauma together with retrospective evidence from analysis of military 
and civilian trauma databases led to new transfusion guidelines including massive 
haemorrhage guidelines in Europe (Spahn, et al. 2007, Rossaint, et al. 2016) and 
trauma guidelines in Scandinavia (Gaarder, et al. 2008).  
 
This study is an example on how these new ideas have changed transfusion practice in 
relation to all patients with massive haemorrhage. After the introduction of the 
massive transfusion package in 2007, the use of platelet concentrates, and plasma 
increased significantly as seen in other studies (Johansson, et al. 2005, Davenport, et 
al. 2011, Bhangu, et al. 2013, Holcomb, et al. 2015, Padhi, et al. 2015). The mean 
ratio of blood components RCC: plasma: platelets used in massive transfusion 
changed in 2002-2006 from a red cell predominant mix of 1.0:0.37:0.39 (n=149) to a 
more balanced ratio of 1.0:0.79:0.85 (n=241) in 2008-2015 (p<0.001). The survival 
figures did not change other than for those patients transfused greater than 30 
components.  The Halmin epidemiological study of 92,057 massive transfusions 
during a similar period showed a slight increase in the median plasma: RBC ratio over 
time but no marked changes in mortality.  The 30-day mortality for all causes of 
massive transfusion was 24.8% giving a survival rate of 75.2%.  Mortality varied with 
age and indication however, they stressed that MT is independently associated with 
high mortality at 5 years (Halmin, et al. 2016). A small study from the Royal London 
group has shown that a major haemorrhage protocol introduced in 2008 improved the 
delivery of blood components.  The outcome again did not show a change in mortality 
but there was a reduced length of stay (Khan, et al. 2013). Later, Green from the same 
institution shows that the overall mortality rate was 33% with transfusion of >10 RBC 
in 24 hours being associated with higher odds of death (Green, et al. 2017). Cardiac 
surgery had the lowest mortality rate.  
 
In our institution 87.1% of episodes were in support of surgery. Trauma accounted for 
only 17.6%.   The figures probably reflect the case-mix in the institution as a regional 
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specialist unit in cardiac services.  Cardiac services encompass interventional 
radiological procedures which are increasingly used to replace open surgical 
procedures.  Anti-platelet medications are often continued. The plasma: RBC ratios 
for cardiac and non-cardiac blood use are shown separately.  Although, the figures are 
small there is a signal from the sub-analysis shown in Figure 4 that cardiac specialities 
used a greater proportion of plasma and platelets.   We propose that this may be 
related to changes in pharmaceutical practice in this group especially anti-platelet 
medication as shown in Table 5. It is well known that antiplatelet drugs increase risk 
of bleeding, and this risk is significantly increased when dual platelet inhibition is 
applied (Shehab, et al. 2010, Giustino, et al. 2016, Grodzinsky, et al. 2016, Kim, et al. 
2016, Ferraris 2017). However, it is also noted that a large proportion (31.8%) of the 
non-cardiac group in this study were on anti-coagulants.  The figure is high and may 
not be representative of the general population. In contrast, the overall use in Norway 
is 98 daily doses/1000 inhabitants (Statens legemiddelverk 2017). However, the study 
does highlight the importance of recognizing the risk of bleeding associated with use 
of anticoagulants. The importance of recognition and correct treatment is addressed in 
several publications (Ufer 2010, Connolly, et al. 2016, Connolly, et al. 2016).  
 
We suggest that massive transfusion remains an uncommon but serious complication 
of major surgery.  It occurs predominantly in the older population in both men and 
women.  The median age was 60 (9-94) with a male predominance of 64%.  Our study 
shows similar age distribution to that seen in both the Halmin and Green papers 
(Halmin, et al. 2016, Green, et al. 2017). Green showed the median age was 61 (42-
74) with a male predominance. We designed our study to be comparable with the 
seminal epidemiology paper from Denmark and Sweden (Halmin, et al. 2016). This 
study is a descriptive cohort study of all patients receiving 10 or more RCC in the 
equivalence of 24 hr.  92,057 patients were identified over a 16-year period.  The 
incidence of MT was 4.5 per 10,000 in Denmark and 2.5 per 10,000 in Sweden.  The 
authors identified that the most common indication for MT was major surgery 
(61.2%), followed by trauma (15.4%).  Prevalence is determined by the definition of 
massive transfusion and these needs to be standardised using clinically relevant 
definitions.  Green’s study identified an impressive 710 MT cases in a three-year 
period (Green, et al. 2017).  This was achieved this using two definitions of Massive 
Transfusion.  These were MT >5 RBC units in 4 hours as well as the traditional >10 
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RBC units in 24 hours. The former has been proposed by Mitra et al., and when used 
together should capture 95% of all cases (Mitra, et al. 2011, Zatta, et al. 2014).   All 
three studies have also shown that overall surgical cases account for the majority of 
MT.  The findings contrast with the general transfusion use studies from the UK 
which show that most red cells (65%) are used for medical specialties especially 
haemato-oncology and gastroenterology (Tinegate, et al. 2014, Wells, et al. 2002).   
The findings from the MT studies are important for Patient Blood Management 
programmes and transfusion demand planning. 
 
Limitations 
This study is subject to the limitations of a retrospective study at a single centre and 
the numbers are relatively small.  Cardiac cases are over-represented, and trauma is 
possibly underrepresented.  However, the general observations would be applicable to 
other large medical centres dealing with massive haemorrhage.  The study inclusion 
criterion requiring 10 or more RCC in 24 hours has excluded some patients with 
significant haemorrhage.  We recognise the limitations of this traditional definition of 
massive transfusion however this was chosen to allow comparison with previous 
studies in Scandinavia.  The definition of MT >5 RBC units in 4 hours proposed by 
Mitra et al., is a much more appropriate marker of active haemorrhage and resonates 
with the definitions used in the military protocols. However, the use of this time 
dependent definition requires a different approach to data collection, i.e. 
contemporaneous digital capture within the clinical space.   Finally, we recognise the 
limited clinical information provided to hospital blood transfusion laboratories with 
requests for transfusion and the difficulty in extracting the information from hospital 
IT systems. However, the strengths of the study include the use of the same ICD 
version and LIMS throughout the 13-year period of study.   
 
Conclusions 
The MT programme implemented at Haukeland University Hospital, Bergen, 
Norway, in 2007 successfully changed massive transfusion practice in that it delivered 
a more balanced treatment. A trend towards improved survival was seen in the multi-
transfused following the programme.  We have shown that Massive Transfusion 
(>10RBC) was primarily used in major surgery, especially cardiothoracic surgery.  
The findings contrast with studies showing that most red cells are used in medical 
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specialities. The proportionally greater use of haemostatic components in cardiac 
surgery may reflect changes in anti-platelet medication. These findings should inform 
future studies, blood service demand planning and patient blood management 
programs especially in cardiac services. 
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Table 1. Number of blood components per transfusion episode (mean ± SD (mode)) 
 
Blood component 2002-2006 2008-2015 2002-2015 P* 
Red cell concentrate (SAGM) 16 ± 10 (10) 15 ± 9 (10) 16 ± 9 (10) 0.507 
Plasma (Octaplas/Octaplasma) 8 ± 8 (4) 16 ± 13 (8) 12 ± 12 (6) <0.001 
Platelet concentrate (65% PAS) 1 ± 2 (0) 3 ± 3 (2) 2 ± 3 (0) <0.001 
All components 25 ± 18 (15) 30 ± 23 (20) 30 ± 21 (21) <0.001 




Table 2. Transfusion episodes and blood component use by specialty (%) 
 










Cardiac/vascular surgery 42.7 41.8 49.2 50.7 
Trauma 17.6 20.1 18.3 18.1 
Other surgery 16.3 15.4 11.0 8.8 
Cancer surgery 10.5 10.2 10.3 9.7 
Obstetric care 6.6 6.0 5.7 7.6 
Other hospital care 5.6 5.8 5.1 4.8 
Hematologic malignancy 0.5 0.4 0.2 0.3 








24 hours 30 days 
2002-2006 2008-2015 p 2002-2006 2008-2015 P 
10-29 
(n=256) 
77.1% 77.5% 0.937 67.8% 71.0% 0.577 
20+ (n=270) 59.7% 70.5% 0.090 53.2% 63.7% 0.111 






Figure 1. Mean blood component use by year. Vertical line indicates transition year 












Figure 3. (A) Plasma and platelet concentrate volume as a ratio of red cell concentrate 
volume. (B) Ratios divided into cardiac and non-cardiac patients. Dotted vertical line 




R E V I E W A R T I C L E
Mass casualty events: blood transfusion emergency
preparedness across the continuum of care
Heidi Doughty,1 Simon Glasgow,2 and Einar Kristoffersen3
Transfusion support is a key enabler to the response to
mass casualty events (MCEs). Transfusion demand and
capability planning should be an integrated part of the
medical planning process for emergency system
preparedness. Historical reviews have recently
supported demand planning for MCEs and mass
gatherings; however, computer modeling offers greater
insights for resource management. The challenge
remains balancing demand and supply especially the
demand for universal components such as group O red
blood cells. The current prehospital and hospital
capability has benefited from investment in the
management of massive hemorrhage. The management
of massive hemorrhage should address both
hemorrhage control and hemostatic support. Labile blood
components cannot be stockpiled and a large surge in
demand is a challenge for transfusion providers. The use
of blood components may need to be triaged and
demand managed. Two contrasting models of
transfusion planning for MCEs are described. Both
illustrate an integrated approach to preparedness where
blood transfusion services work closely with health care
providers and the donor community. Preparedness
includes appropriate stock management and resupply
from other centers. However, the introduction of
alternative transfusion products, transfusion triage, and
the greater use of an emergency donor panel to provide
whole blood may permit greater resilience.
M
ass casualty events (MCEs) in medical
terms are “single or simultaneous event(s)
where the normal major incident response
of one or several health organisations must
be augmented by extraordinary measures in order to
maintain an efficient, suitable and sustainable response.”1
Most are marked by a relatively sudden and dramatic
event that causes a surge in numbers of patients. MCEs
are an important health care issue. Despite a plateau in
the rate of all types of disasters recorded worldwide in the
past 8 years, there has been a continued increase in man-
made disasters and MCEs. The mortality from terrorist
incidents alone has more than doubled since 2007.2,3
Planned mass gatherings such as sporting and religious
events also provide the potential for MCEs. Massive casu-
alty events have the potential to generate many trauma
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victims; therefore, health care services must be prepared
across the continuum of care.
The medical response to the multisite terrorist attacks
in Paris in November 2015 was elegantly described by
Hirsch and colleagues.4 The medical response was
described as the civil application of war medicine and
included prehospital and hospital-based damage control
resuscitation (DCR). DCR assumes hemorrhage control,
restricted use of crystalloid, and access to blood. MCE and
disaster planning has traditionally relied on stockpiles of
virtually indestructible crystalloid with a shelf life meas-
ured in decades. Disaster planning reliant on perishable
blood and blood components is clearly more problematic.
A cross-sectional approach to transfusion planning that is
nested within wider health care emergency management
is required.
The delivery of transfusion support in the context of
these incidents has received increasing interest. The
appropriate management of severe hemorrhage offers a
window of opportunity for improving MCE outcomes.5-13
This opportunity has developed primarily through our
further understanding of the role blood and, more spe-
cifically, coagulation therapy, plays in DCR.14-17 Driving
the focus on optimal transfusion support in DCR is the
increasing use of major hemorrhage protocols (MHPs)
to ensure early delivery of red blood cells (RBCs) and
hemostatic components.18,19 In addition, there has
been a wider acceptance of the restricted use of preho-
spital non–blood-based fluids, in favor of waiting until
MHPs can be provided within hospitals.20-23 The early
provision of blood has driven an international move-
ment toward the delivery of these products in the pre-
hospital environment in an effort to further improve
trauma outcomes.24-26 The practice of prehospital
blood transfusion combined with additional hemostatic
adjuncts such as tourniquets and tranexamic acid form
part of the new overall paradigm of remote DCR
(RDCR).27,28
Providing DCR and RDCR in the setting of an MCE
is still relatively untested. The prospect of delivering
blood components in the volumes now expected in
major hemorrhage already presents a recognized chal-
lenge to MCE planners. Previous studies have illustrated
the effect of applying modern-day MHPs during previ-
ously reported MCEs, showing a possible three to four
times increase in the demand for hemostatic compo-
nents in certain events.13 The addition of delivering this
in the prehospital setting further complicates the issue
and is an aspect of transfusion service preparedness for
MCEs that has not been previously discussed. The
objective of this short article is to review the variation in
the landscape of transfusion response to MCEs interna-
tionally, through the comparison of two northern Euro-
pean countries with similar systems of government-
funded health care deliverance.
Transfusion service delivery for MCEs in the
United Kingdom
The United Kingdom has a population of approximately
64.5 million with a land mass of just under 250,000 km2.29
Less than 20% of this area consists of mountains, moor-
lands, or similar terrain, which would present a challenge
to an emergency service MCE response and the distribu-
tion of emergency blood products.30 Approximately 85%
of the nation’s transfusion needs are provided by the Eng-
lish Blood Service, NHS Blood and Transplant (NHSBT).
NHSBT undertook a review of its MCE transfusion
response plans in preparation for the 2012 London Olym-
pic Games31 and is currently reviewing the implications of
the Paris MCE.
NHSBT applies a policy of maintaining blood stocks
at levels appropriate for the current risk level utilizing
planned donor drives in preparation for periods of poten-
tial or expected surge in demand such as winter supply
shortages. Currently, whole blood is not utilized in the
United Kingdom. Transfusion support is based on compo-
nents. This system aims to rapidly deliver the principal
blood components: RBCs, fresh-frozen plasma (FFP), pla-
telets (PLTs), and cryoprecipitate.31 After an MCE there is
no reliance on emergency donation for the immediate
provision of blood products to casualties; instead, the
response to such incidents is based on optimizing supply
from existing stock and the forward planning of replace-
ment donation.
During the lead-up to a period of expected height-
ened demand, NHSBT calibrates stock levels through a
process of both bottom-up and top-down planning.
Bottom-up plans are based on establishing a range of
potential scenarios and therefore casualty load to which
both a transfusion per casualty requirement and a hospi-
tal demand factor are applied to give an overall stock
demand for an event. This is performed for all four of the
major components. In addition, top-down plans, similar
to business continuity planning for day-to-day needs, rely
on the recent evidence from previous MCE transfusion
responses to ensure the quantities applied in the bottom-
up stage are appropriate and justified.31 International
blood demand prediction tools in trauma have focused
predominantly on early individual casualty physiology
and laboratory results to predict a “dichotomous out-
come” of whether or not a massive transfusion will be
required.32-35 However, UK plans assume wider use of all
blood components.
Prediction and planning tools for transfusion service
and hospital deliverance are now going further with the
use of computer modeling techniques. Simulation models
have been developed to improve our understanding of
blood provision following MCEs, as well as test potential
strategies for managing instances of overwhelming
demand in future events.36 The standard blood stock
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levels held at individual hospitals and within networks are
determined based on the average daily blood use and can
be increased when required. This is controlled and man-
aged centrally through a hub-and-spoke approach that
informs rapid resupply after an MCE. The overall compo-
nent availability can also be manipulated through altera-
tions to the central manufacturing processes. For
example, increased plasma and PLT production can be
generated from whole blood.31
The aim of in-hospital management of MCEs in the
United Kingdom is to provide as close to the gold standard
level of care as possible within the resource constraints
generated by the surge casualty demands. Major trauma
centers form the focus of the response for the most
severely injured casualties providing DCR through MHPs
with the aim of minimizing further blood loss, restoring
circulating volume and preventing or treating trauma-
induced coagulopathy.18,37 The current approach to pre-
hospital care delivery in the United Kingdom in terms of
transfusion support focuses primarily on prevention of
further blood loss and the development of trauma-
induced coagulopathy through hemostatic adjuncts and
restrictive transfusion protocols. Hemostasis is led
through compression of active bleeding, the use of tourni-
quets, and application of pelvic binders where appropri-
ate. Topical hemostatic agents such as factor
concentrators, mucoadhesives, and procoagulant dress-
ings are not widely used within the civilian setting.
Current practice advocates the use of tranexamic acid
within 3 hours of injury combined with restrictive use of
nonhematologic fluids to maintain a central pulse. Other
pharmaceutical adjuncts such as recombinant activated
factor (F)VII, while showing some benefit in reducing RBC
requirements after trauma, are not in routine use within
the UK system. However, it has been employed for major
hemorrhage at certain UK hospitals after previous
MCEs.38-40 The use of prehospital blood is a relatively new
concept in the United Kingdom. The London Air Ambu-
lance was the first to begin carrying RBCs out into the
field in 2012. Since then, a number of regional and
national air ambulance services in the United Kingdom
have introduced a range of capabilities including lyophil-
ized plasma and tranexamic acid.
Transfusion service delivery for MCEs in the
Kingdom of Norway
The Kingdom of Norway’s population is less than 1/10th
of the United Kingdom at just over five million people;
however, this populace is spread over an area 1.4 times
larger than the United Kingdom at nearly 350,000 km2. In
addition and in contrast to the United Kingdom, half of
this land is mountainous terrain or moorland with diffi-
cult access, numerous transportation barriers, and sea-
sonal challenges, especially with prolonged winter
periods.41 Blood and products from blood banks located
and run by local and regional hospitals meet the transfu-
sion needs. The hospital blood bank will maintain blood-
stock levels to match ordinary hospital activity usage for
10 to 14 days for RBCs, approximately 30 days for plasma,
and 4 days for PLTs. Only larger hospitals make PLT
concentrates.
In one of the four health regions in Norway the hospi-
tal blood banks have plans to meet minor surges of blood
and blood products. At times of larger crisis these may be
extended to any affected regional hospital, although on an
ad hoc basis. Single hospitals have their own contingency
plans, but none are scaled to cope with MCEs. There is no
control or coordination of the transfusion needs at a
national level and no government body evaluating
national blood stock levels related to current risk levels or
expected potential surges. In the aftermath of the most
severe civilian MCE in Norway on July 22, 2011,42
improved contingency plans have been made to improve
obvious shortcomings in nearly all areas except transfu-
sion. In this incident, blood product needs were largely
met, and any need for a change in national civilian trans-
fusion strategies was therefore deemed unwarranted.
There is presently no national policy in place on how to
meet transfusion needs after an MCE in Norway.
Trauma teams are located at regional hospitals and
will rely on a balanced transfusion policy of RBCs, FFP,
and PLTs provided by the hospital blood bank as one
“trauma package” containing a balanced quantity of the
three components. No regional hospital provides whole
blood as a part of its DCR program. Most regional air
ambulance services now fly with lyophilized plasma, but
only a few with RBCs and, as of December 2015, one with
PLT-sparing, leukoreduced whole blood. As in the United
Kingdom, there is no reliance on donation following an
MCE for the rapid provision of blood components to casu-
alties; indeed the regional blood bank involved in the July
22, 2011, terrorist incident managed successfully to stem
the flow of nonregistered donors at an early time.11
However, one regional blood bank (Bergen) is in the
process of implementing contingency plans that will
involve prescreened group O low-titer emergency donors.
The donors will be recruited from three locations, at a
local naval base, among the regional hospital employees,
and from city suburbs, and called to donate whole blood
to be fully tested and utilized as soon as possible. These
plans are coordinated with the Norwegian Armed Forces
Medical Services contingency plans for blood product
needs in emergencies. Donated blood is to be leukore-
duced with PLT-sparing filters, tested, and dispensed as
whole blood for immediate use or cold storage. The
plan is based on a projected initial demand of 50 units of
whole blood to meet the demand of five immediate mas-
sive transfusion cases; however, the scheme is easily
upscaleable.
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Literature review
We have briefly described the organization and planned
response to MCEs by transfusion providers in two coun-
tries. One blood bank in Norway is redeveloping the use of
whole blood as a part of its resilience plan. It is a novel
approach for Europe and stimulates debate. Many coun-
tries have faced MCEs but the literature concerning trans-
fusion support is limited. Blood demand in MCEs has been
comprehensively reviewed by Glasgow and colleagues.13
The publications and reports of transfusion service deliver-
ance for MCEs in North America and Israel are particularly
valuable. These nations have significant experience with a
wide range of MCEs and face their own environmental and
logistical challenges in mounting an effective response.13
Hess and Thomas43 and Schmidt44 both highlighted the
issues associated with the US experiences of emergency
donation in the immediate aftermath of such events dur-
ing their reviews of blood and disaster. Colleagues in Israel
have also described their substantial experience with deliv-
ering transfusion support in MCEs, both providing detailed
plans of their transfusion response and offering planning
estimates for future MCE blood needs.5
Dann and coworkers5 stated in a review of the response
to nine individual terrorist MCEs in Israel that the estab-
lished protocol is to prepare three RBC units for each
patient “likely to require blood.” In comparison, Shinar and
coworkers45 reviewed 1645 terrorist attacks, again in Israel,
from 2000 to 2005, involving 7497 casualties. These authors,
from the Magen David Adom (MDA), the national supplier
of blood products to Israel, reported a mean number of
units supplied per MCE casualty of 1.3 U of RBCs and 0.9 U
of other components. Using the total number of casualties
as a denominator, that is, “per casualty,” is a much broader
descriptor for planners than the units per individual casu-
alty expected to require blood. However, the volume of cas-
ualties actually requiring blood is relatively small compared
to the overall injury burden from an event.13,43,44
Most recently, another group from Israel reported the
use of just over 3 units of RBCs “per casualty admitted to
hospital,” therefore negating the issues of accounting for
all casualties with very minor injuries who may be dealt
with at the scene or in minor injury units. The 3 RBC units
per admission figure is supported by a separate report
from a combat hospital in Iraq,46 which describes their
response to three separate civilian MCEs. The most recent
report also stands out in its detailed discussion of compo-
nent use and attainment of modern-day transfusion ratio
deliverance after MCEs affecting civilian communities.9
Blood use is greatest in casualties involved in terrorist
MCEs with injury severity scores greater than 15
(ISS > 15). Blood use in the most severely injured was 7 to
8 units of RBCs supported by components. UK military
and civilian experience suggested even greater require-
ments for the most severely injured by improvised explo-
sive devices, with median requirements of 16 (9-25) units
of RBCs and proportionate amounts of components.40,47
The proportion of injured requiring blood varies
enormously and is dependent on the event, hemorrhage
control, and availability of blood. After the London bomb-
ings, only 23 patients received blood during the first 24
hours out of an estimated 700 injured.40 The planning for
the Olympics assumed a similarly small proportion. The
Paris attacks in 2015 with shootings at four sites and three
explosions have highlighted the requirement to support
many more severely injured. However, there was good
blood component availability during the crisis, demon-
strating that large volumes of components can be rapidly
mobilized if already stocked.
DISCUSSION
MCEs continue to challenge health care emergency pre-
paredness. The definition of MCEs implies that critical
sufficiency and supply of resources will be constrained.
MCEs involving improvised explosive devices are charac-
terized by massive bleeding. The widespread adoption of
lessons learned on the battlefield has led to a more aggres-
sive approach to hemorrhage control. However, the same
paradigm has also led to the introduction of cautious fluid
resuscitation and the early use of blood components in
resuscitation. Such an expectation challenges health care
planners and developed blood transfusion services espe-
cially when a large surge of patients is involved. Effective
prehospital care and emergency system preparedness
across the continuum of care has the potential to reduce
morbidity and mortality as well as reduce the demand for
blood.
Transfusion planning has not traditionally been a
part of MCE planning; however, we suggest that integra-
tion is essential for both blood demand and supply man-
agement. The two European examples presented illustrate
two complimentary approaches currently being used to
prepare for MCEs. Both countries have recently responded
to terrorist bombings. The UK example is a national exam-
ple based on component therapy with access to redistrib-
uted stock. The Norwegian example (Bergen) is that of a
relatively geographically isolated community using a
whole blood program to supplement existing stocks of
blood components. The two transfusion services’ support
to MCE is summarized in Table 1.
Continuity of care
The UK has dealt with a number of civilian disasters but it
was the response to the July 7, 2005, London bombings
that led to the first transfusion service review.40 The review
highlighted a number of issues that have been incorpo-
rated into subsequent planning. These include the provi-
sion of a large volume of universal components. The
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demand was three times greater than the actual amount
of RBCs used during the first 24 hours. This ratio of over-
ordering has previously been described.5,7 The proportion
of group O RBCs ordered during July 7, 2005, was 80%
whereas the proportion of group O in the UK population
is 45%. In addition, there was a demand for hemostatic
components including FFP, PLTs, and cryoprecipitate.
Despite overordering, there was very little reported was-
tage due to the amendment of hospital blood bank stand-
ing orders and the subsequent use of blood. The
subsequent use of blood is due to the ongoing care
required for the severely injured. Early revision surgery
leads to demand for both theater time and blood. The
care of the severely injured may continue for many years
and transfusion support should be mindful of the conti-
nuity of care. The other reason for continued blood use is
the return to planned health care activity.
The impact of military practice on civilian care
Military practice has left a legacy across the continuum of
care. It has changed trauma care and planning and has
stimulated collaborative research. It has also contributed
to MCE planning. MCE planning is facilitated by trauma
networks with shared policies and massive hemorrhage
protocols. A series of guidelines for the management of
massive hemorrhage have developed over the past
5 years.17,48,49 All have been underpinned by military
transfusion practice and enhanced by the developing evi-
dence. Transfusion guidelines now promote hemorrhage
control, early use of tranexamic acid, and a foundation of
RBCs and FFP in a 1:1 to 3:2 ratio followed by goal-
directed therapy.23,50 Good organization is essential to
success with the early involvement of senior experienced
clinicians, well-rehearsed teams, and trauma regis-
tries.17,48,51 The concepts of prehospital care, registry
reviews, standardized massive transfusion protocols,
cross-sector planning principles were successfully inte-
grated into the blood transfusion service for the 2012
London Olympics.31
The use of whole blood has traditionally been used
by defense medical services and offers considerable logis-
tic advantages in the austere medical environment.52,53
The Bergen team has spearheaded the concepts of RDCR
with the use of emergency donor panels (EDPs) and the
introduction of cold whole blood for military units.54 The
use of emergency whole blood is not restricted to the mili-
tary community but may be lifesaving in civilian situa-
tions such as the cruise industry.55 The Bergen model for
transfusion support demonstrates a further example of
military practice used in wider support of the civilian
community, that is, the use of EDPs for whole blood.
EDPs are pretested donors who are prepared to give in
emergencies. Donors are required to maintain their cur-
rency as donors and are normally screened at the time of
donation. It represents the most agile of systems and is an
ideal solution for a geographically isolated population
with a low prevalence of transfusion transmitted infection.
However, it also requires careful preparation and demand
planning.
Transfusion triage and demand planning
Transfusion demand planning is primarily designed to
meet the normal needs of the population at risk. In addi-
tion, consideration must be given to emergency-
TABLE 1. Comparison summary of MCE transfusion preparedness
Transfusion preparedness England Norway
MCE response planning
Historical experience of MCEs Periodic Limited
Integrated military and civilian responses No Yes*
Blood stock management and redeployment Coordinated at national level Regional
Donor management systems National call center Local call-up
In hospital
Whole blood available to civilian community No Regional initiative. Use of
leukoreduced PLT spared whole blood.*
Principal blood components
held within standard inventories
RBCs, FFP, PLTs, and
cryoprecipitate
RBCs, FFP, and PLTs
Emergency blood donation program National blood service Local pool of emergency volunteer donors*
Routine use of tranexamic acid Yes (within 3 hr) Yes
Routine use of recombinant activated
FVII for massive hemorrhage
No† No
Prehospital
Tranexamic acid Increasing use Yes
Tourniquets Yes Yes
Routine access to hemostatic dressings No No
Prehospital transfusion RBCs with limited
availability of lyophilized plasma
Lyophilized plasma with limited availability
of RBCs and leukoreduced
PLT-spared whole blood
* Recent initiative or currently in development.
† Reports of occasional use in response to MCEs.
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preparedness. Emergency-preparedness must respond to
not only the emergency but also ensure the continuity of
critical services. The primary role of the blood transfusion
services and hospital blood banks is to provide blood com-
ponents. The wider use of “massive transfusion” protocols
has led to an increased initial demand for “universal” com-
ponents such as group O D– RBCs and AB FFP. Alternative
universal components can be substituted. Examples are
the use of group A plasma for all and group O D1 RBCs
for males and women over 50.48 Military experience has
demonstrated that hemostatic resuscitation and the intro-
duction of point-of-care testing may increase the demand
for PLTs and cryoprecipitate.47 Resuscitation teams have
become accustomed to large volumes of components for
individual patients. Such trends must be factored into local
and national demand planning.
Stock management of labile components such as
blood and PLTs is a challenge when there is unpredictable
demand. Large stock holding in blood services or blood
banks is associated with wastage due to time expiry,
whereas insufficient stocks may lead to clinical disaster. It
should be assumed that in the unplanned event the
demand for blood components may exceed supply. The
use of preprepared blood shortage plans provides valuable
guidance in the event of RBC and PLT shortages.56,57 In
addition, transfusion triage can provide guidance for both
clinicians and the blood transfusion services. The guid-
ance issued for the Olympics is shown in Table 2. While
such schemes are applicable to individual casualties
where information may be in abundance, in an MCE sce-
nario such detail is often unavailable, both at the planning
stage and early in the course of the event. Historically, it
has been repeatedly shown that blood demand is greatest
within the first few hours of an event and that expectedly
this period correlates with the arrival of the most severely
injured casualties.58,59 Experimental simulation modeling
has recently explored the impact of restricting both the
total number of RBCs and emergency group O blood in
MCEs.36 Restrictive transfusion protocols appear to
increase the overall treatment rates where there are large
casualty loads.
Transfusion safety
Demand planning and stock management should con-
sider blood group mix. There will be considerable pressure
on the universal components. Demand management of
group O blood may promote the early use of group spe-
cific or ABO-compatible blood. However, the greatest risk
associated with transfusion especially in the context of
MCEs is the use of ABO-incompatible blood and the initial
use of group O may be the safest option. Note that the use
of group O before blood grouping may lead to “mixed
fields” and staff should have guidance as to when to revert
to group specific blood. Identification bands should be
worn by patients receiving blood. Emergency identifica-
tion should use gender and be compatible with laboratory
information management systems. Attention must also be
paid to cold chain management especially during the
transport of blood between organizations and depart-
ments. Transfusion is a highly regulated area of health
care. The European Blood Directive 2002/98/EC sets
standards for the collection, testing, processing, storage,
and distribution of human blood and blood compo-
nents.60 Requirements of the legislation include the trace-
ability of blood used and hemovigilance. These are
potentially challenging within the context of MCEs but
must be managed.
Back to whole blood
Most national blood services have developed component
programs designed to meet civilian patient requirements.
The drivers for transfusion support in the UK are medical
patients, in particular, those requiring hematooncology
support.61,62 Components permit not only optimal care of
individual patient groups but also optimal storage.
National component development programs have focused
on targeted safety measures such as those designed to
reduce the risk of transfusion-related acute lung injury
and prion disease rather than MCEs.63 The current man-
agement of traumatic hemorrhage requires hemostatic
components. Frozen products can be stockpiled but must
be thawed to be used which takes time unless prethawed.
Component development such as liquid and lyophilized
plasma may address some of the logistic constraints and
permits treatment in the prehospital space. However,
labile products such as RBCs and PLTs cannot be stock-
piled. For instance PLTs have a shelf life of 5 to 7 days
unless cryopreserved. Another method of delivery of PLTs
is whole blood.
TABLE 2. Guidance for blood component use during the 2012 London Olympics
Priority RBCs (U) FFP (U) PLTs*
Cryoprecipitate
(pool of 5 donations) Category definition
P1 10 6 1 1-2 Immediate, requiring immediate intervention
P2 4 0 0 0 Urgent, requiring intervention < 6 hr
P3 0 0 0 0 Delayed, walking wounded
* PLT minimum dose of 2.4 3 1011 per adult therapeutic dose (Ref: internal reporting to NHSBT by H. Doughty).
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Few European civilian blood services provide whole
blood either routinely or as part of their emergency
response. However, the use of whole blood for hemostatic
resuscitation is predicted to become more mainstream as
evidenced by its inclusion as a research priority in the
NHLBI Transfusion Medicine State of the Science Sympo-
sium Summary Statement.64 Fresh whole blood not only
addresses the concerns about the storage lesion, but also
provides a supply of both liquid plasma and a small dose
of PLTs with less anticoagulant than component therapy.
PLT function is normally related to posttransfusion circu-
lation time and PLTs stored at 1 to 68C have reduced circu-
lation time. However, whole blood stored cold has the
potential to provide some hemostatic effect over a longer
period.54,65 Whole blood availability may be limited due to
other barriers including leukoreduction. However, there is
now an FDA-approved PLT-sparing filter.66 Well-rehearsed
collection, testing, and release can yield a continuous flow
of whole blood bags. The use of whole blood is a poten-
tially more agile and responsive approach and should be
considered as a part of resilience measures. Indeed, as of
December 2015 cold-stored, leukoreduced, PLT-
containing whole blood has been offered to the Emer-
gency Department at the Mayo Clinic in Rochester,
Minnesota.
CONCLUSIONS
Transfusion support is a key enabler in the health care
response to MCEs. Historical reviews have recently sup-
ported MCE blood demand planning; however, each new
event offers further insights for resource management.
The challenge remains balancing demand and supply. The
intervention priority to reduce demand is hemorrhage
control. However prehospital and hospital care has bene-
fited from early access to transfusion support. A surge in
demand for blood components remains a challenge for
any blood provider and transfusion may need to be tri-
aged and demand managed. The options for increasing
supply include redeployment of existing stock, altered
manufacturing, and careful donor management. The
introduction of alternative transfusion products and rapid
access to pretested emergency donor panels may also
offer resilience. In conclusion, transfusion support in
MCEs is important and should be an integrated part of
health care emergency-preparedness.
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